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1.1 Background   
Alzheimer’s disease (AD), is the most common cause of dementia in the elderly and is 
characterized by a progressive memory decline, impairments in language and visual-
spatial skills, impairments in behaviour, results in a loss of independence, reduction of 
quality of life, and ultimately death. Although our knowledge and understanding of the 
disease continues to grow, currently there are no effective treatments for reversing  or 
even stabilizing the process of the disease. AD remains perhaps the most devastating 
disease of older people and constitutes a large social and economic burden to both the 
families and society as a whole. Currently there are 30 million individuals worldwide 
with dementia (Ferry, C.P et al., 2005) and some predictions indicate as much as a 4 
fold increase in the prevalence of AD by 2050 (Brookmeyer et al., 2007). Thus, there is 
an urgent need for better tools for diagnosis, prevention, and treatment to avoid this 
upcoming epidemic. 
Age is the most important known risk factor of AD. As people age, there is a normal 
decline in the physiological functions of their body, in particular the hormonal 
deficiency following reproductive senescence known as menopause in women  and 
andropause in men. A number of studies involving postmenopausal women have shown 
a correlation between decreasing levels of estrogen and increased levels of beta amyloid 
(A), the major component of the neuritic plaques found in the AD brain. Although the 
role of testosterone in men has received less attention, it has been shown to share a 
similar action to that of estrogens on the generation of the Aβ . Therefore, it has been 
suggested that testosterone may have a similar role to  estrogen in the relation to AD. 
At present, a number of studies in the AD field focus on testosterone levels in men and 
its effects on the nervous system. While the results are preliminary and the role of 
androgens in the aged-related cognition is still poorly understood compared to those 
studies of estrogen, it has been proposed that testosterone therapy may delay the onset 
of AD in elderly men. 
Luteinizing hormone (LH), one of the pituitary gonadotropin hormones, is synthesized 
and secreted under the regulation of gonadotropin-releasing hormone (GnRH), pituitary 
factors and gonadal hormone feedback which collectively are termed the 





pituitary into the peripheral circulation which eventually affect target organs expressing 
the LH receptor (LHR). In the gonads, LH stimulate gonadal hormone production, such 
as testosterone, estrogen, progesterone, activin, and inhibin. LHR is highly expressed in 
the hippocampus; a brain region involved in memory function and which is severely 
affected in AD (Barron, A.M et al., 2006). Several studies also confirmed that the brain 
may also be a target organ for LH (Lei, Z et al., 1993; Al-Hader, A.A et al., 1997). 
However, the regulation of LHR in the brain has been largely unexplored. 
In aging men, changes of LH levels have been reported with the levels of serum LH 
shown to be  two to three times higher than men in their mid-20s (Neaves, W.B et al., 
1984). Recent studies by Short et al., 2001   showed that high levels of  LH, are 
associated with AD. However, whether LH plays a direct role in AD pathogenesis still 
remains unclear. Recent studies have linked testosterone depletion and perhaps LH 
elevation with increased risk for the development of AD in men. It is unclear whether 
the altered actions of both testosterone or LH contribute to the pathogenesis of  AD. It is 
unlikely that any one of the hormones from HPG axis plays a single and predominant 
role in the reproductive system but rather it may be a combination of hormones acting in 
concert. 
This chapter will review the current understanding of the characteristics and pathogenic 
mechanisms of AD, focussing on the relationship between testosterone, LH and AD. In 
addition, the review will also discuss the benefits of testosterone and  LH suppression in 
AD.  
 
1.2 Alzheimer’s Disease : Epidemiology and Clinical Characteristics 
Alzheimer’s disease AD) is the most prevalent form of dementia,  accounts for about 
50-60% of all dementia cases, compared to other types of dementia, such as vascular 
dementia (15-20% of the cases), Lewy body dementia (up to 20% of the cases) and 
fronto-temporal dementia (approximately about 10% which is associated with a younger 
age of onset) (Schulz, R., Noelker, S Linda., Rockwood, K., Sprott, R, 2006). The 
number of cases with dementia as well as AD world-wide will increase as the 
population grows, affecting approximately 4-5 million people in the United States and 





such as Australia and Canada will undergo a similar pattern. Although AD is known to 
be a major problem in developed countries, it already poses a great problem in 
developing countries, predominantly in Asian countries where the impact of this disease 
is predicted to be catastrophic if effective prevention measures are not implemented in 
the near future (Ferri et al., 2005). Moreover, in Indonesia, as a developing country with 
a high rate of population growth, AD cases are projected to have 295% increment 
between 1990 and 2030 (Draper and Brian, 2004). The decline in fertility and 
improvements in life expectancy have contributed to the aging population in Indonesia. 
As seen in western countries there is a predominance women compared to men in the 
older age groups which may contribute further to the dementia epidemic. Furthermore 
there is a greater degree of aging in rural areas and taken together with the large rural 
population in Indonesia and its associated lower socio-economic status the prevalence 
of this disease will be considerable.  The absolute number of people in Indonesia has 
increased from 4.9 million in 1950 to 16.3 million in 2000. By 2050, it is estimated that 
one in four Indonesian would be classified as an elderly person compared to one in ten 
at present, resulting in 73.6 million in this population group (Fletcher Robert., 2010). 
Currently there are very few facilities for the treatment and care of people with 
Alzheimer’s disease and the government is poorly aware of the magnitude of this 
problem and is thus unprepared to deal with the looming dementia epidemic and no 
initiatives have yet been taken to develop early diagnostic and prevention programs to 
combat the consequence of this devastating disease.   
AD was first described in 1907 by Alois Alzheimer, a German physician who described 
the neuropathology in the brain of a 51 year old woman named Augusta D. After her 
death, an autopsy revealed dense deposits outside and around nerve cells in her brain, 
and twisted strands of fibre inside dead neurons, which were later known as 
neurofibrillary tangles and neuritic plaques, respectively. AD is characterized clinically 
by the insidious onset and progressive decline of mental functions affecting long-term 
episodic memory (Henderson, 1997). However, AD cannot be definitively diagnosed 
until post-mortem examination of the brain for the neuropathological hallmarks of AD. 
(Mirra et al., 1991). It was later discovered that the major component of neuritic plaques 
is beta amyloid (Aβ), a peptide proteolytically derived from the larger amyloid 





1984; Masters et al., 1985). Although more than a century has passed since Alois 
Alzheimer’s findings and research has been carried out for decades around the world, 
there is still many questions directed at understanding the pathogenesis of  AD and there 
is no effective treatment. 
AD attacks several different regions of the brain including the cerebral cortex, which is 
involved in conscious thought and language; the basal forebrain, which is important in 
memory and learning; and the hippocampus, which is fundamental to memory storage. 
AD can be divided into two forms based on the age of onset, i.e. early onset (EOAD; 
the age of onset before 65 years old) and late onset (LOAD; the age of onset after 65 
years old). EOAD is the more severe form but is less common and accounts for ~5-10% 
of the cases. In some cases, EOAD is caused by autosomal dominant, inherited 
mutations identified in three different genes, the amyloid precursor protein (APP) gene 
(Goate et al., 1991; Murrell et al., 1991), the presenilin-1 (PS1) gene (Sherrington et al., 
1995) and presenilin-2 (PS2) gene (Levy-lahad et al., 1995; Rogaev et al., 1995); and 
characterized by the increased production of Aβ, in particular the longer form and more 
toxic Aβ42 (for review see Kowalska, 2003).  
On the other hand, LOAD is the most common form of the disease, which accounts 
~95% of the cases, and is characterized by several risk factors including age, the 
presence of Apolipoprotein E 4 allele (APOE4) (Strittmatter et al., 1993; Martins et 
al., 1995; Scheuner et al., 1996), brain trauma, diet (i.e. high levels of choleseterol), low 
levels of testosterone and estrogen (Corder et al., 1993; Haskell, Richardson and 
Horwitz, 1997; Short et al., 2001) and more recently increased levels of gonadotropins 
i.e. luteinizing hormone (LH) and follicle stimulating hormone (FSH) (Bowen et al., 
2002; Short et al., 2001 ). 
Each of the major neuropathological hallmarks of AD, namely the senile plaques, 
neurofibrillary tangles, neuronal atrophy or neuronal death, and cerebral amyloid 









Senile plaques (SP) or amyloid plaques are composed of beta amyloid protein (Aβ) in 
the central core surrounded by reactive astrocytes and microglia found in the brain of 
Alzheimer’s disease and normal aging (Figure 1.1). As people get older, from the age of 
60 years, the proportion of the people with plaques increase linearly. In AD, amyloid 
plaques develop in vulnerable regions of the brain, such as hippocampus, which plays 
an important role in the formation of short and long-term memory. Amyloid plaques 
have variable shape and size but are on the average 50µm (Franke, M., 1976). In 
addition, Amyloid plaques also spreads over time in a variety of directions into the 
cerebral cortex, the area that is involved in processing of sensory input and learning 
(Rodgers, 2003). 
According to the amyloid hypothesis (Selkoe,D.J & Hardy,J., 2007) which was 
proposed over 25 years ago, accumulation of beta amyloid in the brain is the primary 
cause of AD pathogenesis. But recently, it is currently unclear whether amyloid plaques 
are actually the primary cause of Alzheimer's disease (AD) or the result of an another 
initiating factor.  Evidence in support of this notion includes the observation that dense 
plaques accumulate with age, even in people who have no cognitive impairment. 
Furthermore, plaques do not correlate with disease severity (Robert,D et al.,1991). In 
addition, Aβ is also deposited in the exterior of neurons in several unrelated disorders. 
 On the other hand, the strongest evidence in support of Aβ playing a key role in the 
onset of AD may be found in the genetic studies of families with autosomal mutations 
that cause AD and are all shown to result in increased production of Aβ.  Interestingly it 
has been suggested that smaller aggregates of Aβ (ie oligomers) and not the amyloid 
plaques per se play the major role in the damaging effect on dendrites (Moolman et al. 
2004;Gandy, S et al., 2010; Selkoe, D.J, 2000). Furthermore, while amyloid plaques per 
se do not correlate with the severity of the disease there is strong evidence to 
demonstrate that soluble Aβ levels, which lead to the development of the amyloid 
plaques do correlate with disease severity.  Additional genetic evidence for the role of 
amyloid in AD is found in patients with Down syndrome (trisomy 21) and it is proven 







Neurofibrillary tangles (NFT) are intracellular lesions composed of abnormal insoluble 
filaments which is paired helical filaments and straight filaments of abnormally 
phosphorylated tau protein accumulates within the neuron  (Goedert et al., 2002). Tau is 
a microtubule associated protein found in neuronal axons throughout the central and 
peripheral nervous systems and to a lesser extent in glial cells. Tau protein is a potent 
promoter of tubulin polymerisation and microtubule stabilisation, thus serving an 
important role of neuronal outgrowth and morphology (Lovestone and McLoughlin, 
2002). There are six isoforms of tau in CNS, differing by possession of N-terminal 
inserts of unknown function and by possession of three or four imperfect repeats that 
bind to microtubules (Goedert et al., 1996). NFTs are found predominantly in neuronal 
cell bodies surrounding SPs. But NFTs also may occur without SPs (Shukla and 
Bridges, 1999). The number and distribution of NFTs shows a moderate correlation 
with the severity of AD (Schonheit et al., 2004). 
The hyperphosporylation of tau has not only been associated with AD but also with a 
number of other neurological diseases such as fronto-temporal dementia, Pick’s disease, 
cortico-based degeneration, and progressive supranuclear palsy (Goedert et al., 2006) 
However, the mechanism that trigger the tau hyperphosporylation are still unclear. 
As mutations in tau give rise to tangles but mutations in APP give rise to both plaques 
and tangles, it follows that Aβ must, biochemically, precede tau pathology in AD. This 
is consistent with the studies on Down’s syndrome brain where it was shown that 
amyloid deposition preceded tangle aggregation REFS. The relative importance of Aβ 
deposition and neurofibrillary tangles in the onset of dementia in AD has been a subject 
of intense debate between amyloid and tau proponents, known as “baptists” and 
“tauists” respectively (Hardy and Selkoe, 2002). However, recently there are some in 
vitro and in vivo findings which suggested that both Aβ and tau play important roles in 









Figure 1.1 : Senile plaque and neurofibrillary tangle. Image courtesy of 
www.maryjosephfoundation.blogspot.com 
 
Cerebral amyloid angiopathy (CAA) 
Cerebral amyloid angiopathy (CAA) is an accumulation of amyloid in cerebral and 
meningeal blood vessels. CAA is observed in more than 80% of AD brains (Attems et 
al., 2007). However, some level of CAA can also be found in the brains of non-
demented elderly. There is now considerable evidence that  CAA is a major factor in the 
pathogenesis of AD (Fryer et al., 2005; Martins et al., 2006 (Maia et al., 2007) 
 
1.2.1 Aβ and Alzheimer’s disease 
 Aβ  is the major protein component of neuritic plaques in the brain of AD patients.  Aβ, 
a 4kDa small oligopeptide, is generated from the proteolytic processing of its much 
larger, 100-130 kDa parent molecule, the amyloid precursor protein (APP) (Glenner and 
Wong, 1984, Masters et al., 1985), the gene for which is located on chromosomes 21, 
expressed in brain and in several peripheral tissues such as testis, ovary, liver, kidney, 





Bates et al., 2009). Aβ which  varies in length from 39 to 42 residues is not the result of 
abnormal or pathological APP processing, as was originally believed, but it is secreted 
constitutively by normal cells in culture (Haas et al., 1992; Shoji et al., 1992) and can 
be detected in plasma and CSF of healthy humans (Seubert et al., 1992). 
 
 Aβ generated in intracellular organelles can be secreted into the extracellular space. 
The most common isoforms are Aβ40 and Aβ42; the shorter form is typically produced 
by cleavage that occurs in the endoplasmic reticulum, while the longer form is produced 
by cleavage in the trans-Golgi network. The Aβ40 form is the more common of the two, 
but Aβ42 is the more fibrillogenic and is thus associated with disease states. The major 
species of secreted Aβ is the soluble Aβ40 found in the CSF at low nano-molar 
concentrations (Vigo-Pelfrey, et al., 1993).  Although Aβ is soluble in biological fluids 
and tissue at physiological concentrations (Mulnard et al., 2000 ; Shumaker et al., 
2003),  at higher concentrations it aggregates to form extracellular deposits found in AD 
plaque (Lenner and Wong, 1988) . Aβ42 is dominantly found in amyloid plaques of AD 
brains and is thought to seed the deposition of Aβ40. These amyloidogenic proteins 
have characteristics such as being insoluble in water and having a high β-sheet 
secondary structure that is associated with a tendency to aggregate or polymerize. 
Ultrastructurally the deposits are mainly fibrillar and show characteristic apple-green 
birefringence when viewed under polarized light after Congo red staining (Asami-
Odaka et al., 1995; Wisniewski, and Frangione, 1992; Goodenough, Engert and Behl, 
2000).  
Aβ is secreted from CNS into the extracellular space via transport through the blood-
brain barrier (BBB) and/or via the ISF bulk flow, allowing its detection in the CSF and 
plasma (for review see Zlokovic, 2004) and its oligomers are stable molecules that can 
exist for long periods in the brain prior to conversion to fibrillar structures (Chromy, et 
al., 2003). It is of particular interest to understand which form of Aβ is toxic to neurons. 
A study by Dodart et al., 1999  showed that it is not the number or the concentration of 
Aβ plaques that predict the extent of memory deficits but the levels of soluble Aβ 
peptides. In addition, soluble Aβ peptide are also implicated in spatial learning deficits 





The fundamental mechanisms underlying the neuronal toxicity of Aβ are complex and 
not well understood yet. Aβ toxicity may be induced by two proposed pathways : the 
first pathway implies that Aβ directly causes injury to the cell by membrane damage 
(Mark, et al., 1997) while in the second pathway  Aβ acts indirectly by enhancing 
neuronal vulnerability to neurotoxic insults, such as excitotoxicity, hypoglycaemia, 
oxidative stress or metabolic impairment (Arias et al., 2002; Matson et al., 1992). These 
different pathways may result from the action of different forms of Aβ. This is 
consistent with not only the  aggregated forms of Aβ being neurotoxic (Lorenzo, et al., 
1994),  but also the overwhelming evidence in support of soluble oligomeric forms 
being neurotoxic (Roher, et al., 1996; Etcheberrigaray, E et al., 1994,  Walsh et al., 
2002; Wang et al., 2002). 
Aβ not only possesses neurotoxic properties but is also shown under specified 
conditions to exhibit neurotrophic properties (Rismann et al., 2002). Aβ is not toxic to 
undifferentiated neurons regulated by cyclin dependent kinase 5 (Cdk-5) but toxic to 
differentiated neurons  (Koo, et al., 1993; Koo et al., 1994). In addition, recent findings 
by Verdile et al (personal communication) indicates that Aβ production increases only 
in the late event of the neuronal cell cycle. 
 
 
1.2.2 The Amyloid Precursor Protein (APP) 
 
APP is an integral membrane protein, with a small intracellular domain and a large 
extracellular domain; it is hypothesized that the extracellular domain mediates cell-cell 
signalling, while the intracellular domain relays those signals to the rest of the cell. APP 
has an important role in helping neurons grow and survive and also may help damaged 
neurons repair themselves, especially after brain injury (Rodgers, 2003). It also plays a 
role in cell adhesion, apoptosis, cell signalling, and as a cell surface receptor (for review 
see Zheng and Koo, 2006). APP is widely expressed in cells throughout the body where 
the amount produced is influenced by the developmental and physiological state of the 





isoforms APP 695 is the most abundant form in the brain, produced mainly by neurons 
(Matson, M.P., 1997).  
 
The generation of Aß from APP is complex, as the APP protein is cleaved several times 
in the cell. APP is normally cleaved by three secretase genes, called α, β, or γ-
secretase.The proteolytic cleavage of APP, a type I transmembrane protein, is 
metabolized by two competing  pathways which are the amyloidogenic and the non-
amyloidogenic pathways (Figure 1.2). In the non-amyloidogenic pathway, APP is 
processed by an α-secretase that cleaves within the Aβ region (thus precluding its 
formation), resulting in the release of a soluble ~110–120 kDa N-terminal APP 
fragment (sAPPα) from the cell surface. This pathway also releases a C-terminal 
fragment (CTF) that is 83 amino acids in length (C83) which remains in the cell 
membrane with a relative long half life and can be detected to different extents in 
metabolically labelled cells (Oltersdorf et al., 1990). The C83 fragment can also be 
cleaved by a γ-secretase to release a small, non-toxic 3 kDa fragment known as p3.  
(Siman, R., Mistretta, S., Durkin, J.T., et al., 1993).  Cleavage  of APP by α-secretase is 
the major proteolytic pathway, and there are candidates for α-secretase such as 
ADAM10, ADAM17, ADAM 19, and TACE (Sangram, S.S et al., 2007). Although 
recent studies suggest that the constitutively active α- secretase is ADAM 10 
(Lichtenthaler, 2011).Only a small fraction of the total APP is cleaved by α-secretase in 
most cell types, resulting in the intact of APP (Strooper and Annaert, 2000). Cholesterol 
is thought to modulate the APP processing pathways. When cholesterol levels are low 
APP is preferentially metabolized via the non-amyloidogenic pathway where it is 
cleaved by α-secretase  whilst at high cholesterol levels  APP is metabolized by β-
secretase (BACE) and γ-secretase through the amyloidogenic pathway   (Kojro, E et al., 
2001).; Ian, J.M et al., 2009). 
In the amyloidogenic pathway, APP is cleaved first at the N-terminus of the Aβ peptide 
sequence by β-secretase (BACE) releasing an APPβ fragment and leaving a 99 amino 
acid CTF  embedded in  the membrane (C99). The C99 fragment is then subsequently 
cleaved by  γ-secretase, within its intra-membrane region to release the Aβ peptide and 
AICD . The result is the generation of Aβ40 and Aβ42. BACE has been identified as the 





aspartyl proteases (Vassar, R et al., 1999). The BACE-1 protein appears to be the major 
enzyme in the amyloidogenic pathway and is highly expressed in neurons (Fluhrer, R et 
al., 2002).  
γ-secretase is a protein complex within the lipid bilayer that cleaves within one of the 
transmembran regions of the APP, which is the C-terminal end of the Aβ sequence and 
it is formed by presenilins (PS), nicastrin, Aph-1 and Pen-2 (Francis, R et al., 2002). 
The participation of PS in the pathogenesis of AD can be seen in many cases of familiar 
AD (FAD) (see review of Davis, J.N et al., 1997). The cellular sites of γ-secretase 
activity remain controversial. Study by Kaether et al., 2006 found that intracellular 




Figure 1.2 :  Schematic representation of APP processing. The proteolytic cleavage 







Changes in the activity of the secretase proteins can impact on Aβ genesis. If α-
secretase activity decreases, or β-secretase activity increases, more Aβ will be formed. 
As expected, several mutations in these secretases have been found in human AD 
patients that affect secretase activity. In addition, mutations in APP itself can favor the 
generation of the  Aβ42 product, which is more pathogenic than the Aβ40 product. 
Interestingly, α and γ cleavage appears to occur extracellularly, while  BACE and γ 
cleavage occurs entirely in the endosomal-lysosomal compartment (Kaether et al., 
2006). Some studies also show that the mis-sense mutations in PS1 and PS2 genes, 
which can often be found in families with early onset AD, result in the increased 
production of Aβ42 peptide as opposed to the less amyloidogenic Aβ40 form of the 
peptide (Selkoe, 1998). In the Alzheimer’s Disease & Frontotemporal Dementia 
Mutation Database by July there are 25 pathogenic mutations in APP, 155 in PS1, and 
10 in PS2 (Cruts and Rademarkers, 2006; http://www.molgen.ua.ac.be/ADMutations/). 
 
 1.3 ApoE and Alzheimer’s disease 
Human apolipoprotein E (apoE [protein], APOE [gene]) is located on the long arm of 
chromosome 19q 13.2 ( Olaisen, Teisberg and Gedde-Dahl, 1982; Das et al., 1985; 
Strittmatter et al., 1993) with a molecular mass 34.2 kDa and is synthesized mainly in 
the liver, and the brain, as well as circulating  cells  including macrophages and 
monocytes (Siest, G, et al., 1995). ApoE plays an important role in the periphery as a 
mediator of lipoprotein metabolism and lipid clearance. In the central nervous system its 
importance is underscored by the low abundance of other apolipoproteins and plays a 
role in the redistribution of lipid and cholesterol during membrane repair and believed 
to be important for maintaining synaptic plasticity especially after neuronal injury. One 
of the first indication that apoE might be involved in AD came from the 
immunochemical localization of apoE in extracellular amyloid plaques and in neurons 
containing neurofibrillary tangles (Wisniewski, T et al.,1992). 
ApoE serves as a ligand for low density lipoprotein receptor (LDLR and LDLRP). The 
three major isoforms of APOE : E2, E3, and E4, are encoded by distinct alleles ε2, ε3, 
and ε4 and therefore have six phenotypes (Utermann et al., 1980); Zannis et al., 1982. 





158 and vary in their metabolic properties (Mahley, 1988). ApoE2 (Cys112, Cys158) 
binds defectively to low density lipoprotein (LDL) receptors. ApoE3 (Cys112, Arg158) 
binds normally to LDL receptors and is associated with normal lipid metabolism. 
ApoE4 (Arg112, Arg158) has a relative stronger affinity than apoE3 for LDL receptors 
and is associated with elevated cholesterol levels ( for review see Raber, 2004). This 
isoform was first shown to be a risk factor and an increased risk for AD since 1993 
(Strittmatter et al., 1993), enhanced Aβ aggregation, increased Aβ deposition, and 
reduces Aβ clearance (Schemechel, D.E et al., 1993; Berr, C et al., 1994), whereas 
APOE2 has a protective effect (Corder et al., 1993) compared to APOE3 (the most 
common isoform).  
Since it was reported that the apoEε4 allele is overpresented in AD patients, 
(Strittmatter et al., 1993) several studies have examined the relation of apoE alleles to 
AD pathology. Studies have shown that apoE associates with high avidity to soluble A 
(Wisniewski et al., 1993; Raber et al., 2004). ApoE is also known to co-localise with 
A plaques (Holtzman, 2002), and APOE 4 is associated with increased plaque density 
and size (Schmechel et al., 1993; Holtzman, 2002). In clinical studies of AD, 
testosterone levels in subjects without the APOE 4 allele were lower in AD cases than 
in controls (Hogervorst et al., 2002). This study also found that cognitively normal 
APOE 4 carriers had lower testosterone levels than individuals without the allele 
(Hogervorst et al., 2002), suggesting that APOE status can affect testosterone levels.  
The mechanism whereby apoE4 promotes AD is not yet established, perhaps by 
accelerating plaque formation or by its association with poor neuronal repair. 
Considerable evidence supports both mechanisms. In vitro study showed all apoE 
isoforms inhibit Aβ aggregation with apoE4 less effectively than apoE3 (Ma et al., 
1994, Moir et al., 1999, Sanan et al., 1994), suggesting a way in which ε4 may increase 
amyloid deposition. In addition, transgenic amyloid-producing mice expressing apoE4 
develop less Aβ deposition than apoE knockout mice (Bales et al., 1997). These 
observations consistent with an effect of apoE isoforms on Aβ aggregation in AD. AD 
patients with at least one ε4 allele tend to have more amyloid deposition than do 





With regard to AD development, the effect of APOE ε4 while dose-dependent, in terms 
of increased risk is not definitely deterministic of developing AD. (Corder, E.H et al., 
1993). At present, the exact mechanism by which APOE ε4 affects the pathophysiology 
of AD is not clear. 
Plasma apoE is primarily derived from liver parenchymal cells and from macrophages 
throughout the body (in a much lesser extent) whilst apoE in the CNS is known to be 
derived exclusively from the brain (Linton, M.F et al., 1991). According to several 
studies, Aβ is directly bound by apoE as demonstrated in vitro (Whittemore, E. R., Loo, 
D. T. and Cotman, C. R, 1994; Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., et 
al.,1993; Wisniewski, T, Frangione, B,1993) and has been shown to co-localize with Aβ 
in AD plaques (Wisniewski, T. and Frangione, B, 1992; Namba, Y., Tomonaga, M., 
Kawasaki, H., Otomo, E. and Ikeda, K, 1991). There are conflicting reports over the 
effects of apoE isoform specific differences on interactions with Aβ. Strittmater et al., 
1993 reported that apoE4 binds Aβ40 more rapidly than apoE3. In contrast, LaDu et al., 
1995 reported the opposite binding preference of apoE in HeK-293 cells, with an 
apoE3-Aβ40 complex occuring more readily than the apoE4-Aβ40 complex over a wide 
pH and concentration range. Subsequent studies by several groups including our own 
have validated and extended the finds of LaDu et al demonstrating that apoE2 and 
apoE3 binds avidly to Aβ  while apoE4 binds poorly if at all under native conditions 
where apoE is fully lipidated unlike the original experiments of Strittmater et al.,1993 
Though many studies have examined the relation of ε4 to AD pathology, the exact role 
of of apoE is yet to be elucidated.  
 
It is not yet known whether different isoforms of apoE have different clearance 
activities. One of the expectations is that apoE4 may have a significantly reduced 
clearance activity when compared to others apoE isoforms. Yang et al., 1993 first 
demonstrated that under in vitro conditions apoE cleared Aβ in an isoform specific 
manner such apoE2 was most efficient in clearing Aβ followed by apoE3 with apoE4 
showing virtually no clearance. Subsequently Sharman et al., 2010 shows that APOE 
genotype significantly altered the peripheral clearance of Aβ42 in transgenic mice. , 






1.3.1 Cholesterol and Alzheimer’s Disease 
The brain must synthesize its own cholesterol de novo, since cholesterol cannot pass the 
BBB (Papadopoulos, 1993; Bjorkhem et al.,2006). Therefore, regulation of cholesterol 
synthesis and metabolism in the brain is largely independent of changes in the periphery 
(Bjorkhem et al., 2006). Nevertheless, there is increasing evidence from clinical, 
epidemiological, and laboratory studies showing that changes in cholesterol metabolism 
play a role in the pathogenesis of AD and that brain cholesterol as well as plasma 
cholesterol metabolites may act as clinically relevant biomarkers (Bjorkhem et al., 
2006). 
Cholesterol metabolism also appears to play an important role in the biology of APP 
and Aβ production (Simons et al., 1998). Interestingly, elevated plasma cholesterol 
levels were reported in individuals carrying APOE4 (Sing and Davignon, 1985; 
Ehnholm et al., 1986), which is the major genetic risk factor for AD (Corder et al., 
1993; Poirier et al., 1993). However, Wolozin et al., 2006  concluded that the link 
between AD and APOE4 was not directly related to cholesterol but the overall literature 
indicates a close relationship between apoE4, cholesterol metabolism and the risk of 
AD. In conclusion, AD may represent an interaction between several different factors 
that together, contribute to its ultimate phenotype. More recently sex hormones such as 
testosterone have been shown to alter Aβ production and mediate alterations in 
cardiovascular risk factors particularly cholesterol metablolism. The following section 
outlines age-related changes in testosterone and gonadatropins and describes  
mechanisms by which these hormones contribute to AD pathogenesis. 
 
 1.4 Testosterone and its role in Alzheimer’s disease risk and pathogenesis. 
 1.4.1 Testosterone  
Testosterone is the predominant androgen in males. Though its a hormone originally 
associated with the modulation of reproductive function and secondary sexual 
characteristics, testosterone is now recognized to also have a potent function in the 
structure and function of the brain as well as behaviour and cognitive function. More 





2500 mg each year. The normal range of plasma testosterone in males is debateable 
(Carruthers et al, 2007), and varies between populations, but is generally taken to be 
260 to 1080 ng/dl2 or 8.8-36.7 nmol/L  which declines by age 80 to 50% of the average 
value of age 20. In females, the circulating testosterone levels are typically about 10% 
of those observed in men (Coffey, 1988).  
 
 
Figure 1.3 : Male Hypothalamus-Pituitary-Gonadal (HPG) Axis  
(http://www.homefertility.comhypothalamus.jpg) 
 
In the normal male, testosterone is produced as follows (Figure 1.3). Gonadotropin-
releasing hormone (GnRH) is secreted from the hypothalamus. This hormone acts on  
the pituitary to secrete Luteinizing hormone (LH) and Follicle-stimulating hormone 
(FSH). LH then stimulates the testicular Leydig cells to produce testosterone in a 
pulsatile manner with a peak in the morning and lowest level in the evening. 





FSH stimulates the testicular Sertoli cells and seminiferous tubules to promote 
spermatogenesis. A Sertoli cell produced hormone to reduce FSH secretion known as 
inhibin. Testosterone production increases rapidly at the onset of puberty, but starts to 
drop as a man approaches 30 years of age. This is further discussed  discussed in section  
1.4.3  
In young males, testosterone acts on a number of other organ systems besides the testes,  
including muscle, bone, central nervous system, prostate, bone marrow, (see review of 
Tenover J.L, 1994). Testosterone  within the bloodstream occurs in two forms : free and 
bound. Roughly 2% of total testosterone is made up of free testosterone, which is the 
most  bioavailable form, and can be transported across the BBB into the CNS . The 
majority is  bound to sex hormone-binding globulin or SHBG (44%) and albumin (44%) 
(Bates et al., 2005). Free testosterone diffuses passively through the cell membranes 
into the target cell, where it binds to the specific androgen receptor (AR). The serum 
free testosterone and the testosterone that binds to albumin are readily available for 
biological action. As a matter of fact, albumin-bound testosterone dissociates during 
tissue transit, whereas the strong binding of testosterone to SHBG will usually not allow 
for substantial dissociation during the tissue transit time (Tenover J.L, 1994). The 
combined free and albumin-bound testosterone (the non-SHBG bound testosterone) is 
often reffered to as the “bioavailable testosterone”. However, the testosterone that is 
actually available for biological action may vary according to the tissue and 
pathophysiological condition, and at present a reliable androgen marker is still lacking.  
Although testosterone binds to the nuclear AR in target cells, its activity is significantly 
less than the more active androgen, dhydrotestosterone (DHT), and is not included in  
the fraction of testosterone which can be aromatized into estradiol in tissues expressing 
P450 aromatase enzyme. Hence, testosterone activity is determined by testosterone 
concentrations, α-reductase and aromatase activity in the amount of available tissue 
such as adipose tissue that converts it to estrogen, together with the level of  expressions 
of the androgen receptor (AR) (Janowsky, J.S, 2006). 
Male aging is associated with a gradual, progressive decline in serum levels of total 
testosterone, bioavailable testosterone, and free testosterone in an approximate 1% 





or 40 years and above, total, bioavailable and free testosterone concentrations fall with 
increasing age with a steeper decline in bioavailable and free testosterone compared 
with total testosterone concentrations ( Harman et al., 2001; Feldman, H.A, 2002; Liu et 
al., 2007). 
Androgen receptors (AR) are found in brain regions involved in memory and cognition, 
particularly the hippocampus and the frontal regions. The hippocampus has been 
studied extensively as it is vulnerable to the course of aging and essential to successful 
spatial navigation performance in animals and humans (see review Driscoll et al., 
2005). The hippocampus is a target structure for gonadal steroids with a relatively high 
concentration of androgen receptors, suggesting a likely relationship between AR and 
hippocampus-dependent cognition. 
 
1.4.2 Testosterone synthesis (Steroidogenesis). 
The conversion of cholesterol into androgens takes place in Leydig cells. Although 
Leydig cells are of major importance for the generation of circulating androgenic 
hormones, the adrenal cortex also contributes to this production. The production of 
steroids (steroidogenesis) is not limited to endocrine glands only, but in very small 
amounts can also be produced in brain cells (Baulieu, 1997). Although the contribution 
of cells in the nervous system to circulating hormone is very small, local production of 
steroids can be physiologically very important (King et al., 2002) especially when 
transport and clearance are low. 
The initial step in steroidogenesis is the conversion of cholesterol to pregnenolone 
(PREG) on the inner mitochondrial membrane by the enzyme cytochrome P450 side 
chain cleavage (P450scc). The amount of P450scc protein can be regulated directly by 
hormone-dependent phosphorylation. When the amount of P450scc is constant, 
cholesterol is being transferred from the outer mitochondrial membrane to the inner 
mitochondrial membrane, which is deficient in cholesterol. And then PREG converted 
to progesterone (PROG), which is the first biologically important steroid in the 
pathway, by the enzyme 3β-hydroxysteroid dehydrogenase-isomerase (3β-HSD) in the 





P450c17 is a key branching point in steroid hormone synthesis, directing pregnenolone 
towards the sex steroids (both hydroxylation and cleavage activities of the enzyme), the 
glucocorticoids (only hydroxylation) or the mineralocorticoids, if neither of the enzyme 
activities is participating The former pathway results in the synthesis of of PROG and 
PROG metabolites. The latter pathways results in the formation of testosterone via 
conversion of andronestedione by 17β-HSD. Testosterone can in turn be converted into 
estradiol via the enzyme P450 aromatase (Figure 1.4). 
 
Figure 1.4 : Steroid hormone synthesis pathways in CNS. All steroid hormones are 
synthesized from cholesterol and the end products can be classified according to their 
principal effects; mineralocorticoids (aldosterone), glucocorticoids (cortisol in human, 
corticosterone in rodents), progestins, androgens and estrogens 
(http://herkules.oulu.fi/isbn951426844X/html/graphic99.png). 
 
Brain steroid synthesis proceeds in the following manner. First, glutamate is released 





influx drives STAR or peripheral benzodiazepine receptor (Papadopoulos, 1993) to 
transport the cholesterol to the mitochondria. The following process of steroidogenesis 
is similar to that in Leydig cells.  
1.4.3 Testosterone and Aging 
 
Age-related changes occur in numerous physiological systems.  Research indicates that 
in both human and non-human animals gonadal function is compromised in aged 
individuals. Unlike the marked changes in the sex hormones that accompany 
menopause in females, the analogous process in males, termed andropause or partial 
androgen deficiency in the aging male (PADAM), is characterized by a subtle and 
generally gradual decline in circulating testosterone levels.  It has been estimated that 
testosterone levels decrease on average at a rate of 1% yearly after 30 years of age ( 
(Rajfer, Jacob,2003) but with variations between individuals and reflecting their state of 
health. This reduction in hormone levels has a number of physiological and 
psychological effects. It can manifest in the aging male as sexual dysfunction, loss of 
muscle and bone mass, increased frailty, depression, and cognitive impairment (Bates et 
al., 2005). Eventually, it will lead to an increased risk of developing AD. It has been 
reported that the primary site of decreasing testosterone in aging is its biosynthesis in 
Leydig cells ( Rajfer, Jacob, 2003). The rate limiting step of testosterone biosynthesis is 
transfer of the cholesterol to the inner membrane of mitochondria to start the 
steroidogenic process as mentioned above. 
In a recent study by Thilers and colleagues (1995), a significant correlation between 
circulating testosterone levels and cognitive function in aged man was found. Lower 
testosterone levels were related to reduced cognitive performance. Low levels of 
testosterone may also be associated with AD where lower free testosterone levels are 
observed when compared to age-matched controls (Hogervorst et al., 2004). In addition, 
blood plasma testosterone levels from a large longitudinal study of men age 32-87 years 
has shown that low free testosterone levels can be detected 5 years prior to AD 
diagnosis (Moffat et al., 2004). However, Geerlings et al., 2006 showed that 
endogenous testosterone levels were not associated with risk for cognitive decline in a 






In order to elucidate the relationship between circulating levels of testosterone and 
cognition in aging men, the understanding of bioavailable testosterone and total 
testosterone in plasma or serum was needed. There is a curvilinear relationship observed 
between sex steroid levels and cognitive functions (see review by Bates et al., 2005). 
Studies in humans concerning the relationship between endogenous androgen levels and 
cognitive performance have produced inconsistent results, although there do exist 
striking sex differences in spatial abilities (Kimura, D., 1996). These inconsistent results 
could be explained in part by the fact that each study employed different preparations 
and doses of testosterone, and participants were treated for various durations, and the 
selection criteria for each target population was different. 
The relationships between aging and a decline of sex steroid levels remains to be fully 
elucidated, particularly when it applies to age-related disorders  such as AD and the 
effects in the brain, an androgen-responsive tissue. Evidence indicates that the brain is a 
steroidogenic organ, with the ability to synthesize steroid hormones from cholesterol. 
The steroids produced in the brain and accumulate in the nervous system are termed 
neurosteroids (Mellon, S.H et al., 2001; Plassart-Schiess E. and Baulieu E.E, 2001). In 
the brain, testosterone can be metabolized to dhydrotestosterone (DHT) and bind to 
androgen receptors (AR). Or it can be converted to estradiol by the enzyme aromatase. 
Both androgen receptor (AR) and aromatase are found in regions of the brain involved 
in memory and learning, including the hippocampus and amygdala (Janowsky, J.S, 
2006; McEwan,I.J, 2004).  
Testosterone inhibits generation of Aβ in the rat brain (Ramsden, M, 2003), reduces Aβ-
induced neurotoxicity in culture (Pike, C.J., 2001), prevents hyperphosphorylation of 
tau (Papasozomenos, S.C, and Shanavas, A, 2002), and protects against oxidative stress 
(Ahlbom, E, et al., 2001). Moreover, testosterone supplementation in aged rats reduces 
glial fibrillary acidic protein (GFAP) expression (Day, J.R., 1998) commonly observed 
in the aging brain in association with inflammatory cytokine. Gouras and colleagues, 
2000   showed that treating cells with testosterone  reduced Aβ  secretion by promoting 
the non-amyloidogenic processing of APP and stimulating the production of αAPPs, 
which has been shown to have neurotrophic and neuroprotective properties   These  in 





the aging organism and some mechanisms by which testosterone may exert its effects 
on the brain. 
 
1.4.3.1 Testosterone replacement therapy 
The earliest study of hormone replacement therapy (HRT) and Alzheimer’s disease was 
published in 1984 by Heyman et al. Previous epidemiological studies concerning 
gender differences in AD have often resulted in conflicting data (Fratiglioni et al, 1997; 
Letteneur et al., 1994), yet most studies support the high prevalence and incidence for 
AD in women (McGonigal et al., 1993 ; Rocca et al, 1991). Because of this gender-
specific reason for AD and not to other dementias, research has been going on in 
focusing on the role of sex steroids estrogen and testosterone in the pathogenesis of the 
disease. In contrast to the considerable work done on estrogen replacement therapy 
(ERT), clinical trials with testosterone replacement therapy (TRT) for AD have been 
relatively scarce and these studies involved small samples of participants.  
 The relationships between aging and lower testosterone levels have led to increased 
interest in the use of TRT with the aim of delaying the aging process. TRT has been 
shown to be effective and beneficial for andropausal men (Matsumoto, A.M.2002; 
Matsumoto, A.M.2003; Gruenewald, D.A, Matsumoto, A.M. 2003). In addition TRT 
has the ability to increase bone density, muscle strength and lean body mass in 
hypogonadal man (Thilers, PP et al., 2006).It has also been reported that aged man 
receiving TRT exhibited increased  muscle mass and strength and improvements in 
cognitive performance (reviewed in Cherrier, MM, 200; Morley, J.E., 2000; Tenover, 
J.S., 1992). Furthermore, an emerging area of research demonstrates that low levels of 
androgen may play a role in the onset and progression of AD (Rosario, E.R et al., 2004; 
Moffat, S.D et.al., 2004).  
Despite nearly a half century of research on aging and sex steroids in men, answers to 
key questions that would allow us to confidently assess risk to benefit ratios for 
testosterone replacement in older men with hypogonadism remain uncertain. Although 
it is now reasonably clear that a significant percentage of healthy older man have 





this change remain uncertain. Testosterone replacement therapy which is approved by 
FDA as a treatment for male hypogonadism, has been found to be effective in 
ameliorating a number of  symptoms associated with low testosterone. However, there 
have been fewer studies, particularly placebo controlled randomized trials, in population 
of middle aged or older men who do not meet all the clinical diagnostic criteria. 
Furthermore, studies of testosterone therapy in older men generally have been of short 
duration, involving only a small number of participants, and often lacking adequate 
controls. In its review from the literature Free Executive Summary about testosterone 
and aging : clinical research directions, 2004, the reviewers identified only 31 placebo-
controlled trials of testosterone therapy in older men with the largest sample size 
involved 108 participants and the duration of therapy in 25 of 31 trials was 6 months or 
less. There is only one study placebo-controlled trial lasted longer than a year. 
Studies that have assessed more specific domains of cognitive function in older men 
have produced mixed results. In a long-term longitudinal study, 407 elderly men aged 
50–91 years at baseline were assessed for cognitive status and testosterone levels. Tests 
of cognitive function and behaviour included verbal and visual memory, mental status, 
visuomotor scanning and attention, verbal knowledge/language, visuospatial ability and 
symptoms of depression. Overall, an increased free testosterone index was associated 
with improved scores on visual and verbal memory, visuospatial function and 
visuomotor scanning. There is a strong biological rationale to support the potential 
protective effects of testosterone against the age-related cognitive decline and the 
development of dementia in men. Cognitive impairment has been observed in men with 
prostate cancer undergoing chemical castration, further indicating that testosterone may 
play an important part in cognitive function. Low serum testosterone levels have been 
associated with low performance in cognitive tests and at least one large longitudinal 
study has demonstrated that low testosterone levels are often present up to 10 years 
prior to the onset of AD. In older healthy men, lower levels of endogenous testosterone 
may be associated with poor performance on at least some cognitive tests. Lastly, the 
results of randomized, placebo-controlled studies indicate that testosterone substitution 
may have moderate positive effects on selective cognitive domains in older men with 
and without hypogonadism. Similar results have been found in studies conducted in 





Animal research demonstrated a link between reduction in testosterone levels, the 
production of  Aβ, and the extent of this change is influenced by the APOEε4 genotype. 
As described above, several studies showed a decline in testosterone correlates with 
aging in men. Some researchers proposed a relationship between the development of 
AD and the reductions of testosterone. Should this hypothesis be true, links should exist 
between AD, aging, cognitive decline, and reduction of testosterone  and also between 
testosterone replacement therapy  and cognition in elderly AD men.  
It is well known from the animal literature that the effects of testosterone mediated 
through the androgen receptors are widespread but complex, and as such may have 
specific effects on certain aspects of cognition. However, studies of exogenous 
testosterone administration in men have provided mixed results. Also, there have been 
relatively few studies examining the relationship between sex steroids and cognition in 
older people. Many of the studies are associative in nature. The possibility remains that 
low testosterone levels are an outcome of age-related cognitive decline and AD 
pathology rather than a marker for the disease. It also remains unresolved whether 
normal levels of testosterone are required for optimal performance on gender and age 
sensitive tests, and further whether its effects are direct or occur through the conversion 
of testosterone to dihydrotestosterone or estradiol. Even though most results support the 
facts that testosterone can enhance cognition in older men, much research is needed to 
be done before recommendations for clinical practice can be made. The results, 
although by no means conclusive, indicate a role for testosterone in cognitive 
processing and suggest a further investigation and replication in larger samples. There 
are quite a lot of reviews about the attention that testosterone is gaining in cognition and 
aging research They all recognize that before we can fully understand the 
neurocognitive effects of steroid hormones, it is imperative to characterize the neural 
and cognitive effects of testosterone loss and its subsequent supplementation. Both 
human and non-human animal studies are needed in order to further our understanding 
of the genetic and environmental effects as well as the processes that may be 
influencing variability in behavior and its functional outcome with aging. An important 
feature of animal models of aging and animal models in general, is that they closely 
mimic the characteristics of human conditions and that they are sensitive to individual 





animal research as we enter the decade where it is important to translating the discovery 
power of neuroscience to improve the diagnosis and treatment of mental disorders. 
 
There are lessons to be learned not only from the non-human animal studies but also the 
literature investigating the effects of hormone replacement therapy in women which is 
much more extensive compared to that available on men. Although the Women’s Health 
Initiative Memory Study (WHIMS) (Shumaker, S.A, 2003) was terminated early as it 
seemed  to contradict the previous promising observations regarding HRT and the 
overall health risks were unexpectedly found to outweigh the benefits, this now much 
criticised trial raised awareness regarding the possible role for hormones in aging and 
cognition. Now that estrogen is no longer seen as the silver bullet for AD and age-
related cognitive decline as many had hoped, the focus has shifted somewhat to 
testosterone and the andropause,. But still we have to be aware that although recent 
findings from observational studies and small-scale testosterone trials in elderly men are 
promising, additional studies on a much larger scale are required before any conclusions 
and recommendations for clinical practice can be reached for the use of testosterone in 
preventing or ameliorating  AD. 
 
Information based on clinical trials as mentioned above has added to evidence for 
benefits and side effects of testosterone replacement in hypogonadal patients and animal 
models. In general, most researchers agree with short term safety of testosterone 
replacement therapy but long term safety is still unknown. In this regard, larger long-
term studies are needed. It has been estimated that approximately 5000-10000 men need 
to be randomized and treated for 5-7 years to assess long term safety that if found t be 
successful would serve as a general recommendation for all men (Bhasin, S., 
Buckwalter, J.G, 2001) 
The discussion above outlines the importance of reductions in testosterone in AD risk 
and pathogenesis and the potential of testosterone in ameliorating the cognitive decline 
and neurodegeneration in AD. However, evidence from the original findings of Bowen 
et al., 2000 and Short et al., 2001 and subsequent findings from our lab and others have, 
implicated another hormone within the HPG axis, luteinizing hormone (LH), in AD risk 





AD risk, cognitive impairment  and modulating Ab levels and discuss lowering LH 
levels as a potential therapeutic strategy for AD. 
 
1.4.4 Regulation of testosterone by LH 
The hormones of the hypothalamic–pituitary–gonadal axis include gonadotropin-
releasing hormone, luteinizing hormone (LH), follicle-stimulating hormone, estrogen, 
progesterone, testosterone, activin, inhibin, and follistatin. Each of these hormones is 
involved in regulating reproductive function by participating in a complex feedback 
loop that is initiated by the hypothalamic secretion of gonadotropin-releasing hormone 
(Genazzani et al., 1992). LH and its receptor are present in increased quantities in brain 
regions susceptible to degeneration in AD with the most abundant in hippocampus and 
known to cross the blood-brain barrier (Bowen R.L, Smith M.A, Harris P.L, et al., 
2002). LH is also known to be mitogenic, and could therefore initiate the cell cycle 
abnormalities known to be present in AD-affected neurons. Therefore, it is thought that 
LH plays a role in the pathology of AD. In this regard, there are epidemiological data 
supporting this notion. Paralleling the female predominance for developing AD (Rocca, 
et al.,1991; Jorm, et al.,1987), LH levels are significantly higher in females than males 
(Zandi et al., 2002), in post-menopausal women, and are still higher in individuals who 
have AD ( Short et al., 2001) Like epidemiological data, experimental data also 
indicates a role for LH in AD. In this regards, experiment in cell culture showed that LH 
increases amyloidogenic processing of amyloid beta protein precursor (Bowen et al., 
2004), and in animal models of AD, pharmacologic suppression of LH and FSH reduces 
plaque formation, a selective GnRH agonist (leuprolide acetate) in AβPP transgenic 
mouse has been shown to reduce LH to undetectable levels compared to aged matched 
controls (Casadesus et al., 2006). Given the evidence supporting a pathogenic role for 
LH in AD, a trial of leuprolide acetate, which suppresses LH release, has been initiated 
in patients. A recently completed phase II clinical trial shows stabilization in cognitive 
decline in a subgroup of AD patients 
(http://clinicaltrials.gov/ct/show/nct00076440?orden=6). These promising findings 
support the importance of LH in AD and gives way for an alternative therapeutic 






LH and FSH are required for the development and maintenance of testicular functions. 
LH is the most important hormone for control of Leydig cell functions and number. LH 
acts on Leydig cells via LH receptors. The importance of LH receptor and its functional 
properties has been learned from many studies dealing with receptor’s mutation (see 
review by Themmen and Huhtaniemi 2000  , Ascoli et al., 2002). 
 
Figure 1.5 : GnRH neurons and the hypothalamic-pituitary-gonadal axis. (A) 
Gonadotropin releasing hormone (GnRH) are discharged from hypothalamic central 
nervous system to stimulate the function of gonadotrophs in pituitary gland. (B) The 
HPG axis. In response to gonadotropins (FSH, LH) the gonads synthesize and secrete 
sex steroids (http://www.cellscience.com/Reviews5/Nunemaker5.gif). 
 
Epidemiologic and biochemical evidence suggests that dysregulation of the 
hypothalamic-pituitary-gonadal (HPG) axis with menopause/andropause may be the 
common mechanism driving degenerative changes in the aging brain. This 
dysregulation leads to the decline in the production of sex steroids and inhibin. The 
subsequent loss of negative feedback by these hormones on the hypothalamus and 
pituitary leads to increases in serum activins, increased release of hypothalamic 
gonadotropin releasing hormone (GnRH), and increased synthesis and secretion of 
gonadotropins. The increased secretion of GnRH that results from increased activin 





negative feedback by the sex steroids results in a 3- to 4-fold and a 4- to 18-fold 
increase in the concentrations of serum luteinizing hormone (LH) and follicle-
stimulating hormone (FSH), respectively, in women.  Likewise, men also experience a 
greater than 2-fold, and 3-fold, increase in LH and FSH (Bowen RL, Atwood CS. 
2004). 
 
Experimental studies for the loss of sex steroids in promoting Alzheimer’s disease has 
come primarily from studies demonstrating an increase in Aß deposition following 
menopause/andropause and ovariectomy/castration which suppress the sex steroid 
concentration, and by the influence of sex steroids to the modulation of AßPP 
processing and Aß generation in vitro. Testosterone have also been shown to alter 
neuronal AßPP processing toward the non-amyloidogenic pathway both in vitro and in 
vivo. Testosterone treatment with 200nM to 2000 nM of  mouse neuroblastoma cells 
and rat primary cerebrocortical neurons increased secretion of sAßPPa and decreased 
the secretion of Aß (Gouras GK, Xu H, Gross RS, et al.2000). The same result was also 
observed in human cell lines and primary cultures of rat and human embryonic 
cerebrocortical neurons (Petanceska et al., 2000; Chang et al., 1997). 
 
Recent study by Tianbing Liu et al., 2007 tested whether LH modulate steroid synthesis 
in the brain. The result of this study is LH induces neuronal pregnenolone production by 
modulating the expression of the LH receptor (suppression of serum LH in young rats 
treated with leuprolide acetate for 4 months increased LH receptor in the brain), 
increasing mitochondrial cholesterol transport (increased in the expression of 
steroidogenic acute regulatory protein / STAR), and increasing P450scc-mediated 
cleavage of cholesterol for pregnenolone synthesis. Other hormonal changes in aging 
males report a small increase in LH until age 70 and then increases significantly partly 
due to the reduced responsiveness to GnRH down-regulation. These changes result in 
the loss of the diurnal rhythm variation of testosterone secretion (Morely, J.E, Kaiser, 
F.E et al., 1997  ; Lamberts, S.W et al., 1997). Overall studies suggest that in addition to 
sex steroids, LH also modulates Aβ generation. Taken together the studies mentioned 
above offer significant evidence to indicate a role for LH in neurosteroidogenesis, 
cognitive functioning, and modulating Aβ production. Thus, lowering LH levels using 





1.5 GnRH agonist and antagonists  as a therapeutic strategy for AD. 
1.5.1  GnRH 
The neuropeptide gonadotropin-releasing hormone (GnRH, also referred to as 
luteinizing hormone releasing hormone, LHRH,) serves as both a hormone and a 
neurotransmitter, and it has multiple actions on reproductive physiology and behaviour. 
At least seven different molecular forms of GnRH have evolved, and nearly all 
vertebrates studied express at least two different forms of GnRH: chicken GnRH II, and 
a second form that varies across classes (Muske, E Linda, 1993). GnRH is a small 
decapeptide that plays a role in the connection between the neural and endocrine 
systems. This oligopeptide is synthesized and stored in the medial basal hypothalamus. 
It acts on anterior pituitary gonadotrope cells, which express GnRH receptors, to signal 
both the synthesis and secretion of gonadotropin hormones : luteinizing hormone (LH) 
and follicle stimulating hormone (FSH) into the circulation (Conn, P.M, 1994). 
 
1.5.2 Leuprolide and its effect on LH 
After the discovery of  GnRH  in 1971,  analogs that  have agonistic and antagonistic 
effects have been used widely in experimental and clinical research.  In men, GnRH 
analogs are the most frequently used treatment for locally advanced or metastatic 
prostate cancer ( Frydenberg et al., 2000) . Leuprolide acetate  is the most used GnRH 
agonist compared to the other GnRH agonists such as goserelin, nafarelin, triptorelin, 
histrelin, buserelin, and deslorelin (www.leaddiscovery.co.uk). It is a potent suppressor 
of Luteinizing Hormone (LH) (Ferin, M. et al, 1984; Ravivarapu, Moyer and Dunn, 
2000) and preliminary data has indicated  that it may offer therapeutic benefits against 
AD.  
Leuprolide or leuprolide acetate is a synthetic gonadotropin-releasing hormone agonist 
(GnRH agonist) that has been designed to mimic the actions of GnRH  to improve the 
cognitive function and slow the progression of Alzheimer's disease (AD). It is a potent 
suppressor of Luteinizing Hormone (LH) (Ferin, M. et al, 1984; Ravivarapu, Moyer and 






Figure 1.6 : Chemical structure of leuprolide 
(www.drugs.com/ingredient/leuprolide.html) 
 
In order for suppression of LH to be successful leuprolide needs to be administered 
continuously at a sustained level. Mode of action of this drug is by causing constant 
stimulation of the pituitary GnRH receptors. Short term exposure to leuprolide 
stimulates  production of LH resulting in increased testicular androgen production. 
However long term continuous administration of leuprolide will soon decrease pituitary 
secretion (down-regulation) of  luteinizing hormone (LH) and desensitization of the 
pituitary – gonadal axis, which will be followed by suppression of sex hormone 
production (Chrisp and Sorkin, 1991, Parmar et al., 1990) . Adequate desensitization is 
usually achieved when there is no significant difference between basal and peak LH 
levels in response to exogenous GnRH. This agonist analog is more potent than natural 
GnRH and appears to be capable of occupying pituitary GnRH receptors. This results in 
a "down-regulation" of  receptor activity and gonadotropin release, ultimately 
decreasing serum testosterone levels to those seen following castration. Numerous 
studies have demonstrated the effect of leuprolide on LH suppression. Like other  
GnRH agonists, leuprolide is commonly used to treat hormone related conditions such 
as prostate cancer, breast cancer, and estrogen-dependent conditions (endometriosis and 





 Bowen et al., 2004 showed that LH modulates the processing of AβPP and the 
generation of Aβ. However in castrated or ovarectomised animals following treatment 
with leuprolide acetate decreased brain Aβ was not observed. (Xu, et al., 1998; Gouras, 
G.K et al., 1998). On the other hand suppression of gonadotropins with leuprolide 
acetate has been shown to improve cognitive performance and decreases Aβ deposition 
in transgenic mice carrying the AβPP Swedish mutation (Casadesus, G, Ogawa, O, 
Bowen, R.L, et al., 2003). This results shows us that treatment with leuprolide acetate  
effectively lowered serum levels of the gonadotropins, luteinizing hormone and follicle-
stimulating hormone, through gonadotropin releasing hormone receptor desensitization.. 
Reduction in the levels of these gonadotropins resulted in a 3.5- and 1.5-fold reduction 
in total brain Aβ40  and Aβ42 concentrations, respectively, in C57Bl/6J mice (Bowen et 
al., 2004).  
 Phase II clinical trials conducted by Voyager Pharmaceutical Corporation leuprolide 
treatment showed stabilization in cognitive decline in a subgroup of AD patients.. 
(ALADDIN Study - Phase III, 2007). Basically, female AD patients treated with high 
doses of leuprolide acetate showed stabilization in cognitive function and activities of 
daily living (http://www.secinfo.com/d14D5a.z6483.htp, pages 56-64). Based on the 
above findings   leuprolide acetate is strong candidate for the treatment of AD.  
 
1.5.3 Naltrexone and its effects on LH 
Naltrexone also is a suppressor of LH. However, unlike leuprolide, it is a pure opioid 
antagonist which has a high affinity for opiate receptor sites, that is used for blocking 
effects of opioid agonist promptly and completely (Gauthier and France, 1999),  This 
receptor antagonism  varies between receptor types with the μ-type receptors being most 
selectively antagonized as measured by PET (Lee et al., 1988). Since naltrexone has 
high receptor affinity, it blocks virtually all of the effects of opioids such as heroin. The 
two opioid antagonists most widely used are naltrexone and naloxone. Naltrexone has 
far greater therapeutic usefulness than the other opioid antagonist naloxone. First, unlike 
naloxone which is administered intravenously, naltrexone retains much of its efficacy 
when administered orally. Secondly, the duration of action of naltrexone is more than 
24 hours after moderate  doses, unlike naloxone which has a relatively short half-life 






Figure 1.7 : Chemical structure of  Naltrexone 
(www.drugs.com/ingredient/naltrexone.html) 
 
An opioid is a chemical that works by binding to opioid receptors, which are found 
principally in the central nervous system and the gastrointestinal tract. Opioid peptides 
are found throughout the central nervous system, and have profound effects on neuro-
endocrine function. The widespread occurrence of opioid peptides and their receptors in 
brain and the periphery correlates with a variety of actions elicited by opioid agonists 
and antagonists on hormone secretion. Interestingly opioid receptor antagonists can 
influence attention and memory. Furthermore, according to study by Zubieta, J.K and 
Roberts E, 1999, it has been hypothesised to be potential therapeutic value in  
Alzheimer’s Disease. 
Narcotic drugs and endogenous opiate peptides inhibit the production of luteinizing 
hormone (LH) by the hypothalamic-pituitary axis in the male and female of several 
mammalian species (Azizi, et al., 1973; Mirin, et al., 1976  ; Cicero, T.J et al., 1976; 
Van Vugt, et al., 1983; Grossman et al., 1981). The administration of opiate-receptor 
antagonists alone significantly increase the pulsatile mode of LH release, with increases 
in the frequency and peak amplitude of both immunoactive and biologically active LH 
pulses ( Veldhuis et al., 1983; Delitala et al., 1983; Ellingboe, J et al., 1982). In 





influence either the frequency or the amplitude of the LH pulse. However, whether there 
is any relationship, between these  inhibitory actions of sex steroid hormones and the 
suppressive effects of endogenous opiates is not known. Recent investigations in the rat 
have suggested that endogenous opiates may participate in testosterone and estrogen's 
suppressive effects on LH secretion (Van Vugt, et al., 1983; Leadem, C.A. et al., 1985  
; Cicero, T.J et al., 1979). However, whether functional coupling between these two 
major inhibitory systems exists in man and is integrated specifically via mechanisms 
that control one or more distinct properties of pulsatile LH release has not been 
elucidated. 
 
Several clinical studies of naltrexone effects in women showed that treating women 
with naltrexone restores menstrual cycles in amenorrheic and/or anovultory women 
with high serum LH levels (Lanzone et al., 1993; Genazzani et al., 1995., Remorgida et 
al., 1990; Wildt et al., 1993; Armeanu et al., 1993; Couzinet et al., 1995) . In addition, 
long term  naltrexone treatment in females with polycystic ovary syndrome (PCOS) has 
been shown to reduce the amount of LH released. Furthermore the BMI in obese PCOS 
women were reduced (Fruzzetti et al., 2002), together with insulin levels (Fulghesu et 
al., 1998; Villa et al., 1997).    
Naltrexone also has been used in a small studies to evaluate  its  potential therapeutic 
benefits for AD (Hyman et al., 1985; Pomara et al., 1985; Knopman et al., 1986) 
although with an inconclusive results. However, the major limitations of these earlier 
studies are the very small sample sizes, in each study with 10 or less dementia patients, 
and particularly the short duration of treatment which was usually administered for 2-3 
weeks. Therefore,  in this study,  Naltrexone will be used in order to mimic situations of 
low levels of LH in an in vivo model which will allow us to assess the effect of LH 
levels and testosterone hormone therapy on Aβ production. 
 
1.6 Role of Glia in Hormonal Signalling 
Glial cells are non-neuronal cells that provide support and nutrition, maintain 





Glial cells are classified in two main groups : microglia and macroglia. Microglia is 
macrophage-like cells that play important roles in responses of the brain to injury or 
infection. Macroglia are subdivided in four specialized cell types : ependymal cells, 
Schwann cells, ologodendroglia, and astroglia. Of these cell types astroglia exhibit 
GFAP expression (see review Luis, M., Garcia-Segura, 2004)  
Over the last several decades research has focused largely on the effects of hormones on 
neuronal metabolism, with relatively little attention given to glial cells. Glial cells 
greatly outnumber neurons in the brain, they express many of the genes linked to AD.  
Together with neuronal cells they share expression of a number of hormone receptors. 
These include receptors for melatonin, thyroid, vasopressin, oxytocins, leptin, and 
steroid hormones and likely targets for steroid hormones (Prevot, 2002), and are 
subjected to many of the same environmental conditions as are neurons. Studies of AD 
patients and of animal and cell culture models of AD have demonstrated altered glial 
expression of a number of AD associated proteins.  It is thought that Aβ plays a role in 
inducing many of these alterations (McGeer et al., 2002). 
In AD, activated microglia congregate around the amyloid plaques and degenerating 
neurons and may produce toxins and inflammatory cytokines that contribute to 
neurodegenerative processes (review by Mattson, M.P, 2004). In response to  cytokines 
or other hormones these glial cells produce a number of proteins particularly glial 
fibrillary acidic  protein as well as steroid hormones. For example, the expression of 
glial GFAP is strongly regulated by gonadal hormones in brain areas including the 
hypothalamus and hippocampus, and the promoter region of GFAP gene contains 
hormone responsive elements (HRE) (see overview Cynthia L.Jordan, 1999). Finlay and 
Kritzer, 1999  presented the first in vivo evidence that glia express androgen receptors 
by examining the cortices of adult rhesus monkeys. Several studies also has 
demonstrated that glial cells express steroid and thyroid hormone receptors ( Barakat-
Walter, et al., 1999; Gudino-Cabrera and Nieto-Sampedro, 1999; Garcia-Segura, et al., 
1999; Vardimon, et al., 1999). Given the evidence that glia in the brain express steroid 
receptors, steroid could potentially alter neuronal function by exclusively regulating a 





Integration of hormonal signalling by glial cells occurs in at least two fundamental 
ways. The first is that the hormone acts directly on the glia, which in turn acts on the 
neuron to modulate its function (Garcia-Segura,1999).. The second way is the hormone 
acts first on the neuron, which then releases a substance to target the glia, which then 
presumably signals back to that and other neurons (Garcia-Segura, 1994). 
Garcia-Segura and colleagues were among the first to show that natural fluctuations in 
estrogen levels stimulate a coordinated and dramatic reorganization of synapses and glia 
(Olmos, et al., 1989). For example, in the arcuate nucleus of the hypothalamus, an area 
that is sexually dimorphic in its synaptic connectivity, the pre-ovulatory surge in 
estrogen affects glia to increase their GFAP expression. (Garcia-Segura, 1994). As 
estrogen levels decline, glia withdraw their extended process. Exogenous estrogen 
produces these same effects in ovariectomized adult females. In addition, estrogen does 
not induce similar morphological changes in the arcuate nucleus of adult males 
(Horvarth, et al.,1997). However, it is still not clear whether estrogens act directly on 
glia or neurons to alter synaptic connectivity. Research regarding testosterone effects in 
glia is still lacking and needs to be explored further. 
Several studies show that steroids regulate the reactive state of astrocytes and microglia 
(Garcia-Segura, et al., 1999; Mor, et al., 1999; Nichols, 1999). As reviewed by Nichols, 
1999 activation of astrocytes and microglia is a well-known marker of brain aging. 
Importantly, glial activation associated with normal aging, can occur in the absence of 
neuronal degradation. Nichols found that while adrenalectomy induced a marked 
increase in GFAP gene expression in the brains of non aged rats, adrenalectomy had no 
effect on GFAP gene expression in aged rats. 
In summary, although there is still much to be learned on the role of glial cells in 
neuroendocrine regulation and hormonal signalling, we know that glial cells are able to 
respond to hormonal and neuronal signals and can produce local active hormonal 
metabolites whenever and whereever they are needed under physiological, pathological 






1.7 Summary and project rationale 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive 
memory loss, impairments in behaviour, language and visuo-spatial skills and is 
ultimately fatal. In the majority of cases, AD onset occurs after the age of 65 (late onset) 
and is sporadic in origin. Only approximately 5-10% of cases have a disease onset 
before the age of 65 (early onset). These are often familial forms  but only a few that are 
caused by autosomal dominant mutations in certain AD linked genes. One of the major 
pathological hallmarks of AD is the presence of neuritic plaques in the brain. These 
plaques are formed from the build-up of a peptide known as beta-amyloid (Aβ). There is 
now evidence to show that sex hormones play an important role in reducing Aβ levels 
and so  has the potential to protect individuals against developing the disease. 
Our laboratory was the first to demonstrate clinically that a reduction in testosterone 
levels following chemical castration resulted in increased plasma beta Aβ  levels and 
subsequently showed that in elderly men a decrease in testosterone levels was 
associated with increased plasma abeta levels. However, the question remains whether 
changes in plasma testosterone result in changes in Aβ in the CSF and the brain.  In 
addition, recent research has shown that high levels of the gonadotropin, Luteinizing 
Hormone (LH), are associated with AD and modulate Aβ production. However, the 
relative contribution of LH and testosterone in the pathogenesis of AD remains to be 
elucidated. 
In order to determine whether testosterone modulates Aβ in the brain I have investigated 
the effects of its removal and replacement on the levels of this peptide in castrated male 
guinea pigs. LH was also investigated in this model by either its chemical suppression 
and through implants. 
The efficacy of testosterone on cognition in high risk men by employing a randomized 
placebo controlled double blind study has been assessed and correlated with a number 
of key blood and brain biomarkers. These findings will serve as the basis for the 






1.7.1  Significance of the Study 
This study will  extend our understanding of the role of testosterone on Aβ metabolism 
in an animal model. It will also investigate the potential roles of testosterone and LH on 
Aβ metabolism and AD pathogenesis in a human clinical trial . The outcome of this 
study has the potential to influence the development of an effective  approach for the 
prevention and/or treatment for AD. While there is a high incidence of AD in Indonesia, 
which is double the incidence of AD in Australia, no clinical trials have been conducted 
on AD in the Indonesian population to date. Therefore, the current project will directly 
benefit Indonesia as it will investigate the role of testosterone in the local population. 
Furthermore the findings generated has the potential of benefitting the global 
community world-wide. 
 
1.7.2  Hypotheses 
- LH increases brain Aβ levels in guinea pigs 
- Testosterone regulates blood and brain Aβ levels in guinea pigs 
- Suppression of LH and testosterone decrease brain Aβ levels in guinea pigs 
- Testosterone treatment in men reduces plasma Aβ levels 
 -Testosterone treatment in men improves cognition in vivo 
- Testosterone treatment in men alters brain metabolites  
- Efficacy of Testosterone treatment in men is determined by baseline hippocampal 
volume.   
 
1.7.3  Objectives 
- To investigate whether testosterone regulates blood and brain Aβ levels in guinea pigs 





- To investigate whether suppression of LH and testosterone supplementation alter brain 
Aβ  levels 
- To investigate whether testosterone treatment in men reduces plasma Aβ levels 
 - To investigate whether testosterone treatment in men improves cognition in vivo 
- To investigate whether testosterone treatment in men alters brain metabolites  
- To investigate whether hippocampal volume determines efficacy of testosterone 
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2.1.1  Participants 
The clinical study was undertaken at the Siloam Hospital in Lippo Karawaci, 
Tangerang, Indonesia. Human ethics approval was obtained from the Independent 
Human Ethics Committee, Faculty of Medicine from the University of Indonesia as well 
as Edith Cowan University, Western Australia prior to commencement of the study. The 
participants were recruited from all areas surrounding Jakarta and Tangerang, Indonesia, 
including patients from Siloam  Hospital, Lippo Karawaci, Indonesia and the nursing 
homes from those areas. All participants were screened based on the eligibility criteria 
(details on Chapter 2 Section 2.1.1.1) prior to the commencement of the study. Only 
male subjects who had provided written informed consent and met the eligibility criteria 
were included in either short term study or the long term double blind randomized 
placebo-control clinical trial. 
 
2.1.1.1 Eligibility Criteria 
The following eligibility criteria were used: 1) Male 50 years of age or older; 2) 
Subjects were selected based on their MMSE assessment. A score of 24 or above 
determined eligibility of inclusion in the trial. Final decision of inclusion was 
determined  jointly by a neurologist, neuropsychologist, and the researchers in charge of 
the project; 3 ) Participants must have a testosterone level of less than 300 ng/dL (~10..4 
nmol/L). 4) must have normal range of prostate-specific antigen (PSA), 5) Blood 
pressure must be within normal limits ) must not have diabetes mellitus, 7) must have 
normal liver and kidney enzyme function and 8) must have not suffered from major 
head injury. The screening test, included a testosterone measurement, Mini Mental State 
Examination (MMSE), and clinical interview about subject’s medical record (i.e. 
whether they have had any medication such as donepezil or rivastigmine), were also 
carried out to decide the eligibility of the subjects. All participants in this study had at 






2.1.1.2  Biochemistry Laboratory Tests 
 
2.1.1.2.1 Collection of Samples   
Blood samples collected from participants at each visit using venipuncture  underwent a 
full  blood count performed by the diagnostic laboratory of Siloam  Hospital, Karawaci.. 
Blood samples ( 45 ml) were collected using serum separating tubes (SST) that include 
a gel and blood clot activator), EDTA, and heparin collection tubes. Blood in SST 
collection tubes were centrifuged at 2500 rpm for 10 minutes   to separate the serum. 
The serum was removed, then aliquoted ~ 1ml  to which 10ul (Xug/ml) of protein 
inhibitor  was added (aprotinin - Sigma) was added. Blood in EDTA and heparin 
collection tubes were centrifuged at 1000 rpm for 10 minutes at RT, to separate the 
plasma, leucocytes, and blood.  Plasma was removed and further centrifuged at 2500 
rpm for 10 minutes to harvest platelets. The resulting supernatant (plasma) was 
aliquoted ~ 1-5 ml and 10µl protein inhibitor (aprotinin - Sigma)  was added to each ml 
of plasma.  
The platelets were washed in 5 ml of saline and then centrifuged at 2500 rpm for 10 
minutes, to remove saline. The platelets were resuspended in 200 – 250 µl of saline 
prior to aliquoting to a fresh tube.    
For harvesting leucocytes, whole blood was centrifuged at 2200 rpm for 5 minutes, the 
leucocytes added to another tube with 3-4 ml ice cold Ficoll and centrifuged again at 
1100 rpm for 15 minutes. The Ficoll was removed and leucocytes were washed with 10 
ml of saline (0,9% NaCl) and centrifuged at 2500 rpm for 10 minutes. This step was 
repeated to remove residue Ficoll or plasma . Leucocytes were preserved in 1ml Fetal 
Bovine Serum (FBS – Invitrogen) containing 10% Dimethyl sulfoxide (DMSO - Sigma) 
for APOE genotyping. All blood products were stored at -80oC prior to shipment to 
Perth. Leucocytes were collected for APOE genotyping (see below section 2.1.1.2.2) 
2.1.1.2.2 Blood Biochemistry 
Serum samples underwent a full blood biochemistry at the Path West Diagnostic 
laboratories (Perth, Western Australia) to be measured of the following hormones : LH, 





Lipid profile such as HDL, LDL, triglyceride, and cholesterol levels were also 
performed in plasma heparin samples. Testosterone and DHT levels were measured in 
serum samples by gas chromatography-mass spectrometry (GC-MS) at the ANZAC 
Research Institute, Sydney. Plasma and CSF underwent analysis for Aβ 42 and Aβ 40 
levels using ELISA as described in section 2.2.5 and was performed in Professor 
Martins laboratory. 
 
2.1.1.2.3 APOE genotyping 
 All the leucocytes were thawed and spun at 4,000 rpm for 3 minutes to separate the 
leucocytes pellet from FBS mixture. The pellet was washed in 1ml 0.9% NaCl and spun 
at 4,000 rpm for 3 minutes to remove all the excess FBS mixture. The washing step was 
repeated twice in order to get a clear pellet. The pellet was gently resuspended in 550l 
TES buffer (10mM Tris-HCl, 100mM NaCl, 1mM EDTA, pH 8), then added 60l of 
20% (w/v) SDS and 20l of proteinase-K. The mixture was incubated overnight with 
movement in a 37oC incubator. An equal volume of phenol (~600l) was then added 
into the mixture and mixed. An addition of phenol resulted in cloudy mixture. After 
centrifugation at 13,000 rpm for 8 minutes, the mixture was separated into 3 layers, i.e. 
(from top to bottom): DNA layer, phenol and cell debris at the bottom of the tube. This 
phenol purification step was repeated with 300l phenol to ensure the purification of 
DNA from protein and cellular debris. DNA was transferred into a clean DNAse-free 
tube with 50l of 3M sodium acetate (NaC2H3O2) and 1ml of 100% alcohol (cold) was 
added to the DNA. The DNA mixture was then gently shaken until the white DNA 
thread is visible. After centrifugation at 13,000 rpm for 15-25 minutes. A DNA pellet  
appeared on the bottom of the tube and the supernatant was discarded. One ml of cold 
100% alcohol was then added to the pellet and centrifuged at 13,000rpm for 5 minutes. 
The DNA pellet was then washed with 1ml cold 70% ethanol and spun at 13,000 rpm 
for 5 minutes. The excess 70% ethanol was discarded and the DNA was air-dried for 5 
minutes to totally remove any residual ethanol. DNA-free water (200-300l) was then 
used to resuspend the DNA pellet prior to APOE genotyping. DNA concentration was 
measured using Nanodrop which requires sub-microlitre volumes for assessment at 





APOE genotyping were determined by observing migration patterns of DNA on 
polyacrylamide gels from each individual following PCR. 1.1l DNA was mixed with 
14l of the master mix contains the following: 
Solution 1 reaction 
(l) 
DMSO 1.5 
10x polymerase buffer  1.5 
2mM dNTPs 1.5 
MgCl2 1.2 
Primer 1 (5’ – TCCAAGGAGCTGCAGGCGGCGCA – 3') 1.2 
Primer 2 (5' – GAATTCGCCCCGGCCTGGTACACTGCCA – 3') 1.5 
AmpliTAQ gold 0.075 
ddH20 5.35 
 
One drop of paraffin oil was then added on the top of the mixture to avoid evaporation 
during PCR (polymerase chain reaction). The mixture was then amplified using PCR 
cycle. The first cycle was the initial denaturation (1X), i.e. 94oC – 5min, 65oC – 30sec, 
70oC – 90sec. The cycle was then continued with 35 repetitive cycles, i.e. 94oC – 30sec, 
65oC – 30sec, 70oC – 90sec and finished with the chase cycle (1X), i.e. 94oC – 30sec, 
65oC – 30sec, 70oC – 10min, 4oC – 1min. The PCR products were then digested using 
HhaI enzyme and resulted in restriction fragments which were then separated based on 
their length by gel electrophoresis. The process is known as restriction fragment length 
polymorphism (RFLP) genotyping. HhaI enzyme (New England Biolabs) was diluted in 
NEBuffer4 to 5U/l. Onel of HhaI enzyme was added into each PCR product and 
incubated at 37oC overnight. The digested product was then run in the 8% 
polyacrylamide gel (10ml of 8% acrylamide mixture, 20l of 25% Ammonium 





buffer (1.5gram Ficoll, 0.02gram bromophenol blue, 0.02gram xylene cyanol in 10ml 
TBE buffer) prior to loading. For the DNA marker, 10l of DNA-free water was mixed 
with 2l PUC19 DNA marker and 2l loading buffer. The gels were then 
electrophoresed at 110 Volt for 1.5 hours using TBE buffer (10.8gram Tris-HCl pH 8.3, 
5.5gram boric acid, 0.94gram Ethylenediaminetetraacetic acid (EDTA) in 1 litre of 
ddH2O. The gels were washed in 50ml ddH20 with 1l etidium bromide (EtBr) with 
shaking for 5 minutes. Three washing steps were followed using 50ml ddH20. The 
visualization of the APOE bands was performed under GelDoc BioRad system. 
 
2.1.1.3 Neuropsychological Testing 
 
In the neuropsychological component of the study, the matched groups of participants 
were assessed at three different time points :1)  baseline and treatment period (week 0-
24) 2) washout period (week 24-28) 3) cross-over period (week 28-52), as shown in 
figure 2.2.  The following neuropsychological assessments were implemented: 1) 
MMSE, a simple test to screen for mental impairment for 5-10 minutes , 2) the Rey 
Auditory Verbal Learning Test (RAVLT) for 35-45 minutes_. The application in this 
study of parallel forms of the RAVLT (matched for equal difficulty) ensured that 
retesting could be conducted over time without the memory data being potentially 
confounded by practice effects.  In addition to these cognitive assessment protocols, a 
questionnaire to self-assess the health status of the participant (SF36) was also applied. 
The three related negative emotional states of depression, anxiety and stress were 
assessed using Geriatric Depression Scale (GDS) and Depression, Anxiety and Stress 
Scales (DASS) questionnaires. These questionnaires provided information on the 
emotional states of participants when they underwent the cognitive assessment as 
depression, anxiety and stress have been known to be associated with cognitive status 
(Insel, 2002;Jorm, 2000).  
2.1.1.4 Brain Imaging 
In addition to the medical examination and neuropsychological testing participants also 
underwent brain imaging which included Magnetic Resonance Imaging (MRI) and 





determine whether the use of testosterone therapy is influenced by hippocampal volume 
ie individuals with reduced hippocampal volume may obtain less benefit. For the MRI 
data, we have done the Medial Temporal lobe Atrophy (MTA) scale, starting from 
rating 0 to 4 in which the higher the scores indicate more atrophy (Korf et al., 2004) 
measured by three of our experienced radiologist. All of the MRI imaging data (T1,T2) 
is stored in DICOM format with 7mm thickness slice (TR = 4802, TE=120).  
While MRI uses anatomical images to localize regions of interest with high resolution, 
MRS is a non-invasive, sensitive tool for measuring the concentration of metabolites in 
the brain, such as N-acetyl aspartate (NAA), Myo-inositol (MI), choline (Cho) and 
creatine (Cr) levels (Firbank, 2002)..1H MRS in this study (TR=1500, TE=272) will 
enhance the diagnostic accuracy of MRI and provide additional information of the brain 
metabolites changes, such as NAA, Cho and Cr, which can be seen in the form of a 
graph with specific peaks for each metabolites e.g 2 ppm for NAA (Figure 2.1).  
 
 






We are using two dimensional MR spectroscopy (2D CSI) which enable us to acquire 
multiple small voxels which gives better information to determine the region of interest 
(ROI) and the spectroscopic points. We are using 5 spectroscopic points : 
1) in the right hippocampus  
2) in the left hippocampus  
3) in the right medial temporal lobe  
4) in the left medial temporal lobe  
5) brain area which have normal spectroscopy   
The voxel information from the spectroscopic points can be used to calculate metabolite 
ratios to creatine-containing compounds. The creatine signal is usually stable over time 
and therefore is often used as an internal standard to which other metabolites resonance 
intensities are normalized.Therefore, from this study we would like to determine : 
1) NAA/Cr ratio (which is found to be lowered in AD) 
2) Cho/Cr ratio (which some found to be elevated in AD) 
MRI and MRS were performed on all participants, with or without testosterone 
treatment, three times i.e.: at the beginning (baseline), at the end of the initial 24-week 
treatment period and at the end of the study (see figure 2.2 for the detail), using the 
Gyroscan Intera 1.5T (Phillip Medical System) at Siloam Hospital Karawaci by the 
original team of radiographers following strict standardized procedures MRI image 
acquisition and data handling. 
 
2.1.2 Animal Trial 
2.1.2.1 Animals  and Treatment Groups 
Animal care and experimentation in this study were carried out in accordance with 
ethical guidelines published by NH&MRC (National Health and Medical Research 
Council) Statement on Animal Experimentation and approved by the UWA Animal 






Adult male guinea pigs weighing 500 grams (± 6-8 weeks old) were obtained from the 
BSAU animal care unit at UWA (Perth, WA, Australia). Animals were kept in a 1:1 
light and dark cycle room at the BSAU animal care unit with free access to water and a 
soy-free diet (in order to eliminate any phytoestrogen intake) obtained from Glenforrest 
Stockfeeders (Perth, WA). The composition of soy-free diet were formulated from 
casein (300g/kg), as the protein source, sucrose, glucose and starch, as a carbohydrate 
sources, cellulose (150g/kg) as a fibre source, refined vegetable oils (100g/kg) as lipid 
source and vitamin, and mineral supplements. As guinea pigs can not produce vitamin 
C, a supplementation of vitamin C was also added to their water. Prior to 
experimentation, all the animals were caged for a week in order for them to adapt to the 
environment. 
2.1.2.2 Hormone treatment pellets and the dosage 
The treatment groups are outlined in table 2.1. All the treatments given in guinea pigs 
were in the form of 40-day slow release pellets manufactured by Innovative Research of 
America, USA.  The active ingredients and dosages used in this study are shown in 
table 2.2. 
Table 2.1. The summary of treatment groups 
Treatment Group Administration of 
hormone pellets 
Day of Sacrifice 
Testosterone treatment  Peripherally  18 and 36 days post 
administration of 
testosterone pellets. 
LH treatment  Peripherally and cortical 
placement - brain 
18 and 36 days 
(peripherally); 15 and 28 
days (cortical placement) 






Leuprolide and testosterone 
treatment 
Peripherally 18 and 36 days post 
administration of leuprolide 
and testosterone pellets.   
Naltrexone and testosterone 
treatment 
Peripherally 18 and 36 days post 
administration of 
naltrexone and testosterone 
pellets. 
 
Table 2.2 A summary of all pellet dosages used in the animal study 
Pellets Dosage 
Placebo 20 mg /kg BW/day 
Testosterone 2.5 mg /kg BW/day (Low) 
5 mg /kg BW/day (Medium) 
20 mg /kg BW/day (High) 
Luteinizing Hormone (LH) 2.25 g /kg BW/day 
(~11.25 IU/kg BW/day) 
Leuprolide 0.02 mg /kg BW/day 




All chemicals used in the study, generally, were of the highest purity and purchased 





Ltd (Victoria, Australia) or BioRad (Irvine, California, USA) unless otherwise 
specified.  
2.1.3.2 Antibodies 
The human-specific APP antibody, C1/6.1, directed against the last 20 residues of APP 
was kindly provided by Dr. Paul Matthews (Nathan Kline Institute, NY, USA).  
 
The mouse monoclonal antibody WO2 was kindly provided by Professor Colin Masters 
(University of Melbourne, Vic, Australia). This antibody, is directed against the amino 
acid sequence 5-8 of the human A The 6E10 antibody (Covance) was used as a 
capture antibody for either A40 or A42, and recognizes residues  of the N-terminus of 
A  and R208 as detection antibody (kindly provided by Dr. Pankaj Mehta) . 
 
For detecting GFAP (glial fibrillary acidic protein), the mouse monoclonal GFAP 
antibody (Sigma chemical Co., Missouri, USA) was used. The polyclonal goat apoE 
antibody (Millipore) was used to detect the apoE levels by western blot. The polyclonal 
rabbit anti-cytochrome P450 side chain cleavage enzyme (P450scc – Milipore) was 
used to detect the levels of P450scc neurosteroid enzyme by western blot. The loading 
control protein, actin, was also examined using mouse monoclonal actin antibody 
(Sapphire Bioscience Pty Ltd, Redfern, NSW, Australia). 
 
Two major secondary antibodies were used in this study, a sheep anti-mouse IgG 
horseradish-peroxidase (HRP) antibody (GE Healthcare, Buckinghamshire, UK) and a 








2.2.1 Clinical Study Design 
The testosterone used in the clinical study was applied in the form of a cream 
(Andromen,® 5% Forte) , which was obtain from Lawley Pharmaceuticals (Perth, 
Western Australia).  
Prior to commencing the main “long-term” study, a pilot “short term” study was 
performed to determine the optimal site to apply the testosterone cream.  
 
2.2.1.1 Short-term (Pilot) Human Study  
 
Short-term (Pilot) Human Study 1 
Four male participants were recruited for the pilot study .Before admission of this study, 
the participants were instructed to fast overnight. At admission, the male participants 
were underwent a medical examination [height, weight, and body mass index (BMI) 
were measured]. For this study, the participants were recruited and admitted into 
hospital for a period of 36 hours. The blood sample were drawn at a baseline (time 
zero), 2, 4, 8, 12 hour prior to the application of testosterone cream. Testosterone (100 
mg in the form of Andromen® 5% FORTE cream) was then immediately applied via 
transdermal route (topically). According to the manufacturer’s information, a once off 
daily dose of 100 mg [4 cm applied to the trunk (side of body above hips)] will increase 
serum testosterone concentrations in healthy testosterone deficient men into the mid-
normal range. The participants were bled again at 2, 4, 6, 8, 10, 12, 16, 20 and 24 hours 
post application. The level of serum testosterone and LH were measured for all the 
blood samples taken.  
Short-term (Pilot) Human Study 2 
As the preliminary result of the first pilot study indicated that application of testosterone 
cream on the side of the trunk (above hip) had a variable effect on increasing blood 





(50 mg in the form of Andromen® 5% FORTE cream) was applied on the scrotum to 
maximise the absorption of the testosterone cream on the skin, as this is an area which 
contains minimal body fat, has thin skin and a good blood supply [insert refs].  
The same male participants were instructed to fast overnight and admitted into hospital 
for a period of 28 hours. At admission in the morning, the participants were underwent a 
medical examination [height, weight, and body mass index (BMI) were measured] and 
were bled for a baseline (time zero), and 4 hours later prior to treatment. Testosterone 
(50 mg in the form of Andromen® 5% FORTE cream) was then immediately applied via 
transdermal route (topically to  the scrotum). The participants were bled again at 2, 4, 6, 
8, 10, 12, 16, 20, and 24 hours post-application. The level of serum testosterone, SHBG, 
(Sex Hormone Binding Globulin) albumin and plasma Aβ levels were measured.  
 
Table 2.3 Comparison between Short-term Human Study 1 and 2 
 Pilot Study 1 Pilot Study 2 
 Duration of  Study          
(36 hours) 
28 hours 
Blood taken prior to the 
application of testosterone 
At baseline (time zero), 4, 
6, 4, 8, 12 hour prior to the 
application of testosterone 
At baseline (time zero) and 
4 hour prior to the 
application of testosterone 
The site for testosterone 
application 
On the trunk (side of body 
above hips), topically 
(transdermal route) 




Blood taken post to the 
application of testosterone 
At 2, 4, 6, 8, 10, 12, 16, 20, 
and 24 hours post-
application 
At 2, 4, 6, 8, 10, 12, 16, 20, 







2.2.1.2 Long-term Human Study 
 
A randomized, crossover, placebo controlled and double-blind study was undertaken to 
study the effectiveness of testosterone (a transdermal formulation) treatment in 
hypogonadal male subjects.  Of the potential participants that were screened, 44 eligible 
males were recruited and assigned to one of the two parallel groups; placebo (n=22) or 
testosterone (n=22) treatment. Assignment was random using stratification to ensure 
each arm of the study was balanced, in terms of individual memory performance at 
baseline. The study design (shown in Fig 2.2) was such that participants received 
testosterone treatment or placebo for a period of 24 weeks, followed by a washout 
period of 4 weeks, after which time, the participant groups were “crossed over”, such 
that the placebo group received testosterone and vice versa for a further 24 weeks. For 
all participants, there were a total of 11 clinic visits to Siloam  Hospital, Lippo 
Karawaci,  within the 52-week study  period. 
 
During the first visit, the participants’ blood pressure, height, weight, body fat 
percentage and body mass index (BMI) were checked and blood drawn for a baseline 
reading of blood counts, chemistries, serum testosterone level, LH and SHBG, DHT 
(dihydrotestosterone) and estradiol, cholesterol, lipid concentrations and plasma Aβ 
levels (as described in section 2.1.1.2.2). The participants’ APOE genotype was also 
determined. The baseline neuropsychological testing, brain imaging (MRI/MRS) and a 
CSF sample (for those participants who consented) were collected. CSF samples were 
collected by lumbal puncture (as described below). 
 
The patient was placed in the lateral decubitus position lying on the edge of the bed and 
facing away from operator. Patient’s position is in a knee-chest position with the neck 
flexed. The patient’s head is rested on a pillow, so that the entire cranio-spinal axis is 
parallel to the bed. Then the operator  found the posterior iliac crest and palpated the L4 
spinous process, and marked the spot. The skin was anaesthetized using 1% lidocaine in 
the 5 ml syringe. Then a spinal needle was inserted and once the needle was properly 
positioned, CSF pressure was measured and the CSF samples were collected. When the 





supposed to be aspirated, because a nerve root might be trapped against the needle and 
risking the possibility of injury. After 3-5 ml CSF were collected, the needle was 
withdrawn and the puncture site was dressed with a bandage. The patient was rested in 
bed for a few hours. 
 
For the testosterone treatment group (n=22), testosterone (50 mg in the form of 
Andromen® FORTE cream) was applied daily on the scrotum via transdermal route 
(topically) for a period of 24 weeks. For the placebo group (n=22) the same amount of 
the cream base [dl- tocopherol acetate (vitamin E), without the active ingredient, 
testosterone] was applied at the same frequency. Since Aβ produces hydrogen peroxide, 
which is a toxic free radical, and antioxidants such as vitamin E have been shown to 
reduce the amount of damage to brain cells by Aβ brain {Butterfield, 1999 #50}, the 
placebo group is important to ascertain what effect, if any, the cream base, may have on 
reducing Aβ levels and enhancing memory performance. At each of the six remaining 
clinic visits i.e. at 4, 8, 12, 16, 20 and 24 weeks during the first treatment period, blood 
pressure, weight, body fat percentage and body mass index (BMI) were checked and 
blood drawn for blood counts, chemistries, measurement of serum testosterone, LH, 
SHBG, albumin, PSA, DHT, estradiol, insulin, cholesterol, lipid and glucose 
concentrations and plasma Aβ levels, while neuropsychological testing were only 
included at 8, 16 and 24 weeks. At the end of 24 weeks a second CSF sample was 
collected (from those participants that consented) and MRI/MRS performed, followed 
by a 4-week washout period. 
 
During the 4-week washout period, the participants were given an equivalent amount of 
cream base containing no active ingredients with the same route of administration. They 
were also clinically examined and assessed neuropsychologically and blood collected 
for analysis as described above. At the end of the washout period, neuropsychological 
testing (as described in section 2.1.1.3) was performed. The placebo and testosterone 
treatment arms of the study were then crossed-over for a further 24-week treatment 
period. During this period, the participants were examined every eight weeks (three 
bleeds in total i.e. at weeks 8, 16 and 24 of the cross-over period); blood collected for 
analysis as described above and neuropsychological testing performed on all occasions. 





trial) a third CSF sample was collected (from those participants that consented) and 





Figure 2.2 : The summary protocol for long-term human study 
 
2.2.2 Animal Trial Design 
Guinea pigs were either left intact (non-castrated) or surgically castrated, to mimic the 
loss of testosterone following andropause in men. All hormone treatments given to the 
animals were in the form of slow release pellets (Innovative Research of America, 
USA) and administered either peripherally (subcutaneuous insertion into the dorsal neck 
fat pad of the guinea pig) or cortical placement on the dura above the left and right 
parietal cortex. The pellets were designed to slowly release the active ingredients over a 
period of 40 days for the hormone treatments or 50 days for the hormone suppression 
treatments (leuprolide and naltrexone).  
 
 Every 4 weeks for 0-28 weeks and every 8 weeks for cross-over period, participants were 
bled for measuring testosterone,DHT,SHBG, LH,estradiol,lipid profile,PSA,insulin and Aβ 
levels  
 Their cognitive status were evaluated using RAVLT,MMSE,GDS and SF36  every  8 weeks 
At these time points, MRI and MRS were performed and a CSF sample was 
collected for measuring Aβ levels
0 4 8 24  12  52 
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2.2.2.1 Surgical procedures 
 
All surgical procedures used in this study were performed at the surgery room of BSAU 




All surgical procedures applied to the guinea pigs were performed under halothane 
anaesthesia by inhalation. Animals were anaesthesized with 3-4% of halothane mix and 
O2/N2 mixture followed by 1-2% of halothane mix in order to maintain anaesthesia 
during the surgical procedure. However, cortical pellet implantation was performed 
under atropine-diazepam-hypnorm anaesthesia. Atropine at a dose of 0.05 mg/kg body 
weight (BW) was given subcutaneously. The 5 mg/kg BW diazepam was then injected 
intraperitoneally after 5 minutes. After the sedation about 15-20 minutes, the 1 ml/kg 
BW hypnorm was given intramuscularly. This procedure provided deep anaesthesia for 
about 45 minutes. If the guinea pigs showed signs of awakening before the surgery was 
completed, a further 10% of initial dose of diazepam and 25% dose of hypnorm, were 
given via the same delivery routes. Immediately after the surgery, the analgesic, 
buprenophine (0.05 mg/kg BW, subcutaneous) was given and the animals were kept in a 




Two hundred and thirty five guinea pigs were allocated for surgical castration and 
weighed prior to the castration. The surgical castration was performed by Dr. David 
Gardner (veterinary surgeon). Halothane anaesthesia was induced with (3-4% 
Halothane) and anaesthesia maintained during the surgical castration (1-2% Halothane). 
All the castrated animals were caged for a week to allow all the endogenous testosterone 







Intact or castrated animals were treated with either testosterone, LH, hormone 
suppression analogues (leuprolide or naltrexone) or a placebo in the form of slow-
release pellet (IRA, USA) and administered by the use of two different approaches. The 
first is peripherally (subcutaneous insertion into the dorsal neck fat pad of the guinea 
pig) (Wahjoepramono et al., 2008) and the second is cortical placement on the dura 
above the left and right parietal cortex (Rapisarda et al., 1977; Wahjoepramono et al., 
2011). The pellets were designed to slowly release the active ingredient over a period of 
40 days for the hormone treatment or 50 days for the hormone suppression treatments. 
A summary of the experimental treatments is provided in Table 2.4. 
For peripheral insertions, smaller pellets were administered subcutaneously using a 
stainless steel reusable precision trochar with regular medical point needle for easy 
implantation of small pellets up to 8 mm in diameter as illustrated in Figure 2.3.  Since 
the trochar can only be used for the small pellets up to 8 mm in diameter, the bigger 
pellets were administered surgically. The animals were anaesthetized under halothane 
anaesthesia and the pellets were placed in a small subcutaneous pocket above the 
scapula. The pockets were then surgically sutured closed and the animals were kept 
warm and allowed to recover from anaesthesia. For the double-pellet implantation 
groups, i.e. leuprolide or naltrexone (as the first pellet) and testosterone (as the second 
pellet) group, a 10-day separation period was included between the first and the second 
administered pellet to let the levels of both testosterone and LH  decrease  to negligible 
levels. A jugular bleed was performed to measure baseline levels of LH and A prior to 
the implantation of the second pellet, i.e. testosterone pellet. In the absence of LH, the 
effect of increased doses of exogenous testosterone on A levels was observed in these 
groups. All the peripheral pellet insertions were performed by Kevin Taddei and Dr 
Gardner.  
The administration of the pellet in the brain (either LH or placebo) was performed using 
atropine-diazepam-hypnorm anaesthesia. Briefly, guinea pigs were placed in a 
stereotaxic head holder and a burr hole drilled in the left and right parietal bones to 
expose the underlying dura. A pellet were placed in the burr hole on either side of the 





given the analgesic, buprenorphine (0.05 mg/kg BW subcutaneous) immediately post 
surgery, and kept in a warm place to recover. 
 
 
Figure 2.3 : Pellet implantation procedures using a trochar (Innovative Research of 
America, USA). 
 
2.2.2.2 Animal sacrifice and tissue collection 
 
At the the conclusion of each time point, i.e. day 7, 18 or 36; and day 14 or 28 for the 
cortical placement group, blood, cerebrospinal fluid (CSF) and the tissues, i.e. brain, 
liver and kidney were collected. All animals in the control group (baseline) were 





parameters for the normal (control) guinea pigs. For each terminal point, the animals 
were anaesthetised prior to the final bleed. Blood was collected via cardiac puncture for 
maximal blood collection and CSF was collected by puncture of the cisterna magna. 
The animals were then euthanized with sodium pentobarbitone immediately following 
the CSF sample collection. The whole blood and the CSF were then spun at 3500 rpm 
for 15 minutes at 4oC to collect the plasma and remove the blood cells, respectively. For 
the tissues collection, all animals were cardiac-perfused with cold saline containing 
1000U/ml heparin. The brain was removed and snapped frozen in liquid N2 for Western 
immunoblotting and ELISA. All the tissues were then stored in -20oC freezer until used. 
2.2.2.3  Preparation and Homogenisation of Brain tissue 
  
Guinea Brains were removed from storage at -20oC and thawed on ice. The brain was 
then dissected into the following brain regions: frontal cortex, hippocampus and 
cerebellum. The tissues were then weighed and homogenized using a Teflon-glass 
homogenizer in 3 ml/g of phosphate buffered saline (PBS) pH 7.4 (mixed powder from 
Fisher Biotec, Perth, WA) containing a commercially protease inhibitor cocktail 
(Roche, Basel, Switzerland) prior to the analysis to measure A and AD related protein 
levels in the tissue. Some of the total brain homogenates (180l) were spun by airfuge 
160,000 x g for 15 minutes to obtain brain extract  for APPs level measurement. Three 
hundred and ten l (310l) of brain homogenates were then processed for ELISA 
measurements (refer to Section 2.2.4). The remainder was aliquoted and stored at -80oC 
until use for western immunoblotting. 
 
2.2.3 Western immunoblotting 
Western immunoblotting was used to measure semi-quantitative levels of AD related 
proteins in plasma, CSF and tissue homogenates. This analysis included sample 
preparation and determination of protein concentration, loading of samples 






2.2.3.1 Preparation and determination of protein concentration 
The protein concentration in each region of the brain was estimated using the Micro 
BCA protein assay kit (Pierce, IL, USA). All homogenates were diluted 1:600, in PBS 
pH 7.4 and loaded in duplicate into 96-well microtitre plate (100l/well). Protein 
extracts used to measure soluble α-APPs were diluted 1/100.  Equal amount of 
standards solutions, made by diluting stock BSA solution (2 mg/ml ddH2O) to a 
working dilution of 80 g/ml (6, 8, 10, 12, 14, 16, 18, 20, 40, 80 g/ml), and blank 
(PBS pH 7.4) were also loaded in duplicate in the same manner.  One hundred l of the 
colorimetric detection mixtures were then added to each well. The plates were then 
incubated at 60oC for 15 minutes. A BioRad model 3550 plate reader was used to read 
the absorbance at 595 nm and the protein concentration determined by reference to a 
standard curve (generated using MCM Plate Manager, BioRad, CA, USA). Each 
homogenate sample containing 25 g of total protein was then resuspended in 4X Tris 
Tricine sample buffer (4g SDS, 2g glycine and 5mg phenol red dissolving in 8.3ml of 
1M Tris, pH 6.8) with the addition of double-distilled water [DDW]) containing 0.1M 
dithiotreitol (DTT) and brought to a  final volume of 50 µl. Samples were then stored in 
-80oC until underwent electrophoresis..  
 
2.2.3.2 Polyacrylamide gel electrophoresis 
Tris tricine polyacrylamide gel was used to run all the AD-related proteins. The gel 
contained a bottom layer of 12% resolving gel (5 cm deep), then an 8% resolving gel (2 
cm deep) and a 4% stacking layer to form the wells. For P450scc, the gel contained only 
the bottom layer of 10% resolving gel (7cm deep) and a 5% stacking layer. The samples 
and the internal control (IC), which is pooled samples from the rest of the brain, were 
mixed in sample buffer and together with molecular weight markers (MW) were then 
vortexed, centrifuged and heated to 95oC for 10 minutes prior to the loading. After the 
final quick centrifugation, samples, IC , and MW  were then loaded and electrophoresed 
at 80 volt for 30 minutes and then 120 volt for approximately 2.5-3 hours for all 
proteins or 4.5 hours for P450scc, in cathode (1M Tris, 2M Tricine, 1% SDS) and anode 
buffer (2M Tric-HCl, pH 8.9) to separate proteins. The gels were removed from the gel 





the transfer buffer (25mM Tris, 200mM glycine, 20% methanol), at 250mA, 4oC for 
overnight or at 350mA, 4oC for 4 hours. 
 
2.2.3.3 Immunoblotting  
The membranes were removed from the transfer tank and stained with a Ponceau stain 
(0.1% Ponceau-S in 5% acetic acid) to determine whether equal protein was loaded and 
the transfer process was performed well. The picture of these membranes was scanned 
using GS-800 scanner (BioRad CA, USA). The membranes were then cut into sections, 
based on specific molecular marker, in order to enable probing for different protein of 
interest from the same blot. All the sections were then washed in hot PBS several times. 
All the incubation and washing steps used in the immunoblotting and detection were 
performed at room temperature with gentle rocking .  
Non-specific binding sites of protein were blocked using blocking buffer (TBS 
containing 5% skim milk) for 1 hour. The blocking buffer was drained, then TBST pH 
7.4 (TBS containing 0.05% (v/v) Tween-20) containing 0.05% skim milk were used to 
dilute the primary antibodies. All the primary antibodies used to detect proteins  of 
interest along with the dilutions are listed in Table 2.5. 
Table 2.4 Primary antibodies used for western blotting (p denotes polyclonal, m 
denotes monoclonal) 
Antibody Protein Dilution used Source of 
antibody 
mC1/6.1 by Dr. Paul 
Matthews (Nathan Kline 
Institute, NY, USA) 
APP 1:5,000 Mouse 
C100 1:5,000 
mWO2 by Professor Colin 
Masters (University of 
Melbourne, Vic, Australia) 
APPs 1:2,000 Mouse 





Co., Missouri, USA) 
papoE (Milipore) apoE 1:10,000 Goat 
pP450scc (Milipore) P450scc 1:1000 Rabbit 
m-actin(Sapphire Bioscience 
Pty Ltd, Redfern, NSW, 
Australia). 
 
-actin 1:20,000 Mouse 
 
The membranes were incubated in the primary antibody for 2 hours and then washed 3 
times for 10 minutes with TBST pH 7.4. The secondary antibody linked to horseradish 
peroxidises (HRP) was then diluted in TBST pH 7.4 containing 0.05% skim milk and 
used to incubate the membranes for 1 hour. All the secondary antibodies used in the 
western immunoblotting are listed in Table 2.6 
 
Table 2.5 Secondary antibodies used for western blotting (all antibodies are linked 
to HRP) 
Antibody Protein Dilution used 




Rabbit anti-goat antibody apoE 1:10,000 
Donkey anti-rabbit antibody P450scc 1:5,000 
 
The membranes were washed with TBST pH 7.4 (3x10 minutes) and rinsed with TBS. 
Finally, the membranes were incubated in Enhanced Chemiluminescence reagent (ECL, 





and exposed to ECL hyperfilm (Amersham Biosciences, UK) with different exposure 
time in order to get the desired signal intensity. All the film were developed in the dark 
room and scanned for semi-quantitative analysis using Quantity One® 1-D Analysis 
Software (BioRad, CA, USA).   
 
2.2.4 Brain ELISA sample preparation 
Brain homogenate (310l) in PBS containing protease inhibitor was resuspended in 
710l of brain ELISA buffer (250mM sucrose, 20mM Tris-HCl, 1mM EGTA [Ethylene 
glycol-bis (2-amino-ethylether)-N,N,N’N’-tetra-acetic acid], 1mM EDTA 
[Ethylenediaminetetra-acetic acid], pH 7.4,. A volume of 1.1ml cold 100mM NaCl 
containing 0.4% diethylamine (DEA) was then added to the brain homogenates and 
mixed using a Teflon-glass homogenizer. The homogenate was then centrifuged at 
1000.000G, 4oC for 40 minutes for all the treatment group except for groups with LH 
and placebo implantation in the brain which were spun at 100,000G, 4oC for 1 hour. A 
1.7ml aliquot of supernatant was mixed with 170l of 0.5M Tris-HCl, pH 6.8,and  
aliquoted into 4 tubes (~ 440l/tube) and then stored in -80oC until use. Each aliquot 
were used to measure A40 and A42 levels by ELISA, as well as the CSF samples. 
2.2.5 Enzyme-Linked ImmunoSorbent Assay (ELISA) 
The ELISA was used to measure A40 and A42 levels in plasma, CSF (from human and 
guinea pigs), and brain homogenates (from guinea pigs)  As levels of A in the CSF are 
very high (above the highest standards of ELISA), the CSF was diluted in  PBS (1:10) 
before the analysis. All the frozen samples were thawed on ice prior to the analysis.  
The ELISA protocol was as follows: Nunc 96 well plates  were coated with 100l/well 
of coating primary (6E10) antibody solution (25l of primary antibody in 10ml of 
CO3/HCO3 solution [0.26g Na2CO3, 0.21g NaHCO3, pH 9.6 with final volume of 50 ml 
was met with addition of DDW]). As guinea pig A is identical to human Aβ (Beck, 
1997), the same primary antibody 6E10 was used for both human and guinea pig 





washed 3 times with PBST pH 7.4 using the plate washer (BioRad, CA, USA) and 
blocked with blocking buffer 200l/well (0.25g of BSA (Bovine Serum Albumin) 
diluted in 25ml PBST) at room temperature for 1 hour, followed by 3 washes in PBST. 
Samples and standards were then loaded into the wells of the plates (100l/well). The 
plates were sealed and incubated at room temperature for 2 hours and then at 4oC 
overnight. The next day, the plates were washed 3 times with PBST, then 100l/well of 
detection antibody solution (10l of secondary antibody [M40 for Aβ40 or R301 for 
Aβ42] diluted in blocking buffer) was added. The plates were sealed and incubated at 
room temperature for 1.5 hours, followed by 3 washes with PBST. The neutravidin-
HRP solution (100l/well) was then added into the wells, and the plates were incubated 
at room temperature for 1 hour. The plates were then washed again with PBST prior to  
adding TMB/KGP reagent  (100l/well). The plates were shielded from the light to 
allow the reaction of TMB/KGP to take place until the wells of the last 2-3 highest 
standard were distinguishable (usually took between 10-15 minutes). A 1M H3PO4 
solution (100l/well) was used to stop the TMB/KGP reaction. The plates were then 
read in a BioRad microplate reader at 450nm to provide of a raw OD reading of A 
levels. The unit of the A calculation depends on the amount of A detection in each 
samples measured (in nanomolar for the brain homogenates samples and picogram or 
nanogram for CSF and plasma samples). The A results obtained from calculation of 
A standard concentrations by comparing the sample absorbance with the absorbance of 
known concentrations of  Aβ40 or Aβ42 standards assayed identically on the same plate. 
Using the wet weight of the brain in the original homogenate, the final values of A in 
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Reduction of CSF and cerebral Aβ levels by 







Studies of estrogen levels and the incidence of AD in women are numerous, and have 
shown that hormone therapy around the time of menopause (but not in much older 
women) may delay the onset of AD (Brinton et al., 2004) In vitro studies supporting 
this effect have shown that estrogen can reduce the production of A in culture, and 
promote the secretion of α-APPs , another proteolytic product of APP known to have 
neurotrophic properties (Brinton et al., 2004)  As in vitro studies have shown that 
testosterone can also reduce production of A, promote α-APPs secretion and promote 
neuronal viability (Goodenough, 2000 ; Gouras, 2000 ; Pike, 2006), possible links 
between testosterone and AD are now being investigated.  
Levels of testosterone on average decline in men by approximately 1% every year from 
the 3rd - 4th decade of life, and the gradual decline in androgen levels that occurs, 
combined with other factors that increase resistance to androgen action, such as rising 
sex hormone binding globulin (SHBG) levels with age, causes androgen deficiency 
symptoms often referred to as andropause (Haren, 2002 ; Pike, 2006). It has been 
suggested that the above-mentioned effects of testosterone do not occur via androgen 
receptors (AR), but occur following aromatisation to estradiol which then binds to 
estrogen receptors (ER). The use of non-aromatisable dihydroxytestosterone (DHT) in 
some of these androgen experiments, and aromatase inhibiting drugs in others, has 
confirmed that some (but not all) of the in vivo and in vitro effects of testosterone can be 
attributed to AR pathways (Pike, 2006). 
An association between low testosterone levels and AD is supported by recent findings 
that testosterone levels are inversely correlated with plasma Aβ levels (Gillet, 2003).  
Low free testosterone has now been found to be an independent predictor of AD, and 
elderly AD cases also appear to have raised levels of gonadotropins (Hogervorst, 2003 ; 
Hogervorst, 2004)  Another study has found that brain testosterone levels in subjects 
with mild neuropathology are similar to levels in subjects with more advanced AD, yet 
significantly lower than age-matched controls (Rosario, 2004). In a large longitudinal 
study, it was found that low free testosterone levels could even be detected 5-10 years 
prior to diagnosis of AD (Moffat, 2004) Not all studies agree with the above findings 





results in increased plasma A levels, providing alternative in vivo proof that 
testosterone can influence Aβ levels (Gandy, 2001 ; Almeida, 2004).  In vivo studies 
also contradict some of the in vitro findings, e.g. whereas many cell culture studies have 
suggested testosterone effects occur via ER following aromatisation to estrogen, in vivo 
studies of castrated animals show the non-aromatisable androgen dihydrotestosterone 
(DHT), and not estrogen, influenced A levels (Ramsden, 2003). The aim of this 
chapter is to investigate further the role of testosterone in Aβ metabolism in vivo, using 
the guinea pig (Cavia porcellus) as an animal model.  In addition to a complete 
sequence identity to the human Aβ protein (Beck, 1997), this non-transgenic rodent 
model offers the advantage of yielding greater amounts of brain tissue and CSF samples 
than can be collected in mice and rats. Further, guinea pigs have a similar cholesterol 
metabolism to humans (Luz Fernandez, 2001 ; Zern, 2003 ; Sharman, 2008)., which is 
important in synthesis of sex steroids and in AD pathogenesis. As a non-transgenic 
animal model, the guinea pig also provides the opportunity to investigate any subtle 
effects of hormones or gonadotropins that may be masked by over-expression of APP in 
transgenic murine models. A number of  other studies have utilized the guinea pig as a 
model for investigating AD related proteins (Beck, 1997 ; Fassbender, 2001; Beck, 
2003) and evaluating the efficacy of inhibitors and modulators of Aβ production 
(Netzer, 2003 ; Lanz, 2005). Guinea pigs have also been used to evaluate the effects of 
oestrogen on brain Aβ levels (Petanceska, 2000), where depletion promoted Aβ 
accumulation, which was alleviated with supplementation of this hormone. In this 
chapter, I describe the effects of testosterone depletion and supplementation on CNS Aβ 
levels. Previous findings have reported correlations between testosterone and peripheral 
levels of Aβ  (Gandy, 2001 ; Gillet, 2003 ; Almeida, 2004) thus I also assessed the 
effects of testosterone reduction and supplementation on plasma Aβ and investigated 
whether there is a relationship between changes in plasma testosterone levels  and 
altered CSF and cerebral Aβ levels. 
3.2 Aims 
The aims of the study were: 
 To determine if CSF and plasma Aβ levels are altered in the presence of reduced 





  To determine if testosterone supplemented to gonadectomised (GDX) guinea 
pigs restored CSF and plasma levels to that seen in non-gonadectomised (non-
GDX) guinea pigs.  
 To determine if a reduction in testosterone or supplementation of this hormone 




Seventy eight adult male guinea pigs, body weight (BW) 500 gram (± 6-8 weeks old), 
were used. During the experiments, animals were kept in a 1:1 light and dark cycle 
room with free access to a soy-free diet (Glen Forrest Stockfeeders, Perth, WA) and 
water. A summary of the animal groups are described in Figure 3.1. 
Twenty three animals were left intact (non-GDX) and 55 animals were then castrated 
(GDX) under halothane anaesthesia. One week following castration, 40-day slow 
release pellets (Innovative Research of America, Florida, USA) were implanted in the 
periphery (subcutaneous insertion into the dorsal neck fat pad of guinea pig), as 
described in section 2.2.2.1. The pellets contains placebo (n=12), low testosterone (2.5 
mg/kg Body Weight (BW)/day, n=12) or high testosterone (20 mg/kg BW/day, n=12), 
The remaining GDX animals were left without any treatment (n=19).  
 






CSF, Plasma and Tissue Collection 
The CSF, plasma and tissue collection was performed as described in section 2.2.2.2 
and 2.2.2.3. Briefly, at each point of sacrifice, (i.e. 0, 18, 27, 36 days), animals were 
anaesthetised with halothane and blood was collected via cardiac puncture. CSF was 
collected from the cisterna magna.  Processing of whole blood (to collect plasma) and 
CSF, prior to analysis of Aβ40 levels is described in section 2.2.2.2. To collect brain 
tissue, all animals were cardiac-perfused with heparinized-cold phosphate buffer saline 
(PBS) and the brain removed. The brains were dissected into regions, such as frontal 
cortex, hippocampus and cerebellum, and homogenized in PBS containing protease 
inhibitor. Brain homogenates were used for protein analysis of the APP metabolites 
protein, Full length (FL) APP, secreted -APP (s-APP) and APP C-terminal fragment 
(APP-CTF)  were assessed by western immunoblotting as described in section 2.2.3.3, 
A40 levels were assessed by ELISA (as described in section 2.2.5).  
 
Measurement of serum testosterone, plasma and CSF Aβ40 levels. 
Serum testosterone was measured by Path Centre (Perth, Australia) and plasma and CSF 
A40 levels were measured by sandwich ELISA using 6E10 as capture antibody (anti-
human ASignet Laboratories, USA) and R208 as a detection antibody (kindly 




All data that was normally distributed were analyzed using ANOVA at the 0.05 
significance level.  The levels of testosterone, CSF A levels, FL-APP and its C-
terminal fragment were found to be not normally distributed and thus were analyzed 







3.4.1 Distinct effects of testosterone reduction or supplementation on CSF and 
plasma Aβ40 levels. 
Guinea pigs were either left intact (non-GDX), GDX only or GDX and supplemented 
with low (2.5 mg/Kg BW) or high (20 mg/kg BW/day) concentrations of testosterone. 
The animals were initially sacrificed 18 and 36 days after treatment and serum, CSF and 
plasma were collected to measure testosterone and Aβ40 levels, respectively. These 
results are shown in Figures 3.2-3.4.  Please note that groups of GDX guinea pigs 
administered placebo implant were also included. However, all animals in this group 
did not show a value for plasma Aβ levels, despite obtaining values for all other groups. 
The assay was performed three times without obtaining a value for samples in the GDX 
+placebo group. However, serum testosterone and CSF Aβ levels were obtained for the 
GDX+ placebo and shown to have similar levels to the GDX only [Testosterone (Mean 
± SEM) nmol/L: GDX = 2.74 ± 0.31, GDX+placebo = 2.76 ± 0.17 ; CSF A40  (Mean 
± SEM) ng/ml ; GDX = 2.65 ± 0.38, GDX+placebo A40 =  2.54± 0.33]   Since the aim 
was to determine the effects of testosterone on plasma Aβ and investigate if there is a 
relationship with any changes observed in the CSF and brain, results from the GDX 
only group were included to represent a reduction in testosterone and comparisons were 
made with this group. 
 
To confirm that GDX resulted in a reduction in testosterone concentration and that 
supplementation resulted in an increase in concentration, serum levels were measured. 
Compared to non-GDX controls, significant reductions in testosterone levels (p<0.05) 
were observed following 18 or 36 days GDX (Figure 3.2).  This decline was associated 
with a significant increase in CSF A40 levels at days 18 and 36 following GDX (see 
Figure 3.3). Compared to non-GDX animals, plasma Aβ levels were similar following 






Administering the low dose testosterone pellets for 18 days caused a rise in serum 
testosterone levels to that seen in non-GDX animals (Figure 3.2). This was 
accompanied by a decrease in plasma A40 to levels seen in non-GDX animals, yet 
CSF A40 levels were almost as high as in the untreated GDX animals (Figure 3.3). By 
day 36, serum testosterone (Figure 3.2) and plasma A40 levels (Figure 3.4) were back 
to levels seen in the untreated GDX animals.  In contrast, CSF A40 levels were lower 
than those seen in untreated GDX animals, closer to A40 levels found in non-GDX 
control animals (see Figure 3.4).  
 
The administration of pellets containing high testosterone resulted initially in supra-
physiological serum testosterone levels at day 18, reducing to levels found in non-GDX 
controls by day 36 (see Figure 3.2). An additional group at which GDX guinea pigs 
were administered testosterone for 27 days was included to determine if this reduction 
was time dependent. The results show that a gradual reduction in testosterone following 
27 and 36 days exposure to the testosterone implant.  Despite these initial supra-
physiological levels of testosterone, A40 levels in CSF at day 18 and day 27 were not 
significantly reduced compared to untreated GDX animals.  A significant reduction in 
CSF A40 levels was only detected on day 36 (p<0.05) (Figure 3.3). On day 18, plasma 
A40 levels in the high testosterone group were similar to levels found in the plasma of 
untreated GDX animals (on day 18), despite the supra-physiological levels of 
circulating testosterone. At day 27 and 36 of treatment, plasma A40 levels increased 
significantly above the GDX or Non-GDX guinea pig test group A40 levels (see 
Figure 3.4).  
 
Overall reducing testosterone, via castration significantly increased CSF and plasma 
Aβ40 levels in experimental guinea pigs. Supplementation of testosterone had distinct 
effects on plasma and CSF Aβ40, where levels were reduced in CSF but increased in 
plasma.  I next determined if brain Aβ40 levels were altered as a response to changes in 










Figure 3.2: Serum testosterone levels in non-GDX, GDX and GDX guinea pigs 
administered testosterone.  Non-GDX animals were sacrificed at baseline (day 0)  
GDX only or GDX guinea pigs supplemented with low (2.5 mg/kg BW/day) or high (20 
mg/kg BW/day) doses of testosterone were sacrificed at 18 and 36 days following 
treatment. An additional group at which GDX guinea pigs were administered a high 
dose of testosterone for 27 days was included. All data are shown as mean ± SEM. 
T=testosterone and D=day of treatment. * p<0.05, testosterone levels significantly 
reduced compared to non-GDX animals.  # p<0.05, testosterone levels significantly 
increased from corresponding untreated GDX animals.  Φ p<0.05, testosterone levels 








Figure 3.3: CSF Aβ40 levels in non-GDX, GDX and GDX guinea pigs administered 
testosterone.  Non-GDX animals were sacrificed at baseline (day 0)  GDX only or 
GDX guinea pigs supplemented with low (2.5 mg/kg BW/day) or high (20 mg/kg 
BW/day) doses of testosterone were sacrificed at 18 and 36 days following treatment. 
An additional group of GDX guinea pigs which were administered a high dose of 
testosterone for 27 days was included.  T=testosterone and D=day of treatment. * 
p<0.05, CSF A40 levels are significantly increased compared to non-GDX animals. # 
p<0.05, CSF A40 levels are significantly lower compared to untreated GDX animals, 











Figure 3.4: Plasma Aβ40 levels in non-GDX, GDX and GDX guinea pigs 
administered testosterone. Non-GDX animals were sacrificed at baseline (day 0)  
GDX only or GDX guinea pigs supplemented with low (2.5 mg/kg BW/day) or high (20 
mg/kg BW/day) doses of testosterone were sacrificed at 18 and 36 days following 
treatment. An additional group at which GDX guinea pigs were administered a high 
dose of testosterone for 27 days was included.  T=testosterone and D=day of treatment. 
* p<0.05, plasma A40 levels are increased compared to non-GDX animals at day 36. # 
plasma A40 levels are significantly increased compared to GDX at day 36. 
 
3.4.2 Effects of testosterone reduction or supplementation on brain Aβ levels and 
APP processing.  
To determine if testosterone altered brain Aβ40 levels, the frontal cortex, hippocampus 
and cerebellum from each experimental group underwent analysis. The results are 
shown in Figure 3.5. Compared to non-GDX control animals, Aβ40 levels in the frontal 
cortex and cerebellum were not significantly altered 18 days after GDX (Figure 3.5 A 





dose of testosterone for 18 days. This reduction was not observed following 36 days of 
testosterone treatment. It was noted, however, that compared to non-GDX, GDX led to 
a reduction of Aβ40 in the frontal cortex and cerebellum. This may account for the lack 
of effect of testosterone at day 36, as levels were already reduced in GDX animals.  A 
significant increase was observed in the hippocampus of GDX animals, at day 18 which 
was significantly reduced below the levels shown in non-GDX animals following 
administering testosterone at highest dose used in this study (20mg/kg BW/day) (Figure 
3.5 B).  Although the effect of GDX was lost at day 36, supplementation of testosterone 
resulted in a reduction in Aβ40 levels at this time point.  
 
Testosterone has been shown to impact on Aβ production in vitro and in vivo, through 
altering APP processing (Gouras, 20003 ; Pike, 20064) . To determine if APP 
metabolism is altered in the GDX guinea pig in the presence or absence of testosterone, 
levels of APP and its metabolites (APP-C-terminal fragments (APP-CTF) and secreted 
APP (α-APPs) were assessed. (Figure 3.6-3.8).  Levels of FL-APP (Figure 3.6) and 
APP-CTF (Figure 3.7) were not significantly altered as a result of castration nor 
testosterone supplementation. Analysis of sAPPα was performed using tissue from the 
frontal cortex.  This region provides sufficient material for ultracentrifugation to obtain 
supernatant-free of cell debris (as described in section 2.2.2.3). Following Aβ analysis 
via ELISA and western immunoblotting analysis of APP, the frontal cortex was the only 
region to have sufficient amount of tissue remaining required to perform this analysis.  
The sAPPα protein was detected via western immunoblotting and underwent 
quantitative analysis. The findings (Figure 3.8) showed that compared to non-GDX 
animals, a significant reduction in α-APPs levels was observed in the frontal cortex of 
GDX animals. The supplementation of testosterone, either low or high levels, restored 
the levels of α-APPs to that seen in non-GDX animals (see Figure 3.8).   
 
Overall the results show that a reduction in testosterone as a result of GDX is associated 
with a reduction in α-APPs .  The addition of testosterone following GDX restored α-
APPs levels to that seen in the non-GDX guinea pigs. Although most prominent in the 





indicate that testosterone may modulate brain APP processing through the non-
amyloidogenic pathway. Parallels were also observed between brain, CSF and plasma 
Aβ40 for some of the experimental treatments. In particular, treatment with the highest 







Figure 3.5: Aβ40 levels in frontal cortex, hippocampus and cerebellum from non-
GDX, GDX only and GDX guinea pigs administered testosterone. Non-GDX 
animals were sacrificed at baseline (day 0)  GDX only or GDX guinea pigs 
supplemented with low (2.5 mg/kg BW/day) or high (20 mg/kg BW/day) doses of 
testosterone were sacrificed at 18 and 36 days following treatment. Homogenates from 
the (A) Frontal cortex, (B) Hippocampus and (C) Cerebellum underwent ELISA 
analysis for Aβ40. Data is represented as mean Aβ40 levels (nmol/g wet tissue weight) 
± SEM. T= administered testosterone pellet. *, p<0.05, Aβ40 levels increased compared 
to non-GDX animals. #, p<0.05, Aβ40 levels decreased compared to non-GDX animals. 







Figure 3.6: Full length (FL) APP levels in frontal cortex, hippocampus and 
cerebellum from non-GDX, GDX only and GDX guinea pigs administered 
testosterone.  Non-GDX animals were sacrificed at baseline (day 0)  GDX only or 
GDX guinea pigs supplemented with low (2.5 mg/kg BW/day) or high (20 mg/kg 
BW/day) doses of testosterone were sacrificed at 18 and 36 days following treatment.   
(A) Homogenates from the frontal cortex, hippocampus and cerebellum underwent 
western immmunoblotting for full length (FL-APP) using antibody C1/6.1  or β-actin.  
Three samples from each group are represented on the immunoblots. (B) Quantitative 
analysis of all samples revealed no overall significant changes in FL-APP levels in any 
of the brain regions analysed. Data is represented as percentage of non-GDX control 






Figure 3.7: APP-CTF levels in frontal cortex, hippocampus and cerebellum from 
non-GDX, GDX only and GDX guinea pigs administered testosterone. Non-GDX 
animals were sacrificed at baseline (day 0) GDX only or GDX guinea pigs 
supplemented with low (2.5 mg/kg BW/day) or high (20 mg/kg BW/day) doses of 
testosterone were sacrificed at 18 and 36 days following treatment (A) Homogenates 
from the frontal cortex, hippocampus and cerebellum underwent western 
immmunoblotting for APP-CTF using antibody C1/6.1   or β-actin. Three samples from 
each group are represented on the immunoblots.  (B) Quantitative analysis of all 
samples revealed no overall significant changes in APP-CTF levels in any of the brain 
regions analysed.  Data is represented as percentage of non-GDX and are shown as 







Figure 3.8: Levels of α-APPs levels in the frontal cortex, from non-GDX, GDX only 
and GDX guinea pigs administered testosterone. Non-GDX animals were sacrificed 
at baseline (day 0)  GDX only or GDX guinea pigs supplemented with low (2.5 mg/kg 
BW/day) or high (20 mg/kg BW/day) doses of testosterone were sacrificed at 18 and 36 
days following treatment (A) Homogenates from the frontal cortex were western 
immmunoblotted for α-APPs using antibody WO2. Immunoblots exhibit 3 
representative samples from each group. (B) Quantitative analysis of all samples 
revealed a significant reduction in levels of α-APPs in GDX animals, which were 
restored to those observed for the non-GDX animals following testosterone treatment.  
Data is represented as percentage of non-GDX and are shown as mean ± SEM.   
  α-sAPP levels are significantly reduced (*, p<0.05, ) from those observed in the intact 
control.  α-APPs levels are significantly increased in the testosterone treated animals 







 Replacement of testosterone or its metabolite, DHT to mice has been shown to improve 
learning and memory and reduce cerebral amyloid accumulation (Ramsden, 2003; 
Rosario, 2006 ; Cherrier, 2007). This chapter describes the use of a non-transgenic 
animal model to further investigate the benefits of testosterone to reduce Aβ 
accumulation. The guinea pig unlike mice, shares Aβ sequence identity and more 
closely mimics cholesterol metabolism as well as hormonal changes seen in humans and 
has the added advantage of having more available tissue (ie brain, CSF and plasma) for 
experimentation. This has enabled the correlation between testosterone and CSF in 
particular to be determined Aβ thereby extending the the correlation between 
testosterone and plasma Aβ studies performed in mice. 
 
To model testosterone depletion, guinea pigs were castrated and left for 18 or 36 days 
prior to analysis of serum testosterone, and Aβ levels in the periphery and CNS. As 
expected, serum testosterone levels significantly declined following castration, and this 
was associated with increased levels of CSF and plasma A40. Other in vivo studies 
have also found that lowering testosterone levels either by orchidectomy or anti-
androgen therapy results in increased plasma A levels (Gandy, 2001 ; Almeida, 2004) 
or brain A levels (Ramsden, 2003 ; Rosario, 2006). Additionally, the lower 
testosterone levels resulting from castration cause a loss of negative feedback of 
testosterone on the  luteinizing hormone (LH), a gonadotropin, leading to elevated LH 
levels, and this has also previously been shown in vitro to favour the amyloidogenic 
pathway, increasing Aβ production (Bowen, 2004) The inclusion of plasma LH values 
in this study  would have provided greater insight into whether changes in the HPG axis 
contributed to the effects observed. However, this was not possible as unfortunately 
there are no standard assays to measure guinea pig LH levels. The -unit of guinea pig 
LH has little or no homology with human or rodent LH, thus appropriate, reliable 
immunoassays for measuring guinea pig LH are not available. However, since guinea 





using a radio-immunoassay for sheep LH but serum values using this assay were 
undetectable. Considering that a change in the hormone levels causes a dysregulation of 
the HPG axis, it is conceivable that testosterone may alter A levels indirectly through 
modulating LH levels. 
 
Androgen receptor (AR) levels in the brain will also have been affected by 
gonadectomy and subsequent androgen treatment. Testosterone treatment increases 
levels of AR phosphorylation, which has been shown to increase AR transcriptional 
activity, whereas in gonadectomised mice, testosterone treatment causes a drop in AR 
synthesis, possibly due to AR promotor methylation (for a review see Fuller, 2007). The 
testosterone treatment in the current experiments will have induced changes to many of 
the above-mentioned components of the hypothalamic-pituitary-gonadal axis, the 
complex interaction of which will have produced the detected changes in A levels. 
 
Many in vitro testosterone studies have found that decreasing production of A via the 
amyloidogenic pathway is coupled to an increase in the secretion of α-APPs , produced 
via the alternative non-amyloidogenic pathway (Goodenough, 2000 ; Gouras, 2000 ; 
Pike, 2006), and increased α-APPs  levels are thought to be neuroprotective. However 
not all in vitro studies have found these pathways to be coupled (Fuller, 1995), and the 
negative correlation between A levels and α-APPs  levels seen in in vitro androgen or 
estrogen studies has not been found in in vivo studies (Petanceska, 2000 ; Ramsden, 
2003 ; Pike, 2006). For example, gonadectomised mice have increased brain levels of 
A when compared to control mice, and treatment of gonadectomised animals with the 
non-aromatisable DHT reduces brain A levels down to levels below that found in 
intact animals, yet with no effect on α-APPs (Ramsden, 2003). In this chapter, I have 
shown that testosterone reduced CSF and cerebral Aβ levels and restored the reduction 
in α-APPs resulting from gonadectomy, indicating that testosterone may modulate APP 






One explanation in the difference between my results and those reported by Ramsden 
and colleagues, 2003  may be due to the type of androgen used. The aromatisation of 
testosterone to estrogen is thought to be involved in the apparent testosterone induced 
secretion of APP, as inhibition of aromatase in the presence of testosterone results in a 
reduction in α-APPs (Goodenough, 2000). Furthermore, estrogen itself has been shown 
to induce α-APPs secretion (Bi, 2000 ; Manthey, 2001). Thus it is plausible that 
testosterone could be altering APP metabolism through estrogen dependent pathways. 
However, DHT which does not undergo aromatisation to estrogen may have effects on 
APP metabolism and A production which are independent of estrogen or the 
enzymatic processing of APP as reported in other studies (Ramsden, 2003 ; Rosario, 
2006). Whether DHT or testosterone has independent effects will need to be clarified in 
studies that directly compare the effects of these androgens on APP metabolism. 
 
The findings in this chapter show that low dose testosterone decreased  A40 levels, 
resulting in a negative correlation between plasma A40, plasma testosterone and α-
APPs levels. This is similar to results found by others who employed either in vitro, 
animal or human studies (Gouras, 2000 ; Gillet, 2003 ; Ramsden, 2003). However, CSF 
A40 levels did not mirror the changes seen in blood plasma.  If anything, changes in 
CSF A40 levels appeared to lag behind changes in plasma testosterone and plasma 
A40 levels by a period of 1-2 weeks. This is conceivable if changes in other 
components of the hypothalamic-pituitary-gonadal axis control A40 levels in the CSF 
(for example, LH levels), as opposed to a more direct action following androgens 
binding to androgen receptors. Gonadectomy followed by fluctuating testosterone levels 
induced by the experimental treatment would cause ongoing re-equilibration in the 
hypothalamic-pituitary-gonadal system, until testosterone returned to a constant low 
level. Alternatively, or in addition, CSF A levels are in general much higher than 
circulating levels of A, leading us to speculate that our results may reflect slow 
clearance of A from the CSF to the bloodstream.  The clearance process of A from 
brain to bloodstream involves various stages, including and not limited to (1) diffusion 
between the interstitial fluid (ISF) and capillaries, (2) the continuous slow removal of 





by carrier proteins such as apolipoprotein E, apolipoprotein J, 2-macroglobulin, and 
(4) transport of A across the brain-blood barrier regulated by the receptor for advanced 
glycation end products and the low density lipoprotein receptor protein-1 (LRP) 
(Silverberg, 2003 ; Deane, 2004) [Silverberg, 2003; Deane, 2004]. Once in the 
bloodstream, A has a short half-life and is believed to be rapidly degraded by the liver 
and kidneys (Hone, 2003). 
 
Feedback mechanisms and components of the hypothalamic-pituitary-gonadal axis 
following castration in young male guinea pigs, e.g. AR, LH and follicle stimulating 
hormone (FSH) levels and testosterone negative feedback effects, are unlikely to be 
identical to those of aging human males with low, but not absent, levels of androgens. 
However, this study provides additional evidence of a role for testosterone in A 
metabolism, and supports the concept that androgen therapy regulates brain A levels 
and hence reduces the risk of AD in men. The high plasma A40 levels in the animals 
treated with the higher dose of testosterone are of particular interest.  Such high levels 
of testosterone would be expected to induce aromatisation to estrogen, which has been 
shown to reduce A levels in female rodent brains, and is thought to improve memory 
in elderly men (Ramsden, 2003 ; Cherrier, 2007). However, this result does not support 
the concept that supra-physiological levels of testosterone will further reduce A levels.  
The significant lowering of CSF A40 levels only occurred by day 36, by which stage 
circulating testosterone levels were either within the normal range or below normal 
levels.  The results are in agreement with results by Ramsden et al., 2003. who also 
found that changes in brain A40 and A42 levels in male castrated mice were lower 
upon treatment with the non-aromatisable dihydrotestosterone (DHT), but were not 
affected by treatment with estrogen. In addition, high testosterone caused a significant 
increase in plasma A40 levels at days 27 and 36. This could possibly be the result of 
clearance of the high brain A40 levels, yet once in the bloodstream, A40 is thought to 
be rapidly broken down (Hone, 2003). Studies are needed to establish why changes to 
CSF and A levels are so different, and importantly, whether the increased levels are 






Similarly, brain and plasma levels of A were found to be affected differently by DHT 
in experiments by Ramsden et al. 2003. Higher doses of most androgens produce more 
aromatisation, as seen with the supra-physiological levels of testosterone reached with 
intramuscular injections of testosterone enanthate in studies of cognition in older men. 
This treatment doubles estradiol levels in moderate doses, and quadruples them with 
large supra-physiological doses (Cherrier, 2007). Only the moderate dosage group 
showed improvements in spatial and verbal tests, suggesting an inverted U-shaped 
response pattern to both testosterone and estrogens. The route of administration of 
testosterone should also be evaluated, as transdermal testosterone administration (as 
opposed to intramuscular or by pellet) only raises estradiol levels slightly, while 
quadrupling DHT levels, due to 5α reductase enzymes in the skin (Swerdloff, 2000). 
The investigation of other APP-related proteins and other hormones and related 
proteins, such as apolipoprotein E, LRP, sex-hormone binding globulin, free 
testosterone, estrogen, DHT, AR, FSH and LH is required to obtain a more complete 
picture of the interactions between components of the hypothalamic-pituitary-gonadal 
axis, and to characterise better the effects of these interactions on A metabolism. The 
next two chapters analyse the effects of one of these components, LH, at modulating Aβ 
metabolism in the guinea pig CNS.  The results presented in this chapter have 
highlighted the need to understand the long-term changes brought about by testosterone 
treatment on components of the hypothalamic-pituitary-gonadal axis, as short-term 
studies provide only a partial understanding of the dynamics of the system. The results 
also demonstrate that the measurement of blood plasma A levels, are not sufficient to 
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Age-associated reductions in sex steroids have been implicated in cognitive impairment, 
dementia and the pathogenesis of AD. Results presented in Chapter 3 show that 
reductions in serum testosterone increased CNS levels of Aβ in the gonadectomised 
guinea pig, providing further evidence for a role of this sex steroid in AD pathogenesis. 
However, there is growing evidence to suggest that increased gonadotropin levels 
during aging may also contribute to AD pathogenesis. Compared to age-matched 
controls, serum levels of gonadotropins have been shown to increase in subjects with 
AD (Bowen, 2000;Short, 2001) . Furthermore, findings from our group have shown that 
increased serum LH levels are associated with poorer cognitive performance in post-
menopausal women (Rodrigues, 2008) and that serum LH levels are associated with 
plasma Aβ40 levels in cognitively normal elderly men (Verdile, 2008) .  
 
Initial evidence that LH may be involved in AD pathogenesis was provided by Bowen 
and colleagues (2002) who reported an increase in LH immunoreactivity in the 
pyramidal neurons of the AD brain compared with age-matched controls. . Coupled 
with findings that LH modulates APP processing and A generation in vitro, and that 
gonadotropin releasing hormone (GnRH) agonists decrease A levels in mouse brain 
(Bowen, 2004 ;Casadesus, 2006) , these findings indicate that the increased 
gonadotropins  are a physiologically relevant signal that potentially modulates 
neurodegeneration in the aging brain.   
 
The mechanisms by which LH modulates A metabolism remain to be determined. 
Earlier studies have shown the presence of pituitary and gonadal hormones in the CSF 
of rabbits (Heller, 1968 ;Knowles, 1972) . More recently a small percentage (<1%) of 
radio-labelled hCG injected into rats was shown to cross the blood brain barrier into the 
CSF and was also detected in the hippocampus (Lukacs, 1995 . In addition, peripheral 
administration of the LH analogue, hCG, to rodents, has been shown to impair 
hippocampal associated behaviours (Barron, 2010 ;Berry, 2008 ;Lukacs, 1995). 





and can impact on memory and learning. There is also evidence that LH is synthesized 
in the brain and components of LH receptor signalling, steroidogenic acute regulatory 
(StAR) protein and cytochrome P450 side-chain cleavage enzyme (P450scc), have all 
been identified in neuronal cells (Bowen, 2002; Liu, 200;Mukai, 2006 ; Murakami, 
2006 ;Webber, 2006 ;Wilson, 2006) . The LH receptor itself has been shown to be 
expressed in neurons from the hippocampus, an area of the brain involved in memory 
formation and severely affected in AD (Lei, 1993). The existence of LH signalling 
pathway in neurons is still not well understood.  However there is some evidence in 
vitro to suggest that modulation of the neuronal LH receptor can impact on 
neurosteroidogenesis (Liu, 2007) . Exposure of neuronal cells in culture to LH has been 
shown to result in an accumulation of Aβ (Bowen et al., 2004). Further, our group and 
others have shown that peripheral administration of hCG, to rodents, increases cerebral 
Aβ (Barron, 2010 ;Berry, 2008) . However, whether LH directly alters Aβ metabolism 
in the CNS, in vivo, remains to be determined. This chapter investigates whether direct 
exposure of LH to the CNS can alter Aβ metabolism in guinea pig brain.  
 
4.2 Aims 
The aims of my study were: 
 To determine if the slow release of LH into the guinea pig CNS increased CSF 
and brain Aβ40 levels. 
 To determine if increased brain Aβ40 levels are associated with changes in 













A total of 44 adult male guinea pigs, body weight (BW) 500 gram (± 6-8 weeks old) 
underwent experimentation. For a set of experiments guinea pigs were either 
gonadectomised (GDX) (n=10) under halothane anaesthesia (3-4% induction and 1-2% 
maintenance with Halothane) or left non-gonadectomised (non-GDX) (n=10). Another 
group of animals (n=24) were GDX as above and left for one week prior to implanting 
slow release pellets (Innovative Research of America, Florida, USA) containing either 
0.045 mg (equal to 2.25 g/kg BW/day) human LH (MP Biomedicals; n=12) or placebo 
(n=12) under combination of atropine-diazepam-hypnorm anaesthesia (0.05 mg/kg BW 
atropine, subcutaneously; 5 mg/kg BW diazepam, intraperitoneally and 1 ml/kg BW 
hypnorm, intramuscularly). This combination provided deep anaesthesia for about 45 
minutes. Once anaesthesia was achieved, guinea pigs were placed in a stereotaxic frame 
(David Kopf Instruments) and partial craniotomy was performed to expose the 
underlying dura. The dura was incised and a pellet (5 mm in diameter) was placed in the 
interhemispheric subdural space of the frontal lobe (stereotaxic coordinate:  A 13.0–A 
9.0, i.e.: 13 to 9 mm anterior to the frontal zero plane, according to Rapisarda and 
Bacchelli, 1977 (Rapisarda and Bacchelli, 1977). After the surgery, the dura was 
stitched, the cranium was replaced and the skin was sutured. An analgesic, 
buprenophine (0.05 mg/kg BW, subcutaneously) was administered and animals were 
kept warm until they recovered. Animals were sacrificed at 14 or 28 days post-
administration of the pellets. Six animals treated with placebo and 6 animals treated 
with LH were sacrificed at each time point.  
 
CSF, plasma and tissues collection 
The CSF, plasma and tissue collection was performed as described in section 2.2.2.2 
and 2.2.2.3. Briefly, at each time point, animals were anaesthetised with halothane and 
blood was collected via cardiac puncture. CSF was collected from the cisterna magna.  
Processing of whole blood (to collect plasma) and CSF, prior to analysis of Aβ40 levels 





with heparinized-cold phosphate buffer saline (PBS) and the brain removed. The brains 
were dissected into regions, such as frontal cortex, hippocampus and cerebellum, and 
homogenized in PBS containing protease inhibitor. Brain homogenates were used for 
identification for APP metabolites. Full length (FL) APP,  and APP-CTF were assessed 
by western immunoblotting as described in section 2.2.3), A40 levels were assessed by 
ELISA (as described in section 2.2.5).  
 
Measurement of serum testosterone plasma and CSF Aβ40 levels. 
Serum testosterone was measured in non-GDX and GDX guinea pigs by Path Centre 
(Perth, Australia) and plasma and CSF A40 levels were measured by sandwich ELISA 
using the monoclonal 6E10 as capture antibody (anti-human ASignet Laboratories, 
USA) and the polyclonal R208 as a detection antibody (kindly provided by Dr. Pankaj 
Mehta, NYS Institute for Basic Research, New York, USA) (see chapter 2.1.3.2). 
 
Statistical analysis 
The student t-test (assuming unequal variance) was used for data comparisons between 
non-GDX and GDX animals. All other data were analysed using two-way analysis of 






4.4.1 CSF and brain Aβ40 levels are altered following LH administration to guinea 
pig CNS. 
To determine the direct effects of LH on CNS A levels, placebo or LH slow release 
implants were administered to the interhemispheric subdural space of the frontal lobe. 
As the guinea pigs were GDX prior to pellet implantation, the effect of GDX on CSF, 
plasma and cerebral A40 levels were assessed in the GDX animals compared to non-
GDX control animals.  
 
As expected GDX led to a reduction in testosterone levels (non-GDX animals = 28.65 ± 
6.22; GDX 3.7 ± 0.62 nmol/L, p<0.001). Analysis of CSF Aβ40 levels revealed that 
GDX resulted in significant increase in CSF A40 levels compared to the non-GDX 
control animals (p<0.05; Figure 4.1A). The addition of the LH implant increased CSF 
Aβ40 levels further. Two-way analysis of variance (ANOVA) showed that the LH 
treatment (F=34.453; p<0.001) and the duration of treatment (F=26.237; p<0.001) both 
significantly impacted on CSF A40 levels. An interaction between the LH treatment 
and duration of treatment was also significant (F=7.692; p<0.05). Post-hoc analysis 
revealed that there was a significant increase in CSF Aβ40 levels following 14 (p<0.05) 
and 28 days (p<0.001) of LH treatment (Figure 4.1B). Overall, these results indicate 
that although GDX led to an increase in CSFAβ40 levels, the addition of exogenous LH 
led to a further increase, which was dependent on duration of treatment.  
 
I next determined if these effects extended to the periphery by measuring plasma Aβ40 
levels from non-GDX, GDX or LH or placebo treated animals. Compared to non-GDX 
animals, GDX did not alter Aβ40 levels (Figure 4.2A). Similarly, compared to animals 
administered with placebo, plasma A40 levels were not altered in those administered 








Figure 4.1: CSF Aβ40 levels from non-GDX, GDX or GDX guinea pigs 
administered placebo or LH for 14 or 28 days. 
Gonadectomised (GDX) guinea pigs were administered placebo or LH slow release 
pellet implants for 14 or 28 and CSF was collected from the cisterna magna. (A) GDX 
resulted in increased levels of CSF A40 compared to the non-GDX control animals 
(*p<0.05). (B) CSF A40 levels were significantly increased in animals administered 
LH at 14 and 28 days pos-treatment compared to guinea pigs administered placebo 









Figure 4.2: Plasma Aβ40 levels from non-GDX, GDX or GDX guinea pigs 
administered placebo or LH for 14 or 28 days. 
Gonadectomised (GDX) guinea pigs were administered placebo or LH slow release 
pellet implants for 14 or 28 and plasma was collected. (A) Plasma A40 levels were not 
altered as a result of GDX (B) No change in plasma A40 levels were observed in 
animals administered placebo or LH. All data are shown in Mean ± SEM. 
Having shown that GDX and the direct cerebral exposure to LH resulted in increased 
Aβ40 levels in CSF, I next investigated whether brain Aβ40 levels were altered in these 
animals. The frontal cortex and hippocampus were isolated and underwent analysis for 





observed for non-GDX animals (Figure 4.3A). Administering the LH implant resulted 
in an increase in Aβ40 levels within the frontal cortex. Two-way analysis of variance 
(ANOVA) showed that there was a main effect of LH treatment (F=12.171, p<0.01; 
Figure 4.3B), however there was no effect of duration of treatment (F=0.789, p<0.385). 
Post hoc analysis revealed that Aβ40 levels were significantly increased following 28 
days (p<0.05), although a trend towards an increase was observed following 14 days of 
treatment.  
In contrast to Aβ40 levels in the frontal cortex, those observed in the hippocampus of 
GDX animals were significantly increased compared to levels from hippocampus of 
non-GDX animals (p<0.01; Figure 4.4A). The addition of LH resulted in a further 
increase in Aβ40 levels within the hippocampus. Two-way analysis of variance 
(ANOVA) exhibited similar findings to that observed in the frontal cortex, there was a 
main effect of LH treatment (F=12.116, p<0.01; Figure 4.4B). However there was no 
effect of duration of treatment (F=0.478, p<0.499). Post-hoc analysis revealed that 
compared to placebo treated animals, hippocampal Aβ40 levels were significantly 
increased following 14 or 28 days treatment with Aβ (p<0.05). Overall the results 
indicate that the addition of exogenous LH, results in an increase in cerebral Aβ40 
levels.  
To determine if the increase in Aβ40 levels observed with LH was due to altered APP 
processing, brain homogenates underwent western immunoblotting for FL-APP and its 
C-terminal fragments (APP-CTF). In frontal cortex tissue, compared with placebo, no 
significant changes were observed in FL-APP and APP-CTF following treatment with 
LH (Figure 4.5A). Analysis of hippocampal tissue (Figure 4.5B) revealed a main effect 
of LH treatment on FL-APP (F=6.762, p<0.05) and APP-CTF (F=9.06, p<0.01) levels, 
this was not dependent on duration of treatment. Post-hoc analysis revealed that FL-
APP and APP-CTF levels were significantly increased following 28 days of treatment 
(p<0.05). The LH associated increase in APP-FL and APP-CTF levels in the 










Figure 4.3: Aβ40 levels from frontal cortex of non-GDX, GDX or GDX guinea pigs 
administered placebo or LH for 14 or 28 days.  
Cerebral A40 levels were measured in frontal cortex of non-GDX control, GDX 
animals and animals administered placebo or LH slow release pellets. (A) There were 
no different in frontal cortex A40 levels between non-GDX control and GDX animals. 
(B) Compared to placebo treated animals, a trend towards an increase in A40 levels 
were observed in the animals treated with LH for 14 days. Following 28 days of 
treatment, A40 levels in the frontal cortex were significantly increased in LH treated 







Figure 4.4: Aβ40 levels from hippocampus of non-GDX, GDX or GDX guinea pigs 
administered placebo or LH for 14 or 28 days. 
(A) Gonadectomy (GDX) resulted in increased levels of hippocampus A40 levels in 
GDX animals compared to non-GDX control animals (**p<0.01). (B) A significant 
increased in hippocampal A40 levels were observed in those animals treated with LH 
at day 14 and day 28 compared to non-GDX control animals (*p<0.05). All data are 






Figure 4.5: Levels of full length APP and its C-terminal fragment in frontal cortex 
and hippocampus of GDX guinea pigs administered placebo or LH for 14 or 28 
days.  
(A) Compared to GDX animals administered placebo, there were no significant changes 
observed in FL-APP and APP-CTF levels as a result of LH supplementation at 14 and 
28 days LH pellet administration. (B) Hippocampal levels of FL-APP and APP-CTF 
levels were significantly increased in homogenates of animals following 28 days of LH 






















4.4.2 Increased brain P450scc protein levels following administration of LH to 
guinea pig.  
 
Our results above indicate that cerebral Aβ levels were significantly altered in the 
frontal cortex and hippocampus of guinea pigs administered LH. We next examined 
expression levels of the P450scc enzyme, in the frontal cortex and hippocampus, as an 
indicator of the activation of LH signalling. The results show expression of the ~ 49 
kDa P450scc enzyme in both brain regions (Figure 4.7A). A similar sized protein band 
(49-50 kDa) has been reported in rodent brain (Chia, 2008 ;Kimoto, 2001) . Analysis of 
levels of P450scc in the frontal cortex (Figure 4.6A) and hippocampus (Figure 4.6B) 
revealed a main effect of LH treatment (F=16.647, p<0.01 and F=16.688, p<0.01, 
respectively) where significant increases were observed at day 28 (p<0.01). 
Unexpectedly, the levels of P450scc in the hippocampus of the placebo groups were 
also significantly decreased from day 14 to day 28 (p<0.05). The experiment was 
performed three times and a similar result was achieved on each occasion. Further, β-
actin levels were shown to be similar in all samples, ruling out the possibility of sample 
loading errors. To investigate this further and determine if the dramatic reduction was 
due to GDX, another aliquot of hippocampal homogenates from non-GDX, GDX or 
GDX animals containing placebo implants underwent western immunoblotting for 
P450scc. The results show that compared to non-GDX control guinea pigs, levels of 
P450 were significantly decreased in GDX or GDX animals implanted with placebo 











Figure 4.6: Levels of cytochrome P450 cholesterol side-chain cleavage enzyme 
(P450scc) in frontal cortex and hippocampus of non-GDX, GDX or GDX guinea 
pigs administered placebo or LH for 14 or 28 days. 
(A) Compared to placebo treated animals, P450scc levels within the frontal cortex 
were significantly increased following 28 days of LH supplementation 
(**p<0.01). (B) In the hippocampus, P450scc levels were also increased 
significantly at 28 days post LH treatment (##p<0.01). Unexpectedly, the levels 
of P450scc in the hippocampus of the placebo groups were significantly 
decreased from day 14 to day 28 (*p<0.05).  (C) Hippocampal levels of P450scc 
were measured in homogenate from non-GDX, GDX and GDX animals 
administered placebo for 14 or 28 days. Compared to the non-GDX control 
animals, P450scc levels were significantly reduced in all GDX animals 
(***p<0.001). Compared to animals administered placebo for 14 days, 
hippocampal levels of P450scc were significantly reduced in those animals 








Evidence supports the notion that LH promotes the amyloidogenic pathway  (Bowen, 
2004 ), and that peripheral administration of its analogue, hCG can impair memory and 
learning in rodents and result in the accumulation of cerebral Aβ levels (Barron, 
2010;Berry, 2008) . However, there is yet no in vivo data to indicate that the direct 
application of LH itself to the CNS can alter Aβ metabolism. This chapter addressed 
this by implanting slow release pellets in the parietal cortex of the GDX guinea pig 
brain.  
 
We have previously shown that plasma and CSF Aβ40 levels were increased following 
GDX of male guinea pigs (Chapter 3, Wahjoepramono, 2008) . Although in the current 
study plasma Aβ40 levels were unaltered [possibly due to the shorter period of GDX in 
this study (14 days) compared with that of [Chapter 3, Wahjoepramono, 2008 (36 
days)], increased CSF Aβ40 levels were observed. We have extended these findings to 
also show increased cerebral Aβ levels.  
 
However, analysis of Aβ40 levels in the frontal cortex and hippocampus revealed 
contrasting results. GDX did not alter levels of Aβ40 within the frontal cortex, whereas 
an increase in Aβ40 levels was observed in the hippocampus. Immunohistochemical 
analysis of brain tissue from GDX male transgenic mice has shown marked deposition 
of Aβ in the subiculum and the CA1 region of the hippocampus (Rosario, 2010 
;Rosario, 2006) . However, these studies did not report any changes within the frontal 
cortex. The availability of larger quantities of brain tissue from guinea pigs has 
provided the opportunity to undertake a quantitative analysis of endogenous Aβ and 
indicates that there are regional specific changes in Aβ levels associated with 
gonadectomy. Reductions in testosterone as a result of GDX would also lead to a 
corresponding increase in peripheral LH levels and evidence exists that this increase 





gonadotropins can cross the BBB and impact on hippocampal dependent memory and 
behaviour in rodents (Heller, 1968 ;Knowles, 1972;Lukacs, 1995) . Further, peripheral 
administration of the more potent analogue of LH, hCG has been shown to impair 
working memory in rodents and increase in cerebral Aβ levels (Barron, 2010 ;Berry, 
2008) . Studies also suggest that LH is localised to the hippocampus and is the most 
likely site of LH signalling in the brain (Bowen, 2002;Liu, 2007 ;Wilson, 2006) . 
Together, these findings indicate that the hippocampus may be a major target for 
gonadotropins within the brain.  
 
Further evidence for this notion has been presented in the findings in the current chapter 
where the addition of exogenous LH, led to differences in levels of Aβ in the 
hippocampus and the frontal cortex. Significant increases in Aβ40 levels were observed 
in the hippocampus earlier (at day 14- post implanation) compared to the increases 
observed in the frontal cortex. Further, there was a significant increase in expression 
levels of APP and its C-terminal fragment in the hippocampus as a result of LH 
treatment.  This increase was not observed in the frontal cortex. Increases in APP 
expression have been previously reported when human embryonic stem cells are treated 
with hCG (Porayette, 2007) , and the amyloidogenic and non-amyloidogenic processing 
of APP have been shown to drive these cells into cell proliferation or differentiaion into 
neuronal precursor cells (Porayette, 2009) . In results presented in Figure 4.5, the 
increase in APP and its fragments within the hippocampus most likely accounts for the 
increase in Aβ40 levels observed in this region of the brain.  
 
Analysis of CSF showed that both LH and duration of treatment impacted on Aβ40 
levels, where there was a significant increase following 14 and 28 days treatment. No 
changes were observed in plasma Aβ40 levels indicating impaired efflux of Aβ from the 
CNS, resulting in the accumulation of Aβ within the CNS. Aβ is known to cross the 
BBB into the periphery through a number mechanisms and impaired efflux of Aβ from 
the CNS is one mechanism thought to contribute to the accumulation of Aβ in the brain 
[reviewed in (Bates, 2009) ]. In chapter 3, data was presented to show that 





and an increase in plasma Aβ levels, suggesting that testosterone may promote 
clearance of Aβ from the CNS (Wahjoepramono, 2008).  
 
Although no significant changes in the brain apoE levels with LH administration (data 
not shown) was observed,, investigating the effects of LH on other transport proteins 
involved in transporting Aβ across the BBB, e.g. RAGE, LRP-1, Aβ degradative 
enzymes or microglia would be of interest to confirm and provide further insight into 
mechanisms involved in the apparent impairment in Aβ clearance from the CNS.  
 
The results presented in this chapter also show for the first time, in vivo, that the 
addition of human LH increases the expression of endogenous brain levels of P450scc. 
In gonadal tissues P450scc converts cholesterol to the steroid precursor, pregnenolone, 
and it is up-regulated when the LHR signalling pathway is activated in vivo (Scott, 
1990)  and (Luo, 2005) ;Rekawiecki, 2005) . Components of the LHR signalling 
pathway have been shown to be present in neuronal cells (Bowen, 2002 ;Liu, 2007 
;Mukai, 2006 ;Murakami, 2006 ;Wilson, 2006)  and in rodent brain (Kimoto, 2001). 
While assessing levels of other components in the LH signalling pathway such as StAR, 
pregnenolone or other neurosteroids would provide further evidence of activation of LH 
signalling, it is probable that the increased levels of P450scc in the frontal cortex reflect 
activation of LH signalling.  
 
It is noted, however, that there was a dramatic decrease in P450scc levels in the 
hippocampus of animals treated with placebo for 28 days compared to 14-day treatment. 
This result was unexpected and the reason for the marked reduction is unclear. 
However, compared to non-GDX animals, a similiar reduction in P450scc levels was 
observed in the hippocampus of GDX animals (which did not undergo surgical 







This reduction may reflect a down regulation of P450scc synthesis due to prolonged 
period of testosterone depletion. While, there is no current evidence for this occuring in 
the brain, age related reductions in testosterone in rat leydig cells have been shown to 
correlate with reductions in P450scc and StAR mRNA tanscript and protein levels (Luo, 
2005) . Although this reduction was observed over months in the Luo et al.,2005  study, 
down-regulation of P450scc may be accelerated under conditions of testosterone 
depletion. Despite this reduction, the addition of LH resulted in an up-regulation of 
P450scc expression, but whether this increase was sustained over a longer period was 
not addressed in this study.  
 
Although our results show an LH-mediated up-regulation of P450scc, whether increases 
in Aβ levels were associated with activation of LH signalling was not addressed in the 
current study. However, findings from a recent study, suggest that the signalling 
pathway may play an important role in Aβ accumulation (Lin, 2010) . In this study, 
crossing of LHR-/- mice with the AD transgenic model Tg2576 resulted in a reduction 
in AD pathology, namely amyloid deposition, astrogliosis and tau phosphorylation (Lin, 
2010). Interestingly, while LHR-/- mice are devoid of sex steroids for the duration of 
life and show increased peripheral levels of gonadotropins, depletion of sex steroids and 
increased accumulation of gonadotropins has previously been associated with 
exacerbated AD pathology (Bowen, 2002 ;Rosario, 2006) .  
 
While it is difficult to explain the reason(s) why ablation of LHR prevents Aβ 
deposition yet leads to other conditions normally associated with increased AD 
pathology, the study by Lin et al (Lin, 2010)  is the first to implicate LHR in AD 
pathogenesis and provides evidence that LH signalling pathways play an important role 
in Aβ metabolism and accumulation. Studies using cell culture models utilising various 
LH receptor binding or signalling mutants may address some of the mechanisms 
associated with LH mediated modulation of Aβ metabolism (Lee, 2002) . However, it 
should also be noted that LH could act through receptor independent mechanisms as is 
evident in findings that have shown gonadotropin-mediated effects on non-gonadal 





2003;Allan, 2010) . Overall the findings from my study have provided initial evidence 
that direct exposure of the CNS to LH can alter Aβ metabolism. Whether this occurs at 
more physiological concentrations of LH, is addressed in the next chapter where LH or 
the  GnRH agonist (leuprolide acetate) that has been shown to lower endogenous LH, 
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Peripheral administration of human 
luteinizing hormone (LH) and leuprolide to 

















As described in detail in Chapters 1 and 4, increases in gonadotropin levels, 
particularly, luteinizing hormone (LH) during aging, may contribute to AD 
pathogenesis (Bowen et al., 2004; Casadesus et al., 2006, 2007, Webber et al., 2007, 
Verdile et al., 2008, Berry et al., 2008, Barron et al., 2010, Wahjoepramono et al., 
2011).There is accumulating evidence (both in vitro and in vivo) in support of 
exogenous human LH (Bowen et al., 2004; Casadesus et al., 2006; Wahjoepramano et 
al., 2011), over-expression of LH (Casadesus et al., 2007) or addition of its more potent 
analogue, hCG (Barron et al., 2010;Berry et al., 2008; Lucaks et al., 2005) can 
modulate accumulation of cerebral Aβ levels and impair hippocampal associated 
behaviours. In the previous chapter, the direct application of LH to the guinea pig CNS 
was shown to increase CSF and cerebral Aβ levels. This chapter investigated  whether 
peripheral administration of LH can modulate CNS levels of Aβ. It also assesses the 
efficacy of the GnRH agonist, leuprolide at modulating CNS Aβ levels in the guinea 
pig. 
 
Leuprolide (Leuprolide acetate) is currently used for the treatment of endometriosis 
(Strowitzkiet al., 2012), prostatic cancer (Trachtenberg, J. 1983; N.J. Wojciechowski, 
1986; Leonard,S.M, 2003, and precocious puberty (Kappy et al., 1989 ; Neely et al., 
1992; Clemons et al., 1993). Both GnRH agonists or antagonists are analogues designed 
by specific amino acid substitutions to alter efficacy, affinity and prolong their duration 
of action (reviewed by Millar et al., 2004). GnRH has a half life of 2-4 minutes 
(Jeffcoateet al., 1974) and its analogues have a half life in the range of hours. 
Administration of the agonist, leuprolide, results in an initial increase or “flare effects” 
in serum gonadotropin secretion for several days which is followed by a precipitous 
reduction. This decrease is a result from the loss of GnRH signalling due to the 
desensitization of pituitary GnRH receptors which will lead to downregulation of 
gonadotropin secretion (Periti et al., 2002).  
 
Administering leuprolide to wild type or APP transgenic mice has been shown to reduce 
brain Aβ levels and deposition (Bowen et al., 2004; Casadesus et al., 2006). The use of 





soluble brain Aβ levels and effects on CSF Aβ levels to be analysed. In addition, the 
absence of APP over-expression and robust amyloid deposition, which may mask the 




 To determine the effects of peripherally administering human LH to guinea pigs 
on CSF Aβ, and levels of brain Aβ, APP and its metabolites. 




Peripheral administration of human LH and Leuprolide to guinea pigs 
A total of 36 guinea pigs were gonadectomised (GDX) under halothane anaesthesia as 
previously described in Chapter 2.2.2.1. One week following GDX, forty-day slow 
release pellets: placebo, LH, and leuprolide (Innovative Research of America, Florida, 
USA) were implanted in the periphery (subcutaneous insertion into the dorsal neck fat 
pad of guinea pigs), as described in section 2.2.2.1. The groups and concentrations of 
active ingredients within the slow release pellets are shown in Figure 5.1. Note that, 
compared to animals that had undergone GDX only (for period of 18 or 36 days), those 
administered slow release implants had undergone GDX 1 week prior to insertion of 
implants. Thus, the total time in which guinea pigs exhibited reduced testosterone levels 



























Figure 5.1: A summary of animal groups and treatments used. 
CSF and tissue collection 
At day 18 or 36 post-implant, animals were sacrificed and CSF and brain were collected 
to measure the A40 levels, as previously described in chapter 2. All animals were 
cardiac-perfused with heparinised-cold PBS. The brain was removed and snap frozen in 
liquid N2 for  ELISA measurement of A40. Prior to each assay, the brain was dissected 
into frontal cortex and hippocampus and was homogenized in cold PBS with protease 
inhibitor. APP and its metabolites were examined semi-quantitatively via western blot 
as described in chapter 2.2.3. -actin was used as a loading control protein. A sensitive 
double-antibody sandwich ELISA assay was used for the detection and measurement of 
A levels in tissue homogenates, plasma, and CSF respectively as described in chapter 
2.2.5. CSF Aβ levels used in this Chapter and the previous two Chapters were all 
measured in the same assay together. 
Statistical analysis 
Data was analysed using the Statistical Package for Social Sciences (SPSS : version 17; 
SPSS Inc., Chicago, Illinois, USA). Experiments were 2x2 factorial designs (presence 
or absence of placebo x presence or absence of LH and/or Leuprolide). Analysis of data 
were performed by two-way ANOVA at the 0.05 significance level to test for treatment 
interactions and main effects. If the data was found to be heterogenous, analysis was 
performed using non-parametric Kruskal Wallis analysis of variance. This is noted in 






5.4.1 Guinea pig CSF and brain Aβ levels are altered following peripheral 
administration of LH.  
To determine the effects of the peripheral addition of exogenous LH on CNS Aβ levels, 
slow release implants of LH or placebo were administered subcutaneously to 
gonadectomised (GDX) guinea pigs for 18 and 36 days. Aβ40 levels were measured in 
the CSF, frontal cortex and hippocampus and results are shown in Figures 5.2, 5.3 and 
5.4 respectively. As described in chapter 3, (section 3.4.1), compared to intact controls 
(non-GDX), GDX for 18 or 36 days led to a significant increase in CSF Aβ40 levels 
(Figure 5.2A). This most likely reflects the reductions in testosterone in these GDX 
animals (see chapter 3, Figure 3.2). Administering exogenous LH led to a further 
increase (Figure 5.2B). Two-way analysis of variance (ANOVA) showed that there was 
a main effect of LH  (F=7.934, p<0.01) and an effect on the duration of treatment 
(F=4.745, p<0.04)(Figure 5.1B). Pairwise comparison analysis revealed that compared 
to placebo treated animals, CSF Aβ40 levels were significantly increased following 36 
days of treatment with LH (p<0.05). Overall, these results indicate that although GDX 
led to an increase in CSFAβ40 levels, the addition of exogenous LH led to a further 
increase, which was dependent on duration of treatment. 
To determine if the effects of LH in the CSF reflected that occurring in the brain the 
frontal cortex and hippocampus were isolated and underwent analysis for Aβ40. As 
reported in chapter 3, 18 days of GDX did not significantly alter Aβ40 levels in the 
frontal cortex; however levels were significantly reduced following 36 days GDX 
(Figure 5.2A).  Administering the LH implant resulted in a reduction in Aβ40 levels 
within the frontal cortex.  Two-way analysis of variance (ANOVA) showed that there 
was a main effect of LH treatment (F=35.645, p<0.01; Figure 5.2B) and duration of 
treatment (F=5.514, p<0.029), where Aβ40 levels were significantly reduced following 
18 and 36 days of treatment (p<0.05). 
In the hippocampus, GDX led to a significant increase in Aβ40 levels (Figure 5.3A). 
This effect of GDX was lost at day 36.  In contrast, administering LH led to a 





effect of LH treatment (F=14.801, p<0.001; Figure 5.3B), however there was no effect 
of duration of treatment (F=0.789, p<0.385). These results indicate that the addition of 
exogenous LH peripherally, negated the effects of GDX on brain Aβ40 levels. 
To determine if administering LH altered the levels of APP and its metabolites, brain 
homogenates underwent western immunoblotting for FL-APP and its C-terminal 
fragments (APP-CTF). Analysis of FL-APP levels in the frontal cortex revealed no 
significant impact of treatment (F=0.896, p<0.356) or duration of treatment (F=0.033, 
p<0.858). The data for APP-CTF levels was not normally distributed and as such two-
way analysis (for normally distributed data) could not be performed. Instead the non 
parametric, Kruskal Wallis analysis was performed. Analysis revealed no statistically 
significant changes in APP-CTF. Similar results were observed in hippocampal tissue. 
Overall, the results indicate that changes observed in cerebral Aβ40 levels due to LH 
administration were not attributed to altered levels of APP and its C-terminal fragment.  
To further determine if the reductions in cerebral Aβ40 levels were associated with 
changes in APP metabolism, levels of α-APPs, were measured in the frontal cortex. As 
mentioned in Chapter 3, this region provides sufficient material for ultracentrifugation 
to obtain supernatant free of cell debris (as described in section 2.2.2.3). Following Aβ 
analysis via ELISA and western blot analysis of APP, the frontal cortex was the only 
region to have sufficient amount of tissue remaining required to perform this analysis.  
The sAPPα protein was detected via western immunoblotting and underwent 
quantitative analysis (Figure 5.6). Analysis by two-way ANOVA showed that there is a 
main effect of treatment (F=8.251, p<0.014) and duration of treatment duration of 
treatment (F=6.126, p<0.029). Pairwise comparison analysis showed that compared 
with placebo, α-APPs levels were significantly increased at day 36 (p<0.05). 
Taken together the results indicate that administering LH peripherally, led to increased 
CSFAβ40, a similar trend to that seen following direct exposure of LH to the brain (see 
Chapter 4, Figure 4.1). However, unlike cerebral exposure to LH, administering the 
hormone, peripherally led to a reduction in Aβ levels in the frontal cortex and 
hippocampus. The reduction in Aβ40 levels corresponded with an increase in α-APPs in 

























































Fig 5.2: CSF Aβ40 levels from GDX guinea pigs administered placebo or LH for 18 
or 36 days. Gonadectomised (GDX) guinea pigs were administered placebo or LH slow 
release pellet implants for 18 or 36 days and CSF was collected from the cisterna 
magna.  
(A) GDX guinea pigs show increased levels of the CSF A40 compared to non-GDX at 
day 18 and 36 following surgery. Data is represented as mean± SEM of 6 animals/ 
group. *, p<0.05.Values significantly increased from non-GDX.  
(B) Compared to the placebo group within the same day of treatment, CSF A40 was 
significantly increased in animals administered LH at day 36.Data is represented mean± 
SEM. For placebo day 18, n=5, for placebo day 36 n=8, for LH day 18 and 36 n=6 for 













































































Figure 5.3: Aβ40 levels from frontal cortex of GDX guinea pigs administered 
placebo or LH for 18 or 36 days. Gonadectomised (GDX) guinea pigs were 
administered placebo or LH slow release pellet implants for 18 or 36 days and Aβ40 
levels were measured in the frontal cortex.  
(A) GDX guinea pigs show increased levels of A40 compared to non-GDX at day 18 
and 36 following surgery. Data is represented as mean± SEM of 6 animals/ group. *, 
p<0.05, Values significantly reduced compared to GDX at Day 18.   
(B) Administering the LH implant resulted in a reduction in Aβ40 levels within the 
frontal cortex. Two-way ANOVA and pairwise comparison analysis revealed that 
compared to placebo treated animals, Aβ40 levels were significantly reduced following 
18 or 36 days of LH treatment (p<0.05). Data is represented mean± SEM. For placebo 
day 18, n=5, for placebo day 36, n=8, for LH day 18 and 36n=4 for each group*, 
p<0.05.Values were significantly reduced compared to placebo treated animals at both 











































































Figure 5.4: Aβ40 levels from hippocampus of GDX guinea pigs administered 
placebo or LH for 18 or 36 days.Gonadectomised (GDX) guinea pigs were 
administered placebo or LH slow release pellet implants for 18 or 36 days and Aβ40 
levels were measured in the hippocampus.  
(A) GDX guinea pigs show increased levels of Aβ40 compared to non-GDX at day 18 
and but not at day 36 following surgery. Data is represented as mean± SEM of 6 
animals per group.*, p<0.05. Value was significantly increased from non-GDX control. 
#, <0.05, Value at day 36 was significantly reduced from day 18 of GDX.  
(B) Administering the LH implant resulted in a reduction in Aβ40 levels within the 
frontal cortex. Two-way ANOVA and pairwise comparison analysis revealed that 
compared to placebo treated animals, Aβ40 levels were significantly reduced following 
36 days of treatment. Data is represented mean± SEM. For placebo day 18, n=4, for 
placebo day 36 n=8, for LH day 18 and 36 n=5/time point ,*p<0.05. Value is 































































Figure 5.5 : Ratio of Aβ40 levels in the CSF to those in the frontal cortex (A) and 
hippocampus (B) of GDX guinea pigs administered placebo or LH for 18 or 36 
days.(A) In the frontal cortex, there was main effect of treatment (F=26.311, p<0.0001). 
No effects of duration of treatment (F=0.029, p<0.867) and interaction effect between 
treatment and duration of treatment (F=0.08,  p<0.781) impacted on rates of Aβ40 
clearance. Compared to placebo, LH treatment significantly increased CSF Aβ40 to 
frontal cortex Aβ40 in both 18 and 36 days post implant. **p<0.0001  (B) In the 
hippocampus, treatment (F=8.336, p<0.011), duration of treatment (F=1.786, p<0.2) 
and interaction effect between treatment and duration of treatment (F=1.715, p<0.209) 
did not impact on hippocampal Aβ40 levels. LH treatment led to a trend towards 
increased CSF Aβ40 to hippocampus Aβ40 ratio in both 18 and 36 days post-
implant.Data is represented mean± SEM, for placebo day 18, n=4, for placebo day 36 



































































































































Figure 5.6 : Levels of full length APP and its C-terminal fragment in frontal cortex 
and hippocampus of GDX guinea pigs administered placebo or LH for 18 or 36 
days. 
Gonadectomised (GDX) guinea pigs were administered placebo or LH slow release 
pellet implants for 18 or 36 days and levels of APP and its C-terminal fragment (APP-
CTF) were assessed by immunoblotting from tissue homogenates of (A) frontal cortex 
or (B) hippocampus. No significant changes were observed for FL-APP and its C-
terminal fragemt in both the frontal cortex and hippocampus. Note that the data from 
APP-CTF in the frontal cortex was not heterogeneous, thus statistical analysis was 
performed using the non parametric Kruskal Wallis analysis of variance.Data is 







Figure 5.7: Levels of α-APPs in frontal cortex of GDX guinea pigs administered 
placebo or LH for 18 or 36 days. 
Tissue homogenates from the frontal cortex underwent processing to isolate the soluble 
fraction to measure secreted -APP by western immunoblotting(A). Administration of 
LH in the periphery increased the levels of α-APPs significantly at day 36 compared to 
the placebo groups(B). Two-way ANOVA and pairwise post-hoc analysis revealed that 
compared to placebo treated animals, α-APPs levels were significantly reduced 
following 36 days of treatment *p<0.05, Value is significantly reduced from 36 day 









5.4.2 Cerebral Aβ levels are significantly reduced in leuprolide treated guinea pigs. 
Previous studies in mice administered leuprolide have shown that this GnRH agonist  
reduced cerebral Aβ deposition (Bowen et al., 2004; Casadesus et al, 2006). The use of 
a larger rodent (non-transgenic) model such as the guinea pig allows regional 
differences in soluble brain Aβ levels and effects on CSF levels to be analysed.  
 
GDX guinea pigs were administered a concentration of leuprolide for 18 or 36 days. 
Following treatment, animals were sacrificed and CSF and brain Aβ levels were 
analysed. The results are shown in Fig 5.7 and 5.8. Compared to animals administered 
placebo those treated with leuprolide did not show significantly altered CSF Aβ40 
levels.  However a trend towards a reduction was observed following 18 days leuprolide 
treatment. Two-way ANOVA revealed there was a main effect of duration of treatment 
(F=9.589, p<0.005), rather than the treatment itself (F=0.072, p<0.079).  This effect was 
particularly evident in the leuprolide group where there was a significant increase at day 
36, compared to day 18 post-treatment (p<0.012).  
Analysis of brain Aβ40 levels revealed changes due to leuprolide treatment, particularly 
in the frontal cortex.Analysis of Aβ40 levels in the frontal cortex revealed main effects 
of both treatment (F=0.937; p<0.006) and duration of treatment (F= 0.935; p<0.007). 
Compared to placebo, leuprolide treatment initially led to a significant increase in Aβ40 
levels at 18 days (p=0.031), and then a reduction following 36 days of treatment 
(p=0.024) (Figure 5.8 A). However, analysis of hippocampal Aβ40 levels showed no 
effects of the treatment (F=1.31, p<0.266) or duration of treatment (F=0.09, p<0.768) 
(Figure 5.8B). 
Analysis of levels of APP and its C-terminal fragment in both the frontal cortex and 
hippocampus revealed no significant changes associated with leuprolide 
treatment(Figure 5.9). However, analysis of α-APPs levels showed that leuprolide 
increased the levels of this APP fragment. Two-way ANOVA revealed there were 
significant effects of leuprolide treatment (F=28.158,p<0.001) and duration of treatment 





following 18 (p=0.002) and 36 (p= 0.001)days post-leuprolide treatment(p<0.05)(Figure 
5.10). 
Overall, the results show the most prominent effects of leuprolide were observed in the 
frontal cortex. The levels of Aβ40 initially increased 18 days after treatment then 
reduced following 36 days of treatment. Prominent increases in α-APPs were also 
observed in the frontal cortex. No leuprolide mediated changes in Aβ40 levels were 


































Figure 5.8 : CSF Aβ40 levels from GDX guinea pigs administered placebo or 
leuprolide for 18 or 36 days. Gonadectomised (GDX) guinea pigs were administered 
placebo or leuprolide slow release pellet implants for 18 or 36 days and CSF was 
collected from the cisterna magna. Although not significant, at day 18 compared to 
animals administered placebo, those administered leuprolide showed reduced levels of 
CSFAβ40. Levels increased in both the placebo and leuprolide groups 36 days after 
administering the slow release implants. Data is represented as mean± SEM of 6 
animals/group. Please note that CSFAβ40 from 2 samples of the day 18 
leuprolidegroup,were not detectable by the ELISA assay.*, p<0.05, Values at day 36 

























































































Figure 5.9 : Aβ40 levels from frontal cortex and hippocampus of GDX guinea pigs 
administered placebo or leuprolide for 18 or 36 days. Gonadectomised (GDX) 
guinea pigs were administered placebo or leuprolide slow release pellet implants for 18 
or 36 days and Aβ40 levels were measured in the frontal cortex and hippocampus.(A) In 
the frontal cortex, treatment and duration of treatment impacted on Aβ40 levels. 
Compared to placebo, leuprolide treatment initially led to a significant increase in Aβ40 
levels at 18 days, and then a reduction following 36 days of treatment. (B) In contrast to 
Aβ40 levels in the frontal cortex, treatment or duration of treatment did not impact on 
hippocampal Aβ40 levels. Data is represented as mean± SEM of 6 animals per 
group*p<0.05. Values significantly increased (Day18) or decreased (Day 36) in 
leuprolide treated animals.  #p<0.05. Values at day 36 were significantly reduced 




























































Figure 5.10 : Ratio of Aβ40 levels in the CSF to those in the frontal cortex (A) and 
hippocampus (B) of GDX guinea pigs administered placebo or leuprolide for 18 or 
36 days. A ratio of Aβ40 levels in the CSF to those in (A) frontal cortex and (B) 
hippocampus was calculated and is presented as a bar graph.(A) In the frontal cortex, 
there were no treatment (F=0.169, p<0.686), duration of treatment (F=2.577, p<0.127) 
and interaction effect between treatment and duration of treatment (F=3.515, p<0.078) 
impacted on rates of Aβ40 clearance. Compared to placebo, leuprolide treatment led to 
a trend towards increases of CSF to Aβ40 ratio following 36 days of treatment.  (B) In 
hippocampus, treatment (F=0.018, p<0.894), duration of treatment (F=2.2, p<0.156) 
and interaction effect between treatment and duration of treatment (F=1.946, p<0.181) 
did not impact on hippocampal Aβ40 levels. Similar trends was observed like in frontal 
cortex. Data is represented mean± SEM, for placebo day 18, n=4, for placebo day 36 



















































































































































Figure 5.11 : Levels of full length APP and its C-terminal fragment in frontal 
cortex and hippocampus of GDX guinea pigs administered placebo orleuprolide 
for 18 or 36 days. 
Gonadectomised (GDX) guinea pigs were administered placebo or LH slow release 
pellet implants for 18 or 36 days and levels of APP and its C-terminal fragment (APP-
CTF) were assessed by immunoblotting from tissue homogenates of (A) frontal cortex 
or (B) hippocampus.(A) Treatment or duration of treatment did not significantly impact 
on FL-APP (F=2.619,p<0.121; F=0.981,p<0.334) or APP-CTF (F=0.133,p<0.72; 
(F=1.565,p<0.225)  in the frontal cortex. (B) Treatment or duration of treatment did not 
significantly impact on FL-APP (F=2.509,p<0.129; F=0.416,p<0.526) or APP-CTF 
(F=6.191,p<0.22; (F=0.327,p<0.574) in the hippocampus. Data is represented as mean± 



































Figure 5.12: Levels of α-APPs in frontal cortex of GDX guinea pigs administered 
placebo or leuprolide for 18 or 36 days  
(A) Homogenates from the frontal cortex underwent western immmunoblotting for α-
APPs using antibody WO2. Immunoblotts show 2 representative samples from each 
group.  
(B) Quantitative analysis of all samples followed by Two-way ANOVA analysis 
revealed a main effect of treatment (F=28.158,p<0.001) and duration of treatment 
(F=9.51,p<0.006). **p<0.01 Values significantly increased compared to placebo. Data 








The findings from Chapter 4 provided initial evidence that direct exposure of the CNS 
to LH can alter cerebral Aβ metabolism. Whether this occurs under more physiological 
conditions is addressed in the current chapter where peripheral LH is administered as a 
slow release implant (Bowen et al., 2004; Casadesus et al., 2006). In addition, 
administration of the GnRH agonist (leuprolide acetate) was also investigated as it has 
been shown to reduce LH levels (Bowen et al., 2004). 
In Chapters 3 and 4, GDX was shown to increase CSFAβ40 levels, and the addition of 
LH was shown promote a further increase (Chapter 4, Fig 4.1), which was associated 
with increases in the frontal cortex and hippocampus. In contrast to these results, 
findings in the current chapter showed that peripheral addition of LH resulted in a time 
dependent increase in CSF Aβ40 levels but a reduction in cerebral Aβ40 levels. This 
reduction was more prominent in the frontal cortex where significant changes were 
observed earlier (18 days). However, by 36 days post- LH implantation, significant 
reductions were observed in both frontal cortex and hippocampus. The reduction in 
cerebral Aβ40 levels associated with a corresponding increase of CSF Aβ40 suggests 
that Aβ clearance is enhanced in guinea pigs administered LH. However changes were 
also observed in other APP metabolites, implying effects on APP processing.  Although 
not significant a trend towards a reduction in full length APP and APP-CTF level was 
observed. This observation may account partially for the reduction in Aβ40 levels 
within the frontal cortex and hippocampus, particularly at day 36 post-implant.  
However significant increases in α-APPs in post-ultracentrifugation supernatants of the 
frontal cortex were also observed.  
 
To date current findings indicate that gonadotropins promote increased neuronal Aβ 
levels (Bowen et al, 2004, Barron et al., 2010). Furthermore, increased serum 
gonadotropins have been shown to be negatively associated with cognitive functioning 
in human (Rodrigues et al., 2008, Hyde et al., 2010) and animal studies (Casadesus et 
al., 2007, Berry et al., 2008, Barron et al., 2010).  Although peripheral LH 
administration did result in an increase in CSF Aβ40 levels, surprisingly cerebral Aβ40 





compared to that presented in chapter 4 (Wahjoepromono et al., 2011), where the 
application of LH directly to the brain resulted in an increase in frontal cortex, 
hippocampal and CSF Aβ40 levels. This is consistent with direct exposure of LH to 
neuronal cells in vitro, which has been shown to increase secreted and intracellular 
levels of Aβ, implicating a role for LH in promoting amyloidogenic processing of APP 
(Bowen et al., 2004). The results presented in this current chapter however provide an 
argument against this earlier notion of LH action, as although treatment with LH 
increased CSF Aβ40 levels, there is a marked reduction in cerebral Aβ levels.  
 
The dose of LH used in the two experiments namely in Chapter 4 and this current 
Chapter were the same [2.25 ug/Kg (11.25 IU/Kg) BW/day].  Taken into account the 
body weight and blood volume of the guinea pigs used (500g and 35 ml, respectively), 
this dose is equivalent to 160 mIU/ml, which is about 16x and 5x the doses shown to 
increase the intracellular accumulation of Aβ and APP-CTFsand increase secretion of 
Aβ (10 mIU/ml and 30 mIU/ml, respectively) in vitro. The most likely explanation for 
the contrasting results is the site of LH application, which most likely led to a different 
level of exposure between the brain and the periphery. The direct application of slow 
release implants to the brain would be expected to lead to much higher levels of LH as 
opposed to its administration in the periphery. It could be argued that the high exposure 
to LH in the guinea pig brain described in Chapter 4 is similar to the situation where 
neurons exposed to LH, in vitro, result in the accumulation of Aβ (Bowen et al., 2004). 
 
Although studies have shown the presence of gonadotropins in CSF (Heller et al., 1968, 
Knowles, 1972), one study has shown that a relatively small percentage (<1%) of 
peripheral gonadotropins (hCG), can cross the blood brain barrier into the CSF and 
hippocampus (Lukacs et al., 1995). Further, LH is rapidly metabolized in the plasma 
with its half-life reported to be about 69 minutes (Schalch et al., 1968).  
  
In the experiments outlined in this Chapter the relatively rapid metabolism of LH would 
be compensated with a constant, daily release of LH ensuring relatively constant levels 
over a long term period.  The concentration of LH used in this current study was about 
5x less than the dose of its more potent analogue, hCG (60IU/kg/day) which was shown 





Given the difference in potency of LH relative to hCG and the dose used it could be 
argued that minimal or no effects (as compared to direct exposure to the CSF) would 
have been observed. Surprisingly the converse is true where marked (opposite) effects 
in the CNS was observed when LH is administered peripherally. 
 
The increase in CSF Aβ40, decrease in cerebral Aβ40 and increase in soluble αAPPs, 
implies the LH may be acting to reduce cerebral Aβ, by actually promoting release of 
this neurotoxic peptide into the CSF. In favour of this notion there is evidence in the 
literature that supports increased secretion of Aβ and enhanced αAPPs generation as a 
mechanism by which to reduce intracellular Aβ. Querfurth and Selkoe, (1994) showed 
that treatment with a calcium ionophore (that leads to an increase in intracellular 
calcium) increased cellular secretion of Aβ, APPs, and also the non-amyloidgoenic 
fragment, p3. More recently, insulin has been shown to increase the secretion of α-APPs 
and Aβ, and reduce intracellular Aβ levels, a response that was mediated by MAPK 
signalling (Gasparini et al., 2001). Similar findings were observed with latrepirdine 
(previously known as DimebonTM), an anti-histamine showing cognitive enhancing 
capabilities. Treatment of neuronal cells with latrepirdine led to an increase secretion of 
Aβ and α-APPs (Steele et al., 2009). The latter study also showed that latrepirdine 
administered to transgenic mice promoted the release of Aβ into the interstitial fluid 
(ISF) and from isolated cortical synpatoneurosomes. It was suggested that latrepirdine 
may enhance synaptic activity. Synaptic activity has been shown to modulate Aβ release 
into the ISF (Cirrito et al., 2008) and promote the transport of APP to synapses and 
secretion of Aβ at the synapses, thereby reducing intraneuronal levels of Aβ (Tampellini 
et al., 2009). 
 
The studies above suggest, intracellular calcium levels and APP trafficking/ synaptic 
activity could all modulate the release of non-amyloidogenic and amyloidogenic 
fragments. It could be speculated that LH may activate these pathways thereby 
promoting release of APP metabolites and reduction in intracellular Aβ, however there 
is no strong evidence in the current findings presented in this chapter or in the literature 
that support this notion. Interestingly though, recent evidence indicates that intracellular 
Ca+2 levels rise in bovine cumulus oocyte complexes (Silvestre et al., 2012) and mouse 





et al (2011) further showed that the LH mediated increase in Ca+2 levels was attenuated 
by protein kinase (PKC and PKA) inhibitors, indicating that the LH mediated changes 
in intracellular calcium homeostasis is through activation of kinases (Costa et al., 2011), 
which are known to regulate APP metabolism (Caporaso et al., 1992; Buxbaum et al., 
1993; Gillespie et al., 1992; Demaerschalck et al., 1993; Gabuzda et al., 1993; Slack et 
al., 1993; Hung et al., 1993). Whether LH has a similar action in regulating calcium 
levels in neurons and whether this is mediated through activating protein kinases that 
regulate APP processing remains to be determined.  
 
This Chapter also investigated whether, leuprolide acetate reduced cerebral Aβ levels in 
guinea pigs similar to studies that have been reported in mice, (Bowen et al., 2004, 
Casadesus et al., 2006). In the Bowen et al., study, a slow release leuprolide depot (1.5 
mg/kg/BW) was injected monthly to C57Bl/6J mice for 8 weeks, resulting in a 1.5 fold 
and ~4 fold reduction in soluble cerebral Aβ levels. Although serum gonadotropin 
levels were not measured, the action of leuprolide in reducing gonadotropin secretion 
indicated that it resulted in the reduction in cerebral Aβ levels.  In a more recognized 
model of AD, a slow release (depot) leuprolide formulation (7.5 mg/kg), was 
administered intramuscularly, twice monthly, for a period of 3 months to 21 months in 
APPswe mice. In this latter study although leuprolide treatment led to a ~ 4 fold 
reduction in serum LH levels, there was a significant but modest ~20% reduction in 
amyloid deposition (Casadesus et al., 2006). 
 
The results presented in this Chapter extended the previous findings by showing that 
leuprolide modulated cerebral Aβ levels in a time dependent manner, which lead to 
contrasting trends in CSF Aβ40 levels compared to cerebral Aβ40 levels. Here, 
administering leuprolide led to an initial increase at day 18 post-treatment. Following 36 
days post-treatment a significant reduction compared to placebo, was observed. This 
effect was most prominent in the frontal cortex when compared to the hippocampus. In 
contrast, the ratio of CSF Aβ40 to frontal cortex levels was reduced following 18 days 
of treatment, and then increased by 36 days of treatment.  These findings parallel the 
effects of leuprolide on altering gonadotropin levels where it results in an initial 





days), followed by a precipitous reduction (Okada et al., 1996, Weckermann et al., 
2004). 
 
The experiments outlined in this current Chapter used a lower concentration of 
leuprolide than that used in the Bowen et al (2004) and Casadesus et al (2006) studies. 
In addition,  leuprolide was administered via a slow release implant, mimicking chronic 
reductions in gonadotropins. Serum LH levels were not measured in this study due to 
difficulties in detecting guinea pig LH (see Chapter 4). However, similar studies have 
shown that administering leuprolide via slow release implants lead to marked reductions 
in serum LH following initial spikes (Okada et al., 1996). 
 
A very recent study also administered leuprolide to the 3xTg AD mouse model via slow 
release implants, but showed contrasting effects to that observed in mice or our guinea 
pig model. In this study, Rosario and colleagues (2012) administered leuprolide to sham 
operated male mice and showed it did not lower cerebral amyloid deposition or improve 
hippocampal dependent memory (compared to GDX animals only). Further, when GDX 
mice were administered leuprolide in combination with testosterone, it negated the 
benefits of administering testosterone only at reducing cerebral amyloid load and 
improving memory.  It is difficult to explain the contrasting results to previous rodent 
studies. Highlighted by Rosario and colleagues was the differences in sex where the 
Bowen and Casadesus studies used female mice. Evidence exists indicating significant 
sex differences in severity of pathology in AD mouse models (Carroll et al., 2010a; 
Oliveira et al., 2011).and leuprolide has been shown to have benefits at improving 
hippocampal dependent memory in female rat models (Bryan et al., 2010, (Ziegler and 
Thornton, 2010). Together, these studies give precedence to the possible sex-specific 
benefits which could be further addressed by a direct comparison of the effects of 
leuprolide on the brains of OVX female and GDX male mice.  
 
It is noteworthy that the two transgenic mouse studies (Casadesus et al., 2006, Rosario 
et al., 2012), showed a subtle or no reduction in amyloid deposition (assessed by 
immunohistochemistry), whilst, similar to the current study, the Bowen et al., 2004, 
showed >2 fold reduction in soluble Aβ levels (assessed by ELISA) in the brains of 





human APP and Aβ, which may mask the potency of leuprolide at modulating Aβ levels 
or the deposition of amyloid. As such it can not completely rule out the possibility that 
leuprolide can still modulate the metabolism of endogenous Aβ resulting in reduced 
soluble Aβ levels.  
  
Although plaque deposition is not evident in guinea pig brain, guinea pig Aβ has the 
capacity to form higher order molecular structures, such as oligomers (Beck, Bruckner 
et al. 2000), widely considered to be the principal contributor to neurotoxicity in AD 
pathogenesis. Thus a reduction in this species would be highly relevant to AD. Whether 
leuprolide may reduce guinea pig Aβ levels in the frontal cortex by modulating APP 
metabolism is not clear. In this Chapter, increases in α-APPs and corresponding 
reductions in Aβ40 levels observed following 36 days leuprolide treatment (Fig 5.9A 
and 5.12 respectively) and no changes in CSFAβ40 levels  (Fig 5.8) at this time point 
suggests that leuprolide may promote non-amyloidogenic processing of APP.  
 
Overall the findings from this Chapter indicate that administering human LH to the 
guinea pig periphery can alter CSF and cerebral Aβ40 levels, but unexpectedly, reduces 
cerebral and increases CSF Aβ40 levels. This provides novel data that can be extended 
to further in in vitro experiments to provide insight into the mechanisms by which LH 
could impact on APP processing or Aβ clearance pathways. Administering the GnRH 
agonist, leuprolide to transgenic mouse models have shown no or subtle changes in 
cerebral Aβ40 levels. The results presented in this Chapter have provided evidence in a 
non-transgenic animal model that leuprolide cansignificantly reduce cerebral Aβ40 
levels, perhaps providing a more suitable model for assessing the benefits of leuprolide 




Chapters 3-5 have investigated the impact of key hormones of the HPG axis, 
testosterone and LH on CSF and cerebral Aβ levels in the guinea pig. Chapter 4 and 5 
have provided evidence for a role of LH in modulating Aβ levels. Chapter 4 has shown 
that the direct application of human LH to the guinea pig CNS, results in an 





culture and in vivo. In contrast, the application of human LH to the guinea pig periphery 
resulted in reduced cerebral Aβ levels. Although not consistent with findings obtained 
in mouse models, it provides an interesting line of research that can be further explored 
in the guinea pig. 
 
The findings presented in Chapter 3 confirm the effects of testosterone depletion and 
supplementation in the guinea pig. Consistent with other in vivo models, testosterone 
depletion through GDX led to an increase in CNS Aβ levels, while testosterone 
supplementation prevented this increase. The following chapters assess the benefits of 
testosterone supplementation on cognition, blood and imaging biomarkers in a cohort of 
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Effect of testosterone supplementation on 
plasma biomarkers in men with subjective 












Male aging is accompanied by a gradual decline in testosterone activity (andropause). 
This can manifest itself in many ways, including sexual dysfunction, diminished 
physical stamina, loss of muscle and bone mass, systolic hypertension, the development 
of abdominal visceral fat mass, insulin resistance, high levels of cholesterol, LDL and 
triglycerides, low HDL levels, and impaired quality of life with symptoms such as 
depression and cognitive impairment (Kenny et al., 2001; Moffat et al.,2002; Schroeder 
et al.,2004; Wang et al.,1996). The decline in testosterone levels starts in the fifth 
decade of life (Gray et al., 1991) , with men 70 years of age and older having the lowest 
levels. Estimates for the prevalence of men with low levels of testosterone range from 1 
in 200 (Morley, J.E, 2000) ,1 in 20 (Araujo et al., 2007) to 1 in 4 (Leifke 2000), 
depending on age of population, ethnicity and health factors. Such men are candidates 
for carefully monitored testosterone replacement therapy. 
Many studies have already been undertaken regarding testosterone replacement therapy. 
However, there is a lack of data based on longitudinal, double-blind, randomized 
placebo-controlled clinical studies of aging men which have investigated 
comprehensively testosterone’s long-term effects on  a wide range of aspects of men’s 
health including the cardiovascular system, the immune system, body metabolism, and 
the brain. Although men in their sixties (in general) are less prone to AD than women of 
the same age (Jorm, 1987), evidence suggests that testosterone deficiency is associated 
with a higher risk for AD (Hogervorstet al., 2004; Rosario et al., 2004). Importantly, a 
study by Moffat et al. 2004 indicates that the  deficiency precedes the onset of 
dementia. 
In the previous chapter, castrated guinea pigs were used as animal models to mimic the 
condition of testosterone deficiency in men. Testosterone treatment in these animals 
was shown to reduce CSF and cerebral Aβ levels. In cell culture studies of primary rat 
cortical neurons testosterone has also been shown to decrease Aβ levels (Gouras et al., 
2000). These findings suggest that testosterone supplementation in elderly men may 
protect against AD. Clinical studies do in fact suggest that testosterone levels can 





levels in men being treated with testosterone suppression drugs for prostate cancer. In 
addition, Almeida et al. 2004 found that low testosterone levels are associated with 
increased plasma Aβ levels in men. Testosterone supplementation in men who have AD 
or mild cognitive impairment (MCI) has been shown to improve spatial memory and 
cognition (Tan et al., 2003; Cherrier et al., 2005). Although there have been some 
inconsistencies in study results, most studies suggest that testosterone replacement 
therapy might prevent or delay AD in testosterone deficient men (Traish et al., 2011). 
Almost universally, a testosterone deficient state in older men is permanent and as a 
result, testosterone replacement therapy (TRT) may be for life. Therefore, any 
testosterone treatment would have to be very carefully designed and well researched. 
The best approach in a clinical context would be via double-blind, randomized, cross-
over, placebo-controlled trials. Improvements in healthcare over the last few decades 
have increased life expectancy considerably. Therefore the increased risks associated 
with age-related low levels of testosterone may have massive implications for both the 
individuals concerned and the community faced with the prospect of an aging 
population that requires more health care facilities than we currently provide.  
For many decades it was thought that raising testosterone levels would increase the risk 
of prostate cancer. Over the last 10 years however, there has been much debate about 
this theory, the evidence for this has been disputed, and in fact testosterone is now 
believed not to increase the risk, even in people already at high risk of developing 
prostate cancer (Rinnab et al., 2009 ;Feneley and Carruthers 2012 in press). 
 
Some studies have linked testosterone treatment to other important adverse health 
outcomes such as increased risks of atherosclerosis and depressive illness. However, 
studies showing unfavourable outcomes usually concern people deliberately trying to 
achieve supraphysiological levels for the purpose of improving athletic performance, for 
example (Aaronson et al., 2011). Results from such studies do not apply to patients 
trying to maintain testosterone within a normal physiological range. However, extra 
care needs to be taken in order to balance the possible therapeutic benefits against the 
potential risks. This chapter describes a clinical study that was undertaken to investigate 
the effect of testosterone treatment in a group of elderly with testosterone in the lower 





brain imaging biomarkers and cognitive performance. Side-effects of the treatment were 
also monitored. The blood biomarkers that were measured include testosterone and its 
derivative dihydrotestosterone (DHT), SHBG, Calculated Free Testosterone, estradiol, 
luteinizing hormone (LH), insulin, PSA levels, and plasma Aβ levels. Lipid profiles of 
the participants were also characterised. The effect of testosterone on cognitive 
performance and brain imaging biomarkers will be presented in chapters 7 and chapter 8 




The aims of this study were : 
 To investigate the effect of testosterone administration on plasma levels of 
testosterone, its derivative dihydrotestosterone (DHT), Calculated Free 
Testosterone, and its aromatization product estradiol. 
 To investigate the effect of testosterone treatment on luteinizing hormone (LH) 
levels in blood plasma. 
 To investigate the effect of testosterone administration on lipid profiles in blood 
plasma, which include levels of cholesterol, triglyceride, LDL, HDL,  Chol/HDL 
and calculated LDL/ HDL ratios.  
 To investigate whether testosterone treatment in  men with low normal and 
below  reduces plasma Aβ levels. 
 To investigate the effects of testosterone treatment on plasma insulin levels. 
 To investigate the effect of testosterone treatment on Prostate Specific Antigen 
(PSA) levels in blood plasma. 









   
  
  6.3 Methods 
 
  Participants 
 
Forty-four of the 50 subjective memory complainers men who met the eligibility 
criteria completed the study. They were recruited and assigned to one of the two 
parallel groups; placebo (n=22) or testosterone (n=22) treatment. Assignment 
was random using stratification to ensure each arm of the study was balanced, in 
terms of individual memory performance at baseline. The study design was such 
that participants received testosterone treatment or placebo for a period of 24 
weeks, followed by a washout period of 4 weeks, after which time, the 
participant groups were “crossed over”, such that the placebo group received 
testosterone and vice versa for a further 24 weeks. For all participants, there 
were a total of 11 clinic visits to Siloam Hospital, Lippo Karawaci (Indonesia), 
within the 52-week study period. The participants and the investigators were 





During the first (baseline) visit, participant blood pressure, height, weight, body 
fat percentage and body mass index (BMI) were checked and blood was drawn. 
Blood samples ( 45 ml) were collected using serum separating tubes (SST, that 
include a gel and blood clot activator), EDTA, and heparin collection tubes. 
Blood in SST collection tubes were centrifuged at 2500 rpm for 10 min to 
separate the serum. This serum was removed, divided into 1 ml aliquots to 
which 10l (100 g/ml) of protein inhibitor (aprotinin – Sigma) was added. 





rpm for 10 min at RT, to separate the plasma, leucocytes, and red blood cells. 
Plasma was removed and centrifuged further at 2500 rpm for 10 min to harvest 
platelets. The resulting supernatant (plasma) was aliquoted (~ 1 to 5 ml lots) and 
10µl protein inhibitor (aprotinin – Sigma) was added to each ml of plasma. 
These blood samples were used for baseline readings of blood counts, serum 
testosterone levels, levels of LH and sex hormone binding globulin (SHBG), 
DHT (dihydrotestosterone), estradiol, cholesterol, insulin, glucose, PSA, plasma 
Aβ levels and lipid (as described in section 2.1.1.2.2). The participants’ APOE 
genotypes were also determined. 
 
For the testosterone treatment group (n=22), testosterone (50 mg in the form of 
Andromen® FORTE cream) was applied daily to the scrotum, thus using a 
transdermal route (topically), for a period of 24 weeks. For the placebo group 
(n=22) the same amount of the cream base [dl- tocopherol acetate (vitamin E), 
without the active ingredient, testosterone] was applied with the same frequency. 
At each of the six remaining clinic visits i.e. at 4, 8, 12, 16, 20 and 24 weeks 
during the first treatment period, blood collection was carried out as described 
for the baseline measurement. During the 4 week washout period, the 
participants were given an equivalent amount of cream base lacking testosterone 
and vitamin E that was also applied to the scrotum. The placebo and testosterone 
treatment arms of the study were then crossed-over for a further 24-weeks 
treatment period. During this period, the participants were examined every eight 
weeks (three bleeds in total i.e. at weeks 8, 16 and 24 of the cross-over period); 




Blood biomarker measurement 
 
Serum samples (n=535) were analyzed for total testosterone (TT) and 
dihydrotestosterone (DHT) using an isotope dilution LC-MS/MS method at the 
Anzac Research Institute, NSW (Handelsman et al, 2011). Other serum samples 





Laboratory, Perth, Western Australia and plasma heparin were analyzed for lipid 
profile and albumin. Serum free testosterone (CFT) was calculated from TT, 
SHBG and albumin using the standard formula of Vermeulen,1999.. Plasma Aβ 




Statistical analysis was performed using The Statistical Package of Social 
Sciences (SPSS version 19, SPSS Inc, Chicago, IL). The Kolmogorov-Smirnov 
and Levene’s test was used to examine normality of distribution of continuous 
variables for each group. The analysis consisted of repeated-measures analysis 
of variance to compare between treatment groups, within-subject changes over 
the course of the treatment period. For parametric data, one way ANOVA  
repeated measures were performed to look at changes in blood biomarkers over 
time and following the different treatments, assuming no carry-over effects of 
testosterone treatment. Carry over effects were tested from differences at 
baseline in the first period (week 0) and at the washout period (week 24-28, 
which is baseline for the second period). For non-parametric data, Friedman’s 
Test and/or Wilcoxon signed-rank test was performed. When directly comparing 
two groups from both arms of the study, as well as comparing two groups based 
on the presence of APOEε4, two tailed independent t-tests were performed. All 














Participant  characteristics at baseline 
There were no differences between the two treatment groups of the study in 
terms of age, years of education, APOE allele status, and Body Mass Index 
(BMI)  as shown in Table 6.1. There were also no significant differences 
observed in BMI and % body fat over time for both arms (Figure 6.1a and 6.1b). 
 
Table 6.1 Mean (SD) age, education, Body Mass Index (BMI), and % Body Fat at 
baseline 
Group n Age Education BMI % Body Fat
Treatment AB 22 59.22 (7.18) 13.95 (2.84) 26.4 (3.64) 
24.29 
(2.65) 
APOE ε 4- 14 59 (5.82) 13.79 (3.31) 25.62 (2.6) 23 (1.16) 
























BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
BMI non‐APOE ε4 (n=14) 25.62 25.78 25.91 25.90 25.74 25.60 25.49 26.16 25.47 25.52 25.64















BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
BMI non‐APOE ε4 (n=18) 24.18 24.08 24.26 24.34 24.27 24.28 24.22 24.27 24.27 24.02 23.86













Figure 6.1(a) : Comparison of non-APOE ε4 and APOE ε4 carriers for Body Mass 
Index (BMI) (n=22) at 11 visits in treatment group AB (A) and treatment group 
BA (B). The bars represent the mean + standard deviation. Values in kg/m2 
underneath the bars are the mean of each group. No differences were observed between 
any of the groups of either arm, and APOEε4 status had no effect. BL= Baseline, A_1 to 
A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 








BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
% body fat non‐APOE ε4 (n=14) 23.00 23.21 22.97 23.27 23.52 23.64 23.21 22.70 21.66 22.71 23.48

















BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
% body fat non‐APOE ε4 (n=18) 20.90 21.17 21.25 21.52 21.51 21.31 21.42 20.93 21.41 20.93 20.79















Figure 6.1(b) : Comparison of non-APOE ε4 and APOE ε4 carriers for % Body 
Fat (n=22) at 11 visits in treatment AB (A) and treatment BA (B). The bars 
represent the mean + standard deviation. Values in percentage underneath the bars are 
the mean of each group. No differences were observed between any of the groups of the 
two arms, and APOEε4 allele status did not influence results. BL= Baseline, A_1 to 
A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 






6.4.1 Effects of testosterone administration on plasma total testosterone levels and 























Figure 6.2 : Boxplots of total serum testosterone levels for both arms at 4 different 
time points: Week 0 (Baseline), Week 4-24 (Treatment), Week 25-28 (Washout), 
and Week 29-52 (Cross-over). Data were in nmol/L and are presented as median + 
quartiles. Values in the first treatment are the averages of 6 measurements and values 
given for the second treatment period (Cross-over) are the average of 3 measurements. 
Testosterone levels were significantly increased in treatment A and cross-over A (ie 
testosterone treatment times) compared to all other treatment periods in the two arms.  
*p<0.05 in comparison  to baseline of each arm of the treatments, # p<0.05 in 







BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
T non‐APOE ε4 (n=14)  16.47 29.72 25.86 22.45 23.38 19.96 22.06 17.52 16.26 16.05 15.23





























BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
T non‐APOE ε4 (n=18) 18.17 17.83 18.32 18.56 18.77 17.40 17.58 18.55 28.27 28.83 31.44


























Figure 6.3 : Comparison of serum testosterone levels in APOE ε4 and non-APOE 
ε4 carriers (n=22) at 11 visits in treatment AB (A) and treatment BA (B). The 
bars represent the mean + standard deviation. Values in nmol/L underneath the bars are 
the mean of each group. Significant differences were observed between non-APOE ε4 
and APOE ε4 group in treatment arm AB (*p<0.05). BL= Baseline, A_1 to A_6 
(graph A) & B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 to 






Dihydrotestosterone (DHT), a peripheral conversion product of testosterone, was also 
monitored (Figure 6.4). Free or unbound testosterone resulting from administration of 
transdermal testosterone will have entered the prostate and been reduced to some degree 
























Figure 6.4 : Boxplots of serum dihydrotestosterone (DHT) levels for both arms at 4 
different time points : Week 0 (Baseline), Week 4-24 (Treatment), Week 25-28 
(Washout), and Week 29-52 (Cross-over). Data are in nmol/L and are presented as 
median + quartiles. Values shown in first treatment are the averages from 6 visits and 
values in the second treatment time (Cross-over) were averaged from 3 visits. Similar to 
total testosterone levels, DHT levels were significantly increased in treatment A and 
cross-over A compared to all groups in both arms.  *p<0.05 in comparisons to baseline 







BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
DHT non‐APOE ε4 (n=14) 1.85 9.81 7.13 7.51 12.27 6.98 7.56 2.01 1.90 1.76 1.83



























BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
DHT non‐APOE ε4 (n=18) 2.15 1.73 1.83 1.83 2.03 1.76 1.68 1.72 8.77 9.15 9.12


























Figure 6.5 : Comparison of serum DHT levels in APOE ε4 and non-APOE ε4 
carriers (n=22) at the individual 11 visits in treatment AB (A) and treatment 
BA (B). The bars represent the mean + standard deviation. Values in nmol/L 
underneath the bars are the mean of each group. Significant differences were observed 
between non-APOE ε4 and APOE ε4 group in both treatment arm (*p<0.05). BL= 
Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,  


























Figure 6.6 : Boxplots of serum DHT/Testosterone ratios for the two treatment 
arms at 4 different time points : Week 0 (Baseline), Week 4-24 (Treatment), Week 
25-28 (Washout), and Week 29-52 (Cross-over). Data are presented as median 
+quartiles. Values shown in the first treatment period are the averages from 6 visits and 
values in the second treatment period (Cross-over) are averages from 3 visits. Similar to 
results observed for testosterone and DHT levels, DHT to testosterone ratios were 
significantly increased in treatment A and cross-over A compared to other treatment 
periods in the two arms.  *p<0.05 in comparison to baseline of each arm of the 










BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
DHT/T non‐APOE ε4 (n=14) 0.38 1.17 0.88 1.16 1.18 1.23 1.11 0.37 0.42 0.41 0.44














BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
DHT/T non‐APOE ε4 (n=18) 0.43 0.35 0.36 0.34 0.38 0.35 0.33 0.32 1.14 1.20 1.04















Figure 6.7 : Comparison of serum DHT/Testosterone ratios in APOE ε4 and non-
APOE ε4 carriers (n=22) at 11 visits in treatment AB (A) and treatment BA 
(B). The bars represent the mean + standard deviation. Values underneath the bars are 
the mean of each group. No significant differences were observed between the APOE 
ε4- and non-APOE ε4 groups in either treatment arm (*p<0.05). BL= Baseline, A_1 to 
A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 
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 Figure 6.8 : Representative data of individual total testosterone and DHT levels in 
treatment AB  
(ε2 ε3) (ε3 ε3)
(ε3 ε4) (ε3 ε4)
 
Figure 6.9 : Representative data of individual total testosterone and DHT levels in 
























Figure 6.10 : Boxplots of serum Estradiol levels for both treatment arms at 4 
different time points : Week 0 (Baseline), Week 4-24 (Treatment), Week 25-28 
(Washout), and Week 29-52 (Cross-over). Data are shown in pmol/L and are 
presented as median + quartiles. Treatment A values are the averages of measurements 
at 6 visits and values in the second treatment period (Cross-over) are averages from 3 
visits. Significantly lower estradiol levels were measured during the placebo treatment 
(Treatment B) compared to washout and testosterone treatment (Cross-over A) in 
treatment arm BA. # p<0.05 in comparison to other treatment periods.    
 
Changes in estradiol level were not found to be significant when comparing the 
different treatment stages of treatment arm AB. However there were subtle changes 








BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
Estradiol non‐APOE ε4 (n=14) 80.00 95.00 95.00 80.00 75.71 66.43 80.00 90.00 76.43 80.71 93.57























BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
Estradiol non‐APOE ε4 (n=18) 76.67 70.56 71.11 66.67 70.56 72.22 84.44 82.22 84.44 95.00 102.78






















Figure 6.11 : Comparison of serum estradiol levels in APOE ε4 and non-APOE ε4 
carriers (n=22) at the individual 11 visits of treatment AB (A) and treatment 
BA (B). The bars represent the mean + standard deviation. Values in pmol/L 
underneath the bars are the mean of each group. No differences were observed between 
the non-APOE ε4 and APOE ε4 groups of the two treatment arms. BL= Baseline, A_1 
to A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, 






















Figure 6.12 : Boxplot of serum Estradiol/Testosterone ratios for both treatment 
arms at the 4 different treatment stages: Week 0 (Baseline), Week 4-24 
(Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are 
presented as median + quartiles. No significant differences were observed between any 
of the treatment stages of either of the arms. However, there was a trend towards 
















BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
T/E non‐APOE ε4 (n=14) 215.78 782.27 300.65 329.36 337.17 317.80 282.76 201.22 236.43 205.51 168.36



























BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
T/E non‐APOE ε4 (n=18) 261.582 282.963 301.042 311.197 307.968 280.703 247.520 245.997 405.222 347.977 320.916























Figure 6.13 : Comparison of the testosterone/estradiol ratios in non-APOE ε4 and 
APOE ε4 carriers (n=22) at the 11 individual visits of treatment AB (A) and 
treatment BA (B). Values are presented as mean + standard deviation. Significant 
differences were observed between the non-APOE ε4 and APOE ε4 groups in both arm 
treatment  within 4 weeks of testosterone treatment(*p<0.05). BL= Baseline, A_1 to 
A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 
to B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) treatment period. 
However it needs to be noted that there were only 4 APOE ε4 patients in the BA 





























Figure 6.14 : Boxplots of serum Luteinizing Hormone (LH) levels for both 
treatment arms measured at the 4 different treatment stages: Week 0 (Baseline), 
Week 4-24 (Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over). 
Data are in U/L and are presented as median +quartiles. Values in the Treatment stages 
are average serum levels from 6 visits and values in the second (Cross-over) treatment 
period are the averages from 3 visits. LH levels were significantly decreased in 
treatment A and cross-over A (ie testosterone treatment times) compared to all other 
treatment periods in both arms. *p<0.05 in comparison to baseline, # p<0.05 in 







BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
LH non‐APOE ε4 (n=14) 4.21 2.04 1.72 1.91 2.09 2.04 2.85 4.28 4.93 4.93 5.07



















Figure 6.15 : Comparison of serum LH levels in non-APOE ε4 and APOE 
ε4carriers (n=22) at the 11 individual visits of treatment AB (A) and treatment 
BA (B). The bars represent the mean + standard deviation. Values in U/L underneath 
the bars are the mean of each group. Significant differences were observed between the 
non-APOE ε4 and APOE ε4 groups of both treatment arms at the end of testosterone 
treatment (*p<0.05). BL= Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) = 
First Treatment period,  WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph B) 























Figure 6.16 : Boxplots of Total serum Cholesterol levels for both treatment arms at 
the 4 different treatment stages: Week 0 (Baseline), Week 4-24 (Treatment), Week 
25-28 (Washout), and Week 29-52 (Cross-over). Data are in mmol/L  and are 
presented as median +quartiles. Values in the Treatment stages are average levels from 
6 visits and values in the second (Cross-over) treatment period are the averages from 3 
visits. There was a significant decrease in total cholesterol levels during testosterone 










BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
Cholesterol non‐APOE ε4 (n=14) 4.86 4.73 4.50 4.77 4.58 4.70 4.21 4.46 4.69 4.74 4.58






















BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
Cholesterol non‐APOE ε4 (n=18) 4.94 4.76 5.04 4.91 4.95 4.87 4.92 4.72 4.58 4.55 4.64






















Figure 6.17: Comparison of total cholesterol levels in non-APOE ε4 and APOE 
ε4carriers: average results from each of the 11 visits for treatment arms AB (A) 
and BA (B). The bars represent the mean + standard deviation. Values in mmol/L 
underneath the bars are the mean of each group. No significant differences were 
observed between the non-APOE ε4 and APOE ε4 groups of the two treatment arms. 
BL= Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,  
WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph B) = Second (Cross-over) 























Figure 6.18: Boxplots of serum Triglyceride (TG) levels for the two treatment arms 
at the 4 different treatment stages: Week 0 (Baseline), Week 4-24 (First 
Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are in 
mmol/L and are presented as median +quartiles. The values in the first treatment stages 
are the average levels from 6 measurements over the treatment period and values in the 
second treatment (Cross-over) period are the average of 3 measurements. There were no 












BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
TG non‐APOE ε4 (n=14) 1.36 1.24 1.21 1.29 1.31 1.33 1.24 1.29 1.40 1.45 1.37


















BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
TG non‐APOE ε4 (n=18) 1.14 1.15 1.26 1.19 1.26 1.09 1.24 1.13 1.18 1.08 1.17


















Figure 6.19 : Comparison of serum triglyceride (TG) levels in non-APOE ε4 and 
APOE ε4 carriers: average results from the 11 individual visits in treatment arms 
AB (A) and treatment BA (B). The bars represent the mean + standard deviation. 
Values in mmol/L underneath the bars are the mean of each group. No significant 
differences were observed between the non-APOE ε4 and APOE ε4 groups in either 





period,  WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph B) = Second 


















Figure 6.20 : Boxplots of serum Low Density Lipoprotein (LDL) levels for the two 
treatment arms showing averages from the 4 different treatment periods: Week 0 
(Baseline), Week 4-24 (Treatment), Week 25-28 (Washout), and Week 29-52 
(Cross-over). Data are in mmol/L and are presented as median + quartiles. Values 
shown in the first treatment period are the average results from blood samples from 6 
visits, and values in the second (Cross-over) treatment period were averaged from 3 









BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
LDL non‐APOE ε4 (n=14) 3.06 2.85 2.87 3.02 2.87 3.00 2.59 2.79 2.92 2.95 2.84















BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
LDL non‐APOE ε4 (n=18) 3.19 3.01 3.33 2.98 3.23 3.08 3.21 3.01 3.01 2.98 3.01















Figure 6.21 : Comparison of LDL levels in non-APOE ε4 and APOE ε4 carriers at 
each of the 11 visits of treatment arms AB (A) and BA (B). The bars represent 
the mean + standard deviation. Values in mmol/L underneath the bars are the mean of 
each group. No significant differences were observed between non-APOE ε4 and APOE 
ε4 groups of either arm. BL= Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) 
= First Treatment period,  WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph 





Overall, no significant changes in LDL level were observed between the stages of either 
of the treatment arms. However, in treatment arm AB, we found a slight decrease in 
LDL levels in the non-APOE ε4 group following testosterone treatment. After 
testosterone treatment, LDL levels returned back to that seen at baseline level. 
Interestingly, in treatment BA, we found a slight increase of LDL following 



































Figure 6.22 : Boxplots of High Density Lipoprotein (HDL) levels for both 
treatment arms during the 4 different treatment periods: Week 0 (Baseline), Week 
4-24 (Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are 
in mmol/L and presented as median + quartiles. The values in the first treatment stages 
are the averages of blood sample measurements from 6 visits and values in the second 
(Cross-over) treatment are the averages from 3 visits. Compared to baseline levels, there 
were significant decreases in HDL levels at all other stages in treatment arm AB. 











BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
HDL non‐APOE ε4 (n=14) 1.16 1.18 1.08 1.13 1.07 1.09 1.05 1.06 1.13 1.13 1.11














BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
HDL non‐APOE ε4 (n=18) 1.21 1.22 1.22 1.18 1.16 1.24 1.16 1.19 1.23 1.07 1.10













Figure 6.23 : Comparison of HDL levels in APOE ε4 and non-APOE ε4 carriers at 
the 11 individual visits in treatment AB (A) and treatment BA (B). The bars 
represent the mean + standard deviation. Values in mmol/L underneath the bars are the 
mean of each group. There were no significant differences observed between the non-
APOE ε4 and APOE ε4 groups of either arm. BL= Baseline, A_1 to A_6 (graph A) & 
B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 to B_3 (graph A) 






















Figure 6.24 : Boxplots of Cholesterol/HDL ratios for each of the 4 stages of 
treatment AB and treatment BA: Week 0 (Baseline), Week 4-24 (Treatment), 
Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are presented as median 
+quartiles. The values in the first treatment stages are the averages of blood sample 
measurements from 6 visits and values in the second treatment (Cross-over) stages are 







BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
Chol/HDL non‐APOE ε4 (n=14) 4.15 4.04 4.27 4.25 4.33 4.36 4.03 4.20 4.22 4.21 4.17



















BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
Chol/HDL non‐APOE ε4 (n=18) 4.14 3.95 4.19 4.24 4.38 3.99 4.35 3.98 4.17 4.28 4.27

















Figure 6.25 : Comparison of plasma cholesterol/HDL ratios in non-APOE ε4 and 
APOE ε4 carriers at each of the individual 11 visits of treatments AB (A) and 
BA (B). The bars represent the mean + standard deviation. Values underneath the 
bars are the mean of each group. No significant differences were observed between the 
non-APOE ε4 and APOE ε4 groups of either treatment arm. BL= Baseline, A_1 to A_6 
(graph A) & B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 to 
























Figure 6.26: Boxplots of LDL/HDL ratios at each treatment stage in treatment 
AB and treatment BA: Week 0 (Baseline), Week 4-24 (Treatment), Week 25-
28 (Washout), and Week 29-52 (Cross-over). Data are presented as median + 
quartiles. The values in the first treatment stages are the averages of blood sample 
measurements from 6 visits and values in the Cross-over (second treatment) stages are 
the averages from 3 visits. There were no differences observed between the stages of 










BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
LDL/HDL non‐APOE ε4 (n=14) 2.60 2.44 2.70 2.68 2.71 2.76 2.46 2.60 2.64 2.61 2.57














BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
LDL/HDL non‐APOE ε4 (n=18) 2.69 2.50 2.78 2.59 2.87 2.53 2.85 2.53 2.72 2.82 2.78













Figure 6.27: Comparison of LDL/HDL ratios in non-APOE ε4 and APOE ε4 at 
each of the individual 11 visits in treatment AB (A) and treatment BA (B). The 
bars represent the mean + standard deviation. Values underneath the bars are the mean 
of each group. No significant differences were observed between the non-APOE ε4 and 
APOE ε4 groups of either treatment arm. BL= Baseline, A_1 to A_6 (graph A) & B_1 
to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 to B_3 (graph A) & 


































Figure 6.28 : Boxplots of average plasma Aβ40 levels at each of the 4 stages of 
treatment  AB and treatment BA. : Week 0 (Baseline), Week 4-24 
(Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are in 
pg/mL and presented as median + quartiles. The values in the first treatment stages are 
the averages of blood sample measurements from 6 visits and values in the Cross-over 
(second treatment) stages are the averages from 3 visits. There were no differences 










BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
Aβ40 non‐APOE ε4 (n=14) 79.39 77.24 74.57 76.69 77.92 83.08 81.68 83.46 79.46 85.49 85.56



















BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
Aβ40 non‐APOE ε4 (n=18) 88.01 78.76 81.22 79.06 82.84 74.25 79.54 79.09 88.08 86.15 70.18



















Figure 6.29 : Comparison of plasma Aβ40 levels in the non-APOE ε4 and APOE 
ε4carriers at each of the 11 individual visits of treatment AB (A) and treatment 
BA (B). The bars represent the mean + standard deviation. Values in pg/mL 
underneath the bars are the mean of each group. No significant differences were 
observed between non-APOE ε4 and APOE ε4 participants. BL= Baseline, A_1 to A_6 
(graph A) & B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 to 


































Figure 6.30 : Boxplots of average plasma Aβ42 levels for each of the 4 stages of 
treatment AB and treatment BA: Week 0 (Baseline), Week 4-24 (Treatment), 
Week 25-28 (Washout), and Week 29-52 (Cross-over). Data are in pg/mL and 
presented as median + quartiles. The values in the first treatment stages are the averages 
of blood sample measurements from 6 visits and values in the Cross-over (second 
treatment) stages are the average results from 3 visits. There were no differences 











BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
Aβ42 non‐APOE ε4 (n=14) 34.80 28.49 28.26 26.21 26.70 28.88 21.13 25.39 23.48 22.27 31.02






















BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
Aβ42 non‐APOE ε4 (n=18) 32.94 25.87 28.69 28.65 29.17 26.26 24.35 23.13 26.81 21.74 14.14






















Figure 6.31 : Comparison of plasma Aβ42 levels  in non-APOE ε4 and APOE ε4 
carriers at each of the 11 visits of treatment AB (A) and treatment BA (B). The 
bars represent the mean + standard deviation. Values in pg/mL underneath the bars are 
the mean of each group. Significant differences were observed between the APOE ε4 
and non-APOE ε4 subjects at baseline of both arm and the end of the treatment in 
treatment arm AB only (*p<0.05). BL= Baseline, A_1 to A_6 (graph A) & B_1 to 
B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 to B_3 (graph A) & A_1 







Plasma Aβ levels, including Aβ40 as well as Aβ42 were rarely found to be significantly 
different between any of the treatment stages. However, from the Figure 6.31 above,  
there seemed to be a trend towards decreasing Aβ42 levels following testosterone 
treatment in the non-APOEε4 subjects of both treatment groups. In treatment AB,  A1 
to A6 show lower testosterone levels compared to baseline, however this doesn’t return 
to baseline levels until end of placebo (cross-over) treatment.  In Treatment BA, 
testosterone treatment is in the A1 to A3 time points, and a trend towards decreasing 
Aβ42 levels can be seen in the non-APOE ε4 subjects during the testosterone treatment 
period.  
 























Figure 6.32 : Boxplots of insulin levels at each of the 4 stages of treatment AB 
and treatment BA: Week 0 (Baseline), Week 4-24 (Treatment), Week 25-28 
(Washout), and Week 29-52 (Cross-over). Data are in mU/L and are presented as 
median +quartiles. The values in the first treatment stages are the averages of blood 
sample measurements from 6 visits and values in the Cross-over (second treatment) 
stages are the average results from 3 visits. Insulin levels were significantly increased in 
Treatment B compared to Cross-over A in treatment arm BA. # p<0.05 but clinical 
relevance is questionable as no changes were seen when compared to baseline in the 






















BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
Insulin non‐APOE ε4 (n=14) 6.71 7.14 6.50 7.29 7.00 6.50 6.64 7.00 8.36 7.86 7.57



















BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
Insulin non‐APOE ε4 (n=18) 7.28 7.44 7.67 7.94 7.67 7.22 6.50 6.44 7.00 6.56 5.61




















Figure 6.33 : Comparison of plasma insulin levels in non-APOE ε4 and APOE ε4 
carriers at each of the individual 11 visits in treatment AB (A) and treatment 
BA (B). The bars represent the mean + standard deviation. Values in mU/L 
underneath the bars are the mean of each group. Significant differences were observed 
between the non-APOE ε4 and APOE ε4 groups of treatment arm AB (*p<0.05), 
participants with APOE ε4 alleles had higher insulin levels. BL= Baseline, A_1 to A_6 
(graph A) & B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 to 






6.4.5 Effect of testosterone on Prostate Specific Antigen (PSA) levels in the plasma, 




















Figure 6.34 : Boxplots of PSA levels at each of the 4 stages of treatment AB and 
treatment BA: Week 0 (Baseline), Week 4-24 (Treatment), Week 25-28 
(Washout), and Week 29-52 (Cross-over). Data are in μg/L and presented as median + 
quartiles. The values in the first Treatment stages are the averages of blood sample 
measurements from 6 visits and values in the Cross-over (second treatment) stages are 
the average results from 3 visits. Significant differences were observed in Treatment A 
and Treatment B compared to baseline (*p<0.05). There were also significant 
differences observed between the testosterone and placebo groups of both arms: the 








BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
PSA non‐APOE ε4 (n=14) 1.10 1.45 1.31 1.25 1.30 1.38 1.13 1.16 1.02 1.16 1.02














BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
PSA non‐APOE ε4 (n=18) 1.23 1.09 0.98 0.95 0.87 0.73 1.07 1.25 1.40 1.35 1.17












Figure 6.35 : Comparison of Prostate Specific Antigen (PSA) levels in non-APOE 
ε4 and APOE ε4carriers at each of the 11 visits in treatment AB (A) and 
treatment BA (B). The bars represent the mean + standard deviation. Values in μg/L 
underneath the bars are the mean of each group. Although not significant, participants 
with APOE ε4 alleles had higher PSA levels compared to the non-APOE ε4 
participants. BL= Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) = First 
Treatment period,  WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (graph B) = 























Figure 6.36 : Boxplots of Red Blood Cell counts (RBC) at each of the 4 stages of 
treatment AB and treatment BA: Week 0 (Baseline), Week 4-24 (Treatment), 
Week 25-28 (Washout), and Week 29-52 (Cross-over). Values are in 106 cells/µL and 
are presented as mean + quartiles. There were significant increases in RBC levels 
following testosterone treatment compared to baseline levels in both treatment arms 







BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
RBC non‐APOE ε4 (n=14) 4.90 5.07 5.15 5.29 5.44 5.41 5.32 5.15 4.95 5.05 5.03






















BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
RBC non‐APOE ε4 (n=18) 4.84 4.81 4.99 4.78 4.82 4.80 4.80 4.77 4.97 5.05 5.00





















Figure 6.37 : Comparison of Red Blood Cell (RBC) levels in non-APOE ε4 and 
APOE ε4 carriers at each of the individual 11 visits of treatment AB (A) and 
treatment BA (B). The bars represent the mean + standard deviation. Values in 106 
cells/µL underneath the bars are the mean of each group. No significant differences 
were observed between the non-APOE ε4 and APOE ε4 groups of the treatment arms.   
BL= Baseline, A_1 to  A_6 & B_1 to B_6 = Treatment period,  WO=Wash-out, B_1 to  

























Figure 6.38 : Boxplots of serum Hemoglobin (Hb)  levels at the 4 stages of 
treatment AB (A) and treatment BA (B). Week 0 (Baseline), Week 4-24 
(Treatment), Week 25-28 (Washout), and Week 29-52 (Cross-over).Values are in 
g/dL and are presented as mean +quartiles. There were significant increases in Hb levels 
following testosterone treatment compared to baseline in both arms of the study 











BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
Hb non‐APOE ε4 (n=14) 14.47 15.11 15.26 15.51 15.71 15.72 15.47 15.00 14.37 14.61 14.65

























BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
Hb non‐APOE ε4 (n=18) 14.27 14.01 14.14 13.96 14.04 13.94 13.98 14.09 14.49 14.59 14.70























Figure 6.39: Comparison of hemoglobin (Hb) levels in non-APOE ε4 and APOE ε4 
carriers at the individual 11 visits in treatment AB (A) and treatment BA (B). 
The bars represent the mean + standard deviation. Values in g/dL underneath the bars 
are the mean of each group. There were no significant differences observed between the 
non-APOE ε4 and APOE ε4 groups of either arm. BL= Baseline, A_1 to A_6 (graph A) 
& B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 to B_3 (graph 























Figure 6.40 : Boxplots of serum Sex Hormone Binding Globulin (SHBG) levels at 
the 4 different stages of treatment AB (A) and treatment BA (B). Week 0 
(Baseline), Week 4-24 (Treatment), Week 25-28 (Washout), and Week 29-52 
(Cross-over).Values are in nmol/L and are presented as mean +quartiles. No significant 

















BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
SHBG non‐APOE ε4 (n=14) 32.43 32.86 31.36 30.21 31.07 28.64 29.14 32.57 30.50 29.36 31.71























BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
SHBG non‐APOE ε4 (n=18) 38.67 35.72 36.28 36.89 36.28 35.89 37.33 36.94 36.83 37.11 34.50
























Figure 6.41: Comparison of hemoglobin (Hb) levels in non-APOE ε4 and APOE ε4 
carriers at the individual 11 visits in treatment AB (A) and treatment BA (B). 
The bars represent the mean + standard deviation. Values in nmol/L underneath the bars 
are the mean of each group. There were no significant differences observed between the 
non-APOE ε4 and APOE ε4 subjects of either treatment arm. BL= Baseline, A_1 to 
A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 
























Figure 6.42: Boxplots of serum Albumin levels at the 4 stages of treatment AB 
(A) and treatment BA (B). Week 0 (Baseline), Week 4-24 (Treatment), Week 25-
28 (Washout), and Week 29-52 (Cross-over). Values are in g/L and are presented as 
mean +quartiles. Compared to baseline levels, albumin levels were significantly lower 

















BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
Albumin non‐APOE ε4 (n=14) 42.36 44.01 42.29 41.29 42.80 42.09 41.00 41.43 38.50 36.57 41.36






















BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
Albumin non‐APOE ε4 (n=18) 41.72 39.28 41.44 39.50 40.83 38.89 41.33 41.83 42.43 42.23 40.50





















Figure 6.43 : Comparison of albumin levels in non-APOE ε4 and APOE ε4 carriers 
at the 11 individual visits in treatment AB (A) and treatment BA (B). The bars 
represent the mean + standard deviation. Values in g/L underneath the bars are the mean 
of each group. No significant differences were observed between the non-APOE ε4 and 
APOE ε4 groups of either treatment arm. BL= Baseline, A_1 to A_6 (graph A) & B_1 
to B_6 (graph B) = First Treatment period,  WO=Wash-out, B_1 to B_3 (graph A) & 







BL A_1 A_2 A_3 A_4 A_5 A_6 WO B_1 B_2 B_3
CFT non‐APOE ε4 (n=14) 334.8 694.1 625.2 550.3 575.4 500.7 526.5 384.2 373.3 373.5 328.9




























BL B_1 B_2 B_3 B_4 B_5 B_6 WO A_1 A_2 A_3
CFT non‐APOE ε4 (n=18) 354.50 389.28 401.50 409.39 407.33 366.11 381.11 405.61 669.06 739.33 757.11


























Figure 6.44 : Comparison of Calculated Free Testosterone levels in APOE ε4 and 
non-APOE ε4 carriers (n=22) at 11 visits in treatment AB (A) and treatment 
BA (B). The bars represent the mean + standard deviation. Values in ng/dL 
underneath the bars are the mean of each group. Significant differences were observed 
between non-APOE ε4 and APOE ε4 group in treatment arm AB (*p<0.05). BL= 
Baseline, A_1 to A_6 (graph A) & B_1 to B_6 (graph B) = First Treatment period,  










Our knowledge and understanding of testosterone replacement therapy in aging males 
has greatly improved over the last 15-20 years, however data on many of its effects 
remain inconclusive. There is a growing need for clinical studies that can help us 
improve our understanding of the long-term effects of testosterone treatment.   
The study design in this trial involved the treatment of subjective memory complainers 
for a period of nearly 6 months. This length of time was necessary to differentiate true 
benefits of therapy from placebo effects. Moreover, in this double blind, randomized, 
and placebo-controlled trial, all participants underwent both testosterone treatments and 
placebo treatments within the trial’s one year duration, thus all participants served as 
their own “controls”. Part of the strength of this study is due to this design, as it reduced 
the problems of patient to patient variability when comparing the placebo to the 
testosterone effect. Another strength of the study came from the fact that both potential 
orders of treatment were tested – testosterone followed by placebo, as well as the 
reverse. From the point of view of the participants, their role was the same for a whole 
year – for all stages a cream was to be applied daily.  
In the initial screening of elderly men who presented with signs and symptoms of 
testosterone deficiency, we measured total testosterone levels. The conventional view is 
that total testosterone is the test of choice, it also has the advantage of being one of the 
most widely available and the gold standard of the testosterone assays. Total 
testosterone levels were also used to monitor the efficacy of testosterone treatment. 
Total plasma testosterone represents testosterone that is tightly bound to sex hormone 
binding protein (SHBG, 44%) as well as that weakly associated with albumin (54%), 
with the remaining 2% free (and able to pass the blood brain barrier) (Bates et al., 2005) 
With aging, the rate of decrease in total testosterone level is on average, approximately 
110 ng/dL (~3.8 nmol/L) per decade (Morley et al., 1997). The most commonly used 
test is early morning serum total testosterone level. If it is less than 300 ng/dL (~ 10.4 
nmol/L) then the patient should be considered testosterone deficient (Basaria and Dobs, 
2001). However, the threshold of testosterone levels varies for various symptoms and 





testosterone levels that correspond to or are below the lower limit of the normal range 
for young men, which is 10.4 nmol/L (Wu et al., 2010; Orwoll et al., 2010; Mulligan et 
al., 2006; Araujo et al., 2007; Kelleher et al., 2004). The mean of the total testosterone 
levels from the 44 participants in our study was slightly above the borderline for 
testosterone deficient men, since the determination of the borderline was based on the 
normal testosterone levels found in Indonesian people in Siloam Hospitals, using 
VIDAS Testosterone Immunoassay kit (Bio-Merieux). After the samples being 
analyzed with gas chromatography-mass spectrometry (GC-MS), the level of total 
testosterone levels at baseline was above 300 ng/dL. Therefore, the limitation in this 
study is the screening measurement methods of total testosterone. The therapy was 
aimed to raise serum testosterone levels to that seen in the mid-normal range, which for 
these Indonesian people was 600-1000 ng/dL, based on the laboratory reference range 
using immunoassays. In addition, calculated free testosterone was also measured in this 
experiment, and showed similar results to those observed with  total testosterone levels 
following testosterone treatment (Fig 6.44). 
 
6.5.1 Effects of testosterone administration on plasma total testosterone levels and 
its metabolites, DHT and estradiol 
The day to day variation in testosterone levels may be considerable, therefore repeated 
testosterone measurements at 4 week intervals in weeks 4-24 (first treatment period) and 
at 8 week intervals in weeks 28-52 (second treatment period) were undertaken. From the 
total testosterone level results (Figs 6.2 & 6.3) it is easy to see that treatment A is 
testosterone whilst treatment B is placebo. Testosterone levels were significantly higher 
following testosterone treatment in both treatment groups. Within four weeks post-
testosterone treatment, referred to as the washout period, testosterone levels were back 
to that seen at baseline which indicated no carry-over effects. Individual levels of 
testosterone varied in response to testosterone treatment (Fig 6.8 & 6.9; Appendices 
Table 1 & 2). This may have been due to the androgen receptor polymorphisms (CAG 
repeats) conferring differential individual sensitivity to testosterone or due to the 
possibility that inadvertently different amounts of testosterone may have been applied 





exon 1 of the androgen receptor determines the transactivation activity of the receptor, 
in which shorter CAG repeats are associated with higher androgenicity and longer CAG 
repeats with lower androgenicity in healthy (Zitzmann et al., 2001; Zitzmann et al., 
2003a) as well as in testosterone deficient men (Zitzmann et al., 2003b). 
Furthermore,the number of androgen  receptor CAG repeats is negatively correlated 
with AR sensitivity and positively correlated with body fat, insulin levels, and leptin in 
healthy men (Stanworth et al., 2008). 
 
The mechanisms of action of testosterone on target organs are relatively complex since  
effects may be mediated directly via testosterone or indirectly via its metabolic 
products, dihydrotestosterone (DHT) and estradiol. Furthermore, testosterone only has a 
short half-life of approximately 12 minutes in the blood (Carruthers, 2004).  In the 
curent study, the testosterone cream resulted in elevated serum DHT levels with no 
carry-over effect, most likely as a result of the high concentrations of 5- reductase in 
the scrotum. The DHT produced would have been available to bind to androgen 
receptors (Fig 6.4 & 6.5). These results are in agreement with those of Cunningham et 
al., 1989, where it was found that DHT is elevated following testosterone treatment 
using a transdermal cream. The results in Figs 6.6 and 6.7 show that elevating 
testosterone levels resulted in a relatively greater increase in DHT, as observed by the 
increased ratios in these figures. These results indicated that the testosterone has been 
converted mostly to DHT, which is consistent with application of the cream- based 
hormone to the scrotum. 
The transport of testosterone and its metabolites into various tissues of the body is 
dependent on their binding to the transport proteins, their rate of dissociation, their 
membrane permeability and their capillary transit time through an organ 
(Pardridge,W.M, 1981). Testosterone is known to affect body composition in men, for 
example testosterone reduces abdominal fat and increases muscle mass. The quantity of 
fat, both subcutaneous as well as visceral, correlates with levels of both testosterone and 
DHT (Nielsen et al. 2007). DHT and testosterone levels also affect proliferation of fat 
cells - they block the transformation of pluripotent cells into adipocytes (Singh et al. 





on bone density (Ilangovan et al. 2009). These are all studies that support the notion that 
low testosterone and DHT are detrimental to health. 
Determining whether testosterone or DHT levels are low or not, is in itself difficult – 
normally ratios of DHT/testosterone do not vary much past puberty, yet can be different 
depending on race. For example, although testosterone levels were found to be very 
similar in a large US study, higher DHT levels and lower DHT/testosterone ratios were 
found in black people when compared to white or Hispanic people. Geographical 
differences have also been found, with people from similar racial backgrounds having 
quite different DHT levels depending on country of residence (Duskova and 
Pospisilova, 2011). It is likely that diet and other health issues may play an important 
contributory role to these differences. 
The conversion of testosterone to estradiol via the enzyme cytochrome P450 aromatase 
in men, unlike women, helps to maintain or modulate levels of serum estradiol as men 
age (Burger, 2000; Gray, 1991). Thus, in the presence of aromatase, testosterone can 
exert its effects on cell metabolism by influencing estrogen receptors as well as 
androgen receptors (Tietz, 1986). Our results show moderate changes in estradiol levels 
do occur following testosterone treatment (Fig 6.10 & 6.11).  
However, some studies have observed an increase in estradiol levels with age, resulting 
from increased adiposity or increased body fat which would be responsible for an 
increase in levels of serum sex-hormone-binding globulin (SHBG) and enhanced 
peripheral aromatization of androgens (Basaria et al., 2001). Estradiol should be in the 
mid- to lower-normal range, which is 10-82 pg/mL in fertile Asian men (Yamamoto et 
al., 1995). If estradiol levels are at least one-third above the normal reference range, this 
excessive level of estradiol should be reduced.  The results from this study showed that 
estradiol levels were still in the normal reference range in baseline and all of the 
treatment groups (Fig 6.10 & 6.11). 
The normal production ratio of testosterone to estradiol is approximately 100:1 and the 
normal circulating ratio of testosterone to estradiol is approximately 300:1 
(www.emedicine.medscape.com). Increased production or action of estradiol compared 
to testosterone will result in gynecomastia: benign enlargement of the male breast; an 





Morgentaler, 2004  have shown that 6 months of testosterone treatment can induce 
gynecomastia in men with history of gynecomastia. Therefore, in these studies the ratio 
of testosterone to estradiol was also calculated to monitor the risk of gynecomastia. 
Findings from this current study revealed an almost 2-fold increased ratio of circulating 
testosterone to estradiol in the first 4 weeks following testosterone treatment in both 
arms, which subsequently decreased until the end of the treatment (Fig 6.12). These 
results indicate that increased testosterone levels were more prominent than the 
increased estradiol levelswhich indicates that risk of gynecomastia was minimal 
following this testosterone treatment. 
From Figures 6.14 and 6.15, it can be seen that testosterone, DHT, and estradiol had 
inhibitory effects on LH levels in plasma. Once the participants stopped using the 
testosterone cream, the LH levels rose back to levels seen in the baseline readings which 
indicated no carry-over or long-term effects. Thus the normal feedback loops and 
enzymatic conversions of testosterone were occuring during the treatment times. In 
men, both testosterone and DHT exert their effects on LH mainly at the hypothalamic 
level, by decreasing the frequency of LH pulses, whilst estradiol reduces the amplitude 
of LH at the pituitary level (Carruthers, 2004). Among testosterone deficient men, LH 
has been shown to be suppressed (reduced) down to levels in the eugonadal range 
following injectable and implantable testosterone (Fennel et al., 2010; Conway et al., 
1988).  
Apolipoprotein E (ApoE), a major carrier of cholesterol in the central nervous system is 
produced from the APOE gene, which exists mainly as three different alleles in humans 
– APOE ε2, ε3 and ε4. The possession of one or more APOE e4 alleles is the strongest 
known risk factor for sporadic or late onset AD. Participant APOE allele status was also 
determined in this study to try to evaluate any effect apoE protein isoform differences 
may have on testosterone treatment. Hogervorst et al., 2002 found that persons with at 
least one APOE ε4 allele had significantly lower testosterone levels than those without 
an ε4 allele. However, from their results it remained  unclear how the ApoE protein may 
interact with testosterone. In the current study, total testosterone levels were not found 
to differ between APOE ε4 and non-APOE ε4 carriers at their baseline levels. However, 





carriers compared to the non-APOE ε4 carriers, at some of the testing periods during the 
testosterone treatment (Figure 6.3). However, this result was observed in one arm only 
(treatment AB), and the trend in the BA treatment group appeared to go in the 
opposite direction. These unexpected results may be a discrepancy due to the very small 
number of APOE ε4  participants in the two arms, particularly in the treatment BA 
group which had only 4 ApoE ε4 carriers, and two of these participants did not respond 
to testosterone treatment (see Appendices Table 2 and Figure 2). In other studies, 
Panizzon et al. 2010 demonstrated an interaction between testosterone and the 
possession of APOE 4 alleles with regards to hippocampal volume in middle-aged men 
with low testosterone levels. APOE 4 men with low testosterone levels had the 
smallest hippocampal volumes. The reason for this is not clear. APOE allelic 
differences may interact with androgen receptor polymorphisms and/or genes associated 
with testosterone production. Many more studies are required to elucidate such 
relationships. 
Further studies with larger numbers of participants would be needed to get a clearer 
picture of any differences in total testosterone levels caused by APOE allele differences. 
We also pooled the participants from both treatment arms of the study to increase the 
statistical power (number of participants), but found no significant differences between 
APOE ε4 and non-APOE ε4 carriers for all of the blood parameters, despite this 
increase in statistical power.    
 
6.5.2 Effects of testosterone administration on lipid profiles in the plasma 
The hormonal regulation of lipid metabolism in men is complex and has not been 
researched in depth.  Sex steroids appear to be key regulatory factors, exerting influence 
on lipid metabolism in both men and women. However, there is little information in the 
literature concerning the effects of exogenous testosterone on serum lipids and 
lipoproteins, especially after prolonged administration. The effects of testosterone on 
different lipoproteins and lipid levels is of particular interest due to the similarity 
between cardiovascular disease risk factors and factors thought to influence the risk of 





supraphysiological testosterone levels has been reported to have unfavourable effects on 
the cardiovascular system (Aaronson et al., 2011) – for example as mentioned below, 
supraphysiological testosterone has been shown to lower HDL levels. In the 
experiments reported here, the testosterone dose restored levels of testosterone to an 
average of 27 nM (see Figures 6.2 and 6.3), and as mentioned at the start of this chapter, 
the mid-normal range for these Indonesian people is 600-1000 ng/dL, which translates 
to 21-35 nM. There were differences in responses to testosterone treatment depending 
on APOE allele status, yet it was found that two of the APOE ε4 participants in 
Treatment BA did not respond to the treatment, as mentioned above. Characterising 
further the effects of testosterone on lipid profiles may shed some light into the possible 
roles of this hormone in the pathogenesis of AD. Many studies now show there are 
strong links between lipid profiles (cardiovascular risk factors), APOE allele status and 
androgen response, and these require further study.  
Within the blood, ApoE delivers and transports lipids, especially triglycerides and 
cholesterol, by mechanisms that involve the binding, uptake and catabolism of 
lipoproteins. Compared to the APOE ε2 and ε3 alleles, ε4 is associated with poorer 
transport and clearance of serum cholesterol (Mahley, 1988; Davignon et al., 1988 and 
Eichner et al., 1993). Researchers have shown that APOE ε4 carriers have higher than 
average serum cholesterol levels, and interestingly, several animal studies have shown 
elevated serum cholesterol level are associated with rises in brain Aβ levels (Kuo et al., 
1998; Pappolla et al., 2003). One might assume that there is an effect of APOE allele 
status causing higher serum cholesterol levels, which would then lead to increased brain 
cholesterol levels. However, it is important to note that brain cholesterol levels are 
maintained independently - serum cholesterol levels do not influence brain cholesterol 
levels directly because cholesterol does not cross the blood brain barrier (Hooijmans et 
al., 2007). Therefore any increases in brain Aβ levels may not be due to changes in 
brain cholesterol per se, but rather to effects of increased circulating cholesterol or other 
influences of ApoE ε4.  
 
In these experiments, no differences were found in total cholesterol, triglyceride, LDL, 
and HDL results between APOE ε4 carriers and non-APOE ε4 carriers (Figures 6.17, 





and LDL to HDL levels observed in both arms of the study were within normal 
desirable ranges for Indonesian people in Siloam Hospitals, based on the American 
Heart Association and National Cholesterol Education Program with total cholesterol 
ranges being 4.6 - 5.2 mmol/L, triglyceride 0.5 - 1.7 mmol/L, LDL < 3.4 mmol/L and 
HDL > 1.04 mmol/L. When it comes to measurement of LDL and triglyceride values, a 
lower level is better because these lipids drive the development and progression of 
atherosclerosis. In contrast, when it comes to HDL, with few exceptions, a higher level 
is better because HDL is beneficial and protects patients from the development and 
progression of atherosclerotic disease (Toth, 2005).   
 
There have been many studies concerning the effects of testosterone on lipid 
metabolism with conflicting and inconsistent results. Similar to the current study, 
several studies have found no significant effects on LDL levels (Figure 6.20 & 6.21) but 
testosterone has been found to result in a mild decrease in HDL levels (Thompson et al., 
1989; Freidl et al., 1990; Bhasin et al., 1997). However, several studies have 
consistently demonstrated an inverse correlation between testosterone and LDL (Saad et 
al., 2007; Saad et al., 2008; Howell et al., 2001; Ly et al., 2001). The findings in the 
current study although only showing  a trend towards decreasing LDL levels following 
testosterone treatment are in agreement with these latter studies.   
From the results in Figure 6.22 it can be seen that HDL levels were significantly 
decreased following testosterone treatment, and that these lower levels were maintained 
until the end of the study. If the participants were classified based on their total 
cholesterol baseline threshold levels, only those who started off with higher than normal 
or desirable levels of total cholesterol (moderate) showed significant changes in HDL 
levels following testosterone treatment, whilst for those participants who initially had 
low and desirable total cholesterol levels at baseline, it may be that the treatment may 
not be able to lower levels further, because the body’s metabolism will compensate and 
produce cholesterol to maintain cholesterol levels above a certain minimum level, so 
these people are not likely to show any change (Appendices).  
There have been many studies of effects of testosterone on various aspects of lipid 





results, a study by Arver et al. (1997) found that transdermal testosterone replacement 
in testosterone deficient men resulted in a decrease in HDL cholesterol and an increase 
in the total cholesterol/HDL ratios. Tyagi et al, 1999 also showed that testosterone 
administration in supraphysiological doses reduced plasma HDL-cholesterol levels, and 
a study by Handa et al., 1997 showed an inverse relationship between testosterone 
levels and HDL levels. In other studies, testosterone treatment was found to increase 
cholesterol, LDL and triglyceride levels (Traish et al., 2009). Furthermore, Malkin et 
al., 2004 demonstrated that testosterone treatment in hypogonadal men resulted in 
significant increases in IL-10, a reduction in IL-1 and TNF-α as well as a reduction in 
total cholesterol and LDL levels, with no significant effect on HDL levels. On the other 
hand, some studies have shown beneficial effects of testosterone on serum lipids. For 
example, many epidemiological studies have shown a positive correlation between 
serum testosterone levels and HDL in healthy men (Khaw, et al., 1991; Freedman et al., 
1991). Tenover J.S, (1999) found that testosterone replacement therapy led to an 11% 
decrease in LDL. In yet other studies, Morley et al., 1993 reported a 9% decrease in 
total cholesterol levels and no changes in HDL, and a study by Wang et al., 2000 
indicated no adverse effects on lipid profile following the administration of testosterone 
gel. 
The clinical significance of a small decrease in HDL levels is still unknown. Serum 
high-density lipoproteins (HDL) are lower in men than in premenopausal women (Heiss 
et al.,1980). The enzyme which is primarily responsible for clearance of HDL, hepatic 
endothelial triglyceride lipase, has been found to have greater activity in men and has 
been shown to be stimulated by androgens and suppressed by estrogens (Glueck, et al., 
1976) . Recently, it has been found that a decrease in CAG repeat polymorphisms of the 
androgen receptor lowers HDL but concurrently lowers the risk of cardiovascular 
disease (Hersberger et al., 2005). The reason for the discrepancy above may be that the 
effects of exogenous testosterone on lipids differ from those of endogenous 
testosterone, doses and formulations of testosterone used, patient age or testosterone 
deficiency state or that effects may depend on the route of administration (Thompson et 
al.,1989). Nevertheless, the effects of testosterone on lipid profiles as well as 





Cross-sectional studies indicate an inverse relationship between coronary heart disease 
(CHD) incidence and/or severity and endogenous testosterone levels, irrespective of age 
(Wu et al., 2003), and testosterone treatment increases coronary blood flow and 
improved signs on myocardial ischemia in men with CHD (Webb et al., 1999; English 
et al., 2000). Therefore, total cholesterol/HDL ratios as well as the LDL/HDL ratios 
were monitored to predict the chances of developing cardiovascular disease. Managing 
the total cholesterol/HDL ratio below 5:1 is the goal and the ideal one is 3.5 : 1. Results 
presented in this chapter show no significant changes in total cholesterol/HDL ratios, 
and the ratios were still below 5 (Fig. 6.24). Also, no significant changes in LDL/HDL 
ratios (Fig. 6.26) following testosterone treatment were observed which indicates there 
is no increased risk of cardiovascular disease. 
Testosterone has been found to affect estrogen levels that are required to induce 
apolipoprotein CII and apolipoprotein AI by a mechanism that involves high-affinity 
androgen receptors (Tam, 1986). In this same study, testosterone was found not to affect 
the rates of apolipoprotein secretion. At this stage, it appears that few studies have 
investigated whether testosterone or DHT can influence apolipoprotein production. 
Other studies have shown that testosterone is lipophilic, suggesting testosterone would 
be able to intercalate into bilayer cell membranes, potentially altering the fluidity and 
function of membranes (Whiting, 2000). Considering the low circulating levels of 
testosterone, this would depend on where and how much the hormone could be 
concentrated, and factors that would influence where the testosterone would 
concentrate. 
When investigating lipids specifically, animal and human studies have suggested that 
androgen deficiency is associated with increased triglyceride, total cholesterol, and LDL 
levels.  As mentioned above, similar investigations of HDL levels have been 
inconclusive, with some people reporting a decrease in HDL levels (Thompson et al., 
1989; Bagatell et al., 1984) as found in this study, some showing no change 
(Zgliczynski et al., 1996; Uyanik et al., 1997), and most of the studies showing 
increased HDL associated with normalizing testosterone (Saad et al., 2007; Zitzmann 
and Nieschlag, 2007) . A significant decrease in HDL is a change that would be 





androgen therapy have shown an increase in HDL levels, which may be associated with 
improved reverse cholesterol transport (Traish et al., 2009a).  
 
6.5.3 Effects of testosterone on Abeta (A) levels in plasma 
Abeta (A) peptides, the main constituent of amyloid plaques found in brain in AD, are 
produced in most tissues and can be detected in the cerebrospinal fluid (CSF) and 
bloodstream. CSF levels of Apeptides, particularly the more amyloidogenic A42 are 
being considered for inclusion in a panel of biomarkers for AD. Plasma levels of 
Apeptides are currently thought to be much less reliable, yet as plasma is much more 
accessible than CSF (which requires lumbar puncture), characterising changes in plasma 
A levels is still worthwhile. It may be that A levels in the bloodstream are influenced 
by testosterone and our earlier work looking at endogenous testosterone levels support 
this notion (Bowen et al., 2005). 
Aβ in the blood originates from tissues, or blood components such as platelets  (Chen et 
al., 1995). A is also produced in the brain (CNS), and can be transported across the 
blood-brain barrier into the periphery (Zlokovic, 2004) and be detected in plasma. Once 
in the bloodstream, Aβ is rapidly taken up by the liver and degraded.  
Several studies have demonstrated the diagnostic utility of plasma levels of Aβ40 and 
Aβ42. However, the results of these studies are not consistent. (Prvulovic & Hampel, 
2011). Our results (Figs. 6.28, 6.29, 6.30 & 6.31) showed no significant changes in 
plasma Aβ40 or Aβ42 levels following testosterone treatment, although there was a 
strong trend towards decreasing Aβ42 levels. This results maybe because most of the 
Aβ in the plasma is bound to albumin and lipoproteins, with very little free Aβ (Biere et 
al., 1996) and thus measured Aβ levels may be affected by confounding factors 
(Prvulovic & Hampel, 2011). Interestingly, participants in both treatment arms with 
APOE ε4 alleles also showed a trend towards reduction of Aβ40 following testosterone 
treatment as opposed to non-APOE ε4 participants (Fig 6.29) which indicates the 





 Plasma Aβ levels will have been influenced by many factors: age, cerebrovascular 
disease, liver catabolism, and advanced AD-related pathology are all factors known to 
affect plasma Aβ metabolism (Lopez et al., 2008). In addition, lipoproteins in plasma 
might influence immunological detection of plasma Aβ  (Kawarabayashi and Shoji, 
2008). From an assay point of view, this problem is exacerbated by the levels of plasma 
Aβ peptide which are about 10-fold lower than in the CSF and by the diversity of 
ELISA antibodies used (Prvulovic & Hampel, 2011).  
Studies by Almeida et al. 2004 demonstrated that low levels of testosterone are 
associated with increased plasma Aβ levels in men. In relation to Alzheimer’s disease, 
recent follow-up studies have shown that declining plasma Aβ42, but not Aβ40 levels 
may be related to AD progression (Mayeux et al., 2003). Before Aβ deposition in the 
brain begins, it is hypothesized that high plasma Aβ levels will be observed, and with 
the initiation of Aβ deposition in the brain, it is postulated that Aβ in the plasma then 
declines (Locascio et al., 2008). 
 
6.5.4 Effects of testosterone on insulin levels in plasma 
The components of the condition known as metabolic syndrome include insulin 
resistance, glucose abnormality, high blood pressure, obesity or increased waist 
circumference, and hyperlipidemia. All of the components above are also known risk 
factors for cardiovascular disease. It has been found that there is an increased risk of 
testosterone deficiency in men with metabolic syndrome or its individual components, 
especially insulin resistance, considered by some to be at the core of metabolic 
syndrome (Guay, 2009). It should not be surprising that testosterone may influence the 
metabolic syndrome or cardiovascular risk, since testosterone influences lipid 
metabolism, and can affect a wide range of tissues. For example, vascular cells contain 
steroid hormone receptors and testosterone can exert effects on vascular walls either 
directly or indirectly via aromatization (Shabsigh et al., 2005) In addition, androgen 
deprivation therapy, similar to testosterone deficiency, has been found to increase 
cardiovascular risk factors and to have adverse effects on cardiovascular function 





Based on these findings, there is a strong need to assess the value of testosterone 
therapy regarding benefits to cardiovascular health. In an early study, testosterone 
therapy was not associated with the risk of cardiovascular disease in elderly men (Hajjar 
et al., 1997). Most recent studies have found that many indicators of cardiovascular 
health, such as high blood pressure, glycemic control, insulin resistance and high LDL 
levels are altered favourably on treatment with testosterone (for example, Jones et al., 
2011). 
However some studies have reported transient improvements or no change in one or 
more variables. For example, data on the effect of testosterone replacement therapy on 
insulin sensitivity have yielded conflicting results. Some studies have reported favorable 
effects in men with obesity (Marin et al., 1992) or type 2 diabetes (Kapoor et al., 2006) 
and in healthy older men (Emmelot-Vonk et al., 2008). Contradictively, other studies 
have shown no changes in insulin sensitivity on healthy young and older men.  Other 
cross-sectional studies have shown a negative correlation between total testosterone and 
insulin levels in the plasma (Seidell et al., 1990; Pasquali et al., 1991; Simon et al., 
1992).  The current study showed some effects of testosterone on insulin sensitivity, 
although no strong correlation was observed (Figs. 6.32 & 6.33). Perhaps if this study 
was repeated with a much larger cohort, statistically different results would be obtained. 
More recently, epidemiological studies have suggested that low levels of total 
testosterone and SHBG can be considered to be predictive of metabolic syndrome and 
to increase the risk of diabetes Type II (Saad, 2009). Low testosterone levels appear to 
precede elevated fasting insulin, glucose, and hemoglobin A1c (HbA1C) values and 
have been associated with increased deposition of visceral fat, which serves as an 
endocrine organ, producing inflammatory cytokines and thus promoting endothelial 
dysfunction and vascular disease (Traish et al., 2009c). In fact recent comprehensive 
reviews have found that testosterone treatment may be able to slow the progression 
from metabolic syndrome to diabetes Type II or cardiovascular disease, via beneficial 
effects on insulin regulation, lipid profile and blood pressure (Saad et al., 2011; 
Makhsida et al., 2005). The positive effects that androgen replacement therapy may 
have in combating obesity in testosterone deficient men remains largely unknown to 
medical professionals, partly because of the (incorrectly) perceived increased risk of 





failure, pulmonary embolism and stroke in men following androgen abuse have also not 
helped to promote the restoring of normal levels of testosterone (Weidemann and 
Hanke, 2002).  
Recent studies suggest that long-term treatment with low doses are safe (Miner et al., 
2008). Due to studies of individuals keen to achieve supraphysiological testosterone 
levels, it has nevertheless been suggested that there may be an ideal testosterone 
“physiological window”: within this window testosterone has favourable effects, but 
above or below the safe window these androgens can have a negative effect on the body 
(Blouin et al., 2008; Basaria et al., 2010). These reported negative effects of 
supraphysiological levels of testosterone are likely deterring physicians from 
considering testosterone therapy for the treatment of androgen deficiency.  
Future studies are required to determine how hormone changes and hormone therapy 
can help reduce the health problems associated with the increasing number of people 
suffering from metabolic syndrome, and determine if such treatment can also reduce the 
risk or development of AD.  
 
6.5.5 Effects of testosterone on Red Blood Cell (RBC) counts and Hemoglobin 
levels 
Androgens have long been known to stimulate red blood stem cell numbers (Shahidi, 
1973). Several androgen replacement therapy treatments have reported significant 
increases in hemoglobin and hematocrit levels in a dose-dependent manner (Hajjar, et 
al., 1997; Sih et al., 1997; Bachman et al., 2010; Covellio et al., 2008), with greater 
increases in red blood cells in older men than in young men (Covellio et al., 2008).  
The results in the current study are in agreement with these previous studies, as they 
show that the administration of testosterone enhances red blood cell levels in the plasma 
(Figure 6.36 and Figure 6.37). It has been found that testosterone treated-men are nearly 
four times as likely to have hematocrits of >50% as compared to placebo-treated men 
(Calof et al., 2005) . Therefore, it is important to note that testosterone treatment should 
not be administered to men with baseline red blood cells or hematocrit of 50% or 





2010) since testosterone treatment can worsen pre-existing erythrocytosis. Although it 
had been postulated that testosterone stimulates eryropoiesis by modulating 
erythropoietin and stem cell proliferation, recent data suggests that testosterone 
increases red cell mass by inhibiting hepcidin (Bachman et al., 2010). 
Testosterone deficiency has also been associated with lower hemoglobin levels, as 
shown by the lower normal range for haemoglobin in women. In line with studies by 
McCullagh et al., 1942 and Hamilton et al., 1964 which showed that testosterone 
replacement restores the red blood cell counts, this study has also found a significant 
increase in hemoglobin levels following testosterone treatment (Figs 6.38 & 6.39), 
similar to that seen in the results of the red blood cell levels. The normal range of 
hemoglobin in men is 14-18 ng/dL (Billet, 1990), and although significant increases in 
hemoglobin were observed following testosterone treatment, the levels seen in our 
results were still in the safe range in all of the treatment groups in both arms. 
 
6.5.6 Effects of testosterone on Prostate Specific Antigen (PSA) levels in plasma 
In the past there have been major concerns regarding testosterone therapy promoting the 
growth of metastatic prostate cancer. However, it has now been established that there is 
no evidence of increased risk of prostate cancer (Jackson, 2012; Feneley and Carruthers 
2012 pub on-line JSM). The general view now is that testosterone does not promote 
prostate cancer but can exacerbate existing cancer (Fowler et al., 1981; Bhasin et al., 
2003) and should not be administered in men with already high PSA levels (Bhasin et 
al., 2010). In fact in one study an increased risk of prostate cancer has been associated 
with low plasma level of testosterone (Raynaud, 2006). Therefore, testosterone therapy 
should be accompanied by a standardized monitoring plan which includes periodic 
ascertainment of prostate specific antigen (PSA) levels and digital prostate examination. 
Most studies have shown no significant increases in PSA or prostate volume following 
testosterone administration to testosterone deficient men (Behre,H.M, 1994). 
The results in this Chapter (Figs 6.34 & 6.35) show a significant increase in PSA levels 
following testosterone treatment, although levels still remained within the safe and 





American Cancer Society, a PSA level between 4 and 10 μg/L indicates a 25% risk of 
having prostate cancer. A PSA higher than 10, increases the risk of having prostate 
cancer to 50% and above. Since PSA levels tend to increase with age, the use of age-
specific PSA reference ranges has been suggested to improve the accuracy of PSA tests 
(National Cancer Institute). In accordance with our study, Khera et al., 2011 have 
shown a small increase in PSA levels following 12 months of testosterone treatment. A 
number of open-label trials have also reported that testosterone treatment results in very 
low rates of developing prostate cancer (Agarwal et al., 2005; Kaufman et al., 2004). 
Although PSA levels were higher in the testosterone treated group compared to placebo, 
these results was not found to be significant (Calof et al., 2005).   Interestingly, subjects 
with APOE ε4 alleles had higher levels of PSA than non-APOE ε4 subjects (Fig. 6.35). 
All of the participants in both arms had normal PSA levels at baseline (Appendices). 
 
6.5.7 Effects of testosterone on Body Mass Index (BMI) and body fat percentage 
According to the World Health Organization (WHO), the normal reference range for 
BMI is 16-19 kg/m2 for the Indonesian population. A BMI of over 22 kg/m2 is 
considered to be overweight and a person with a score over 27 kg/m2 is considered 
obese. Therefore, according to their BMI levels, most participants in both arms of this 
study were considered to be overweight (see Appendices Table 7 & 8). Although no 
significant changes in BMI levels were observed in any of the treatment groups, most of 
the participants showed an increase in BMI following testosterone treatment at 
individual levels in both arms (see Appendices). However, it is important to note that 
BMI includes both the body fat mass as well as body muscle and there was no 
differentiation between the two. 
The WHO has concluded that the Asian population generally has a higher percentage of 
body fat than Caucasian people of the same age, sex, and BMI. However, there is no 
reference range of body fat percentage in Asian populations to date. Gallagher et al. 
2000 established that people aged 41-60 with an age-adjusted body fat percentage of 
over 27% should be considered to be obese. Based on this reference, only 5 participants 
in this study should be considered to be obese at baseline (see Appendices Table 9 & 





following testosterone treatment, most of the participants showed a trend towards 
increasing body fat at individual levels in both treatment arms. Taken together, an 
increased BMI and body fat percentage in these men following testosterone treatment 
suggests most of the participants produced more fat cells compared to muscle mass. 
This result may be due to the fact that most of the participants were already overweight 




In conclusion from this Chapter, testosterone replacement therapy for 6 months in 
testosterone deficient men caused a significant increase in testosterone and DHT levels 
(but not estradiol) as expected, a significant decrease in LH, a decrease in HDL, a trend 
towards increasing plasma insulin, and a significant increase in the number of red blood 
cells and hemoglobin. No changes in estradiol, total cholesterol, triglycerides, or LDL 
levels were found. The slight increase in PSA levels is unlikely to be sufficient to 
influence risk of prostate changes. Aβ40 and Aβ42 levels in the plasma were not 
significantly affected by testosterone treatment, although, there seemed to be an 
encouraging trend towards decreasing levels of Aβ42 following testosterone treatment. 
With the increasing number of people suffering from metabolic syndrome, future 
studies are required to determine how hormone changes and hormone therapy can help 
reduce the health problems associated with metabolic syndrome, and determine if such 
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Aging is associated with a general decline in many cognitive functions, with the rate of 
decline varying between individuals. Serum testosterone levels also decline with aging 
in men after 30 years of age (Harman et al., 2001), decreasing at an annual average rate 
of 0.2-1% for total testosterone and 2-3% for free testosterone (Feldman et al., 2002).  It 
has been shown in many laboratory-based studies that sex steroid hormones such as 
estrogens and testosterone, have  neurotrophic and neuroprotective properties,  and 
many clinical reports suggest these hormones could provide neuroprotection during 
aging (Lee et al., 2001; McEwen et al., 1997; Torrand-Allerand et al., 1992). Similarly, 
age-related declines in testosterone levels have recently been associated with declines in 
cognitive function, such that low testosterone is now believed to be  a risk factor for 
cognitive decline. Elderly men generally have higher sex hormone levels than elderly 
women (Hogervorst et al., 2001; Hogervorst et al., 2004). Therefore, theoretically, 
aging men should preserve certain aspects of cognitive function to a better extent than 
aging women. Studies of elderly subjects which have investigated the relationship 
between cognitive function and endogenous as well as supplemented (hormone 
replacement therapy) steroid hormone levels have provided some support for this 
theory, however these relationships also seem to be modified by other gender-related 
factors (Hogervorst et al., 2007) 
There has been extensive research into the association between the age-associated 
decline in testosterone levels in men and their performance in various cognitive 
measures. Serum levels of testosterone have been found to correlate with cognitive 
performance in a number of neuropsychological tests in elderly men. Cross-sectional 
studies have shown positive associations, such that higher levels of bio-available 
testosterone, but not of bio-available estradiol, are associated with better cognitive 
function in older men (Yaffe et al., 2002). Moreover, there were curvilinear associations 
between total testosterone and verbal memory (Muller et al., 2005) as well as between 
free testosterone and attention or working memory (Barret-Connor et al., 1999; 
Matousek et al., 2010), and global cognition (Yeap et al.,2008). These curvilinear 
associations suggests an optimal testosterone level for particular cognitive tasks. 
Meanwhile, these curvilinear associations may contribute to negative associations 





(Wolf et al., 2002; Carlson et al., 2000). These associations further suggest that there is 
an optimal level for testosterone, above or below which there is no further improvement 
in cognition and more likely there will be negative effects. However, there are many 
longitudinal studies which have reported no significant associations between 
testosterone and cognition (Moffat et al., 2002 ; Hogervorst et al., 2010). All these 
studies have produced a variety of results, and this is most likely  due to significant 
differences in age ranges, types of cognitive tests used, cohort and sampling 
methodologies, inclusion and exclusion criteria, different assays for measuring 
testosterone, and the absence of follow-up testosterone measurements. 
Testosterone has demonstrated neuroprotective effects in laboratory-based studies. Such 
results from cell culture and animal studies indicate that testosterone could also provide 
neuroprotection in the brain, especially in those regions that are susceptible to AD 
pathogenesis. Such regions include the hippocampus and cortical regions which have a 
high density of androgen receptors (Simerly et al., 1990). In the brain, testosterone can 
mediate its neuroprotective effects directly through binding to androgen receptors, or 
following conversion to estradiol (Pike et al., 2009). There is growing evidence to 
support these neuroprotective effects of testosterone. However, the effects of 
testosterone on the brain in terms of cognitive function are not fully understood and the 
available data are not conclusive. 
Beneficial effects of testosterone supplementation have been reported previously 
(Alexander, et al., 1998; Janowsky, et al., 1994; Klaiber, et al., 1971). However, 
testosterone supplementation in testosterone deficient men have not always 
demonstrated any significant effects on cognition (Ly et al, 2001; Cherrier et al., 2003; 
Kenny et al., 2002; Kenny et al., 2004; Vaughan et al., 2007; Sih et al., 1997). 
On the other hand, testosterone depletion does tend to increase depression.  A study by 
Almeida et al. (2003) showed that chemical castration resulting in testosterone 
depletion caused an increase in depression and anxiety. This suggests that age-related 
depression may be due to the age-related declines in testosterone levels. There are 
studies which suggest that depression and the development of AD may be linked: for 
example, two studies (Dal Forno et al., 2005;  Fuhrer et al., 2003) have demonstrated 





Therefore, current depression levels and any history of depression need to be considered 
carefully when assessing elderly men and their risk of AD.  
The role of estradiol, luteinizing hormone (LH), and genetic factors when considering 
AD risk in men is also not fully understood. During normal aging, testosterone levels 
gradually decline, but estradiol levels do not change significantly (Rosario et al., 2009 ; 
Twist et al., 2000). Several observational studies have shown negative associations 
between high estradiol levels and cognition. There is a possible role for gonadotropin 
levels that may further modify the role of testosterone in relation to cognition and brain 
function. The LH levels may have a negative association with cognition (Hyde et al., 
2010). The potential role of genetic factors is also of interest. In particular, the optimal 
level of testosterone may be influenced by  APOE genotype. In male non-APOE ε4 
carriers, testosterone levels have been found to correlate with performance on cognitive 
tests that investigate working memory, attention and executive functioning, whereas in 
men carrying APOE ε4 alleles, higher testosterone concentrations have been associated 
with a lower performance in such cognitive tests (Burkhardt et al., 2006). 
This chapter shows results of the assessment of the effect of transdermal testosterone 
supplementation on cognitive performance, verbal memory, depression, as well as 
quality of life in testosterone-deficient elderly men. This study assessed the efficacy of 
testosterone in improving cognitive function during a six month treatment trial while 
statistically controlling for the effects of  age and education.     
 
7.2 Aims 
The aims of this study were : 
 To investigate the effects of testosterone administration on global cognitive 
functioning; 
 To investigate the effects of testosterone administration on verbal memory; 
 To investigate the effects of testosterone administration on depression; 
 To investigate the effects of testosterone administration on health-related quality 





 To investigate whether there are different responses to testosterone treatment in 





Participants were healthy older men with low levels of testosterone, aged 50 to 75 years 
old (mean age 61 years +8 years) who had some concerns about their memory 
functioning and were recruited from the community through flyers. The study protocol 
was approved by the Edith Cowan University (Western Australia), and the Faculty of 
Medicine, University of Indonesia Independent Ethical Commitee, and approved 
informed consent procedures were followed. Details of the study design are described in 
section 6.3.Participants underwent a screening assessments at the baseline visit to 
determine eligibility criteria as described in section 2.1.1.1. The following eligibility 
criteria were used: 1) Males 50 years of age or older; 2) A Mini Mental State 
Examination (MMSE) score of 24 or above; .3) A normal range of prostate-specific 
antigen (PSA); 4) Blood pressure within normal limits, 110/75 – 130-85  5) No history 
of diabetes mellitus; 6) Normal liver and kidney enzyme function; and 7) No history of 
major head injury, based on the medical track record. Apart from blood tests to measure 
plasma testosterone levels, participants also underwent a cognitive screening test 
(MMSE) at baseline. Participants with MMSE scores below the recommended cut-off 
score (<24) were excluded from the study.  
Neuropsychological test measures 
In clinical practice, neuropsychological tests have always been fundamental in the 
clinical diagnosis of AD and other dementias. The recent development of potential drug 
treatments and preventative therapies has raised the issue that earlier diagnosis, as well 
as a more solid framework of neuropsychological assessment of AD are required. The 
majority of current tests have an acceptable sensitivity and specificity for screening of 
mild to moderate stage of AD. For example, the MMSE shows a sensitivity of 87% and 
specificity of 92% with the cut-off score 24 (Grut et al., 1993) and the Rey Auditory 





dementia, or between AD and other forms of dementia with a diagnostic accuracy of 83-
86% (Gilhus et al., 2011). 
In these studies, the cognitive test battery consisted of the MMSE  and the RAVLT. The 
MMSE is a brief cognitive measure which has been translated into many languages to 
assess memory, attention, language, orientation, aphasia and apraxia and it is widely 
used in clinical trials and research (Dufoil et al., 2000).  
The RAVLT evaluates a wide diversity of functions: short-term auditory-verbal 
memory, rate of learning, learning strategies, retroactive, and proactive interference, 
presence of confusion in memory processes, retention of information, and differences 
between learning and retrieval.  The test was administered to each participant according 
to standard procedure (Lezak, 1983). The RAVLT consists of a list of 15 unrelated 
words that need to be remembered. After presentation of Trial 1 – Trial 5, followed by 
free recall of the words immediately and consecutively, participants were presented with 
an interference list of 15 words. After free recall of interference list, participants were 
asked to recall words from the original list without additional presentation of the words 
(Trial 6). The last recall trial was followed by a 20-minute interval (Trial 7). Finally, 
participants were presented with word lists for recognition consisting of of 15 words 
from list A, 15 words from list B, and 20 words as distracters. Participants were to 
indicate words they recognized. The recognition measures used in this study include: 
List A recognition score (true positives), the number of words correctly identified from 
List A; List B recognition score, the number of words correctly identified from List B; 
distractors correctly identified score (true negatives); and the number of words 
mistakenly identified from either List A or List B. The application of  RAVLT list of 
words in this study used parallel forms of the RAVLT (matched for equal difficulty) to 
ensure that retesting could be conducted over time without the memory data being 
potentially confounded by practice or learning effects. RAVLT Test type A, B, C, and 
then D were administered starting from the baseline until the end of the study. 
Depression levels were measured by the Geriatric Depression Scale (GDS). The GDS 
has demonstrated an acceptable specificity and sensitivity, and is widely used for 





scores range from 0-30 with a score of >11 as the cut-off score for depression. A higher 
score is indicative of a higher depression level. 
Health-related quality of life was measured using the Short-Form Health Survey (SF-
36). The SF-36 comprises 36 items measuring 8 different dimensions including physical 
functioning, physical status, mental health, emotional status, social functioning, vitality, 
pain, and general health perceptions. From the results, two aggregate scores can be 
generated which indicate physical health and mental health. The scores on each scale 
range from 0 (the worst health state) to 100 (best health state) (Ware et al., 1992).  
The MMSE and SF36 tests were conducted at baseline and repeated at week 24 (end of 
treatment period), week 28 (washout period), and week 52 (end of cross-over period). 
The RAVLT and GDS tests were conducted at baseline and were repeated every 2 
months following the first treatment period, the washout period, and following the 
second treatment period (cross-over period). All neuropsychological tests were 
translated into Indonesian and have  been validated in Indonesian hospitals. Physicians, 
participants, and investigators were blind to the treatment conditions. 
 
APOE genotyping 
At the end of cognitive and clinical assessment sessions, whole blood samples were 
collected and were separated into various components using standard centrifugation 
techniques. White blood cells were used for APOE genotyping, which was determined 
using PCR as already described in section 2.1.1.2.3. 
Statistical analysis 
Statistical analysis was performed using The Statistical Package for Social Sciences 
(SPSS version 19, SPSS Inc, Chicago, IL). The Kolmogorov-Smirnov and Levene’s 
tests were used to examine normality of distribution of continuous variables for each 
group. The  data from the MMSE, RAVLT, GDS, and SF36 tests were found to be 
normally distributed. Therefore, one-way repeated measures ANOVA were performed. 
Carry-over effects were tested from differences at baseline in the first period (week 0) 
and at the washout period (week 24-28, which was baseline for the second period). 





memory, depression level and quality of life over time and in various groups. When 
directly comparing two groups from both arms of the study, as well as comparing two 
groups based on the presence of APOE-ε4 alleles, two tailed independent t-tests were 
used. Correlations of cognitive performances were assessed by Pearson product-
moment correlation coefficient (r) for parametric data, whilst Spearman (rho) was used 




Table 7.1 Mean (SD) age and education 
Non-APOE ε4 APOE ε4 p value 
Treatment A-->B 
Age 59 (5.82) 59.625 (9.58) 0.87 
Education 13.79 (3.31) 14.25 (1.91) 0.68 
Treatment B-->A 
Age 62.72 (7.31) 63.75 (13) 0.88 
Education 13.47 (3.62) 15 (2) 0.25 
 
Based on the statistics above, neither age nor education was significantly different when 
comparing any of the groups. The p value indicates that there were also no significant 
differences in age or education between non-APOE ε4 and APOE ε4 carriers. 
Therefore, age and education would not be expected to influence the following 







The end of Testo 
(A6) Washout (WO) 
The end of 
Placebo (B3) 
MMSE non‐APOE ε4 (n=14) 27.14 28.14 27.86 28.00 
MMSE APOE ε4 (n=8) 27.50 28.50 28.25 28.63 





















The end of 
Placebo (B6) Washout (WO) 
The end of Testo 
(A3) 
MMSE non‐APOE ε4 (n=18) 27.11 28.06 27.78 28.22 
MMSE APOE ε4 (n=4) 27.75 27.50 27.75 28.00 



















Figure 7.1 (a) : The MMSE score for treatment AB (A) and treatment BA (B) 
at 4 different time points : BL= Baseline (Week 0), A_6 & B_6 = End of First 
Treatment period (Week 24),  WO=Wash-out (Week 28), B_3 & A_3 = End of 
Second Treatment or Cross-over period (Week 52). Bar represent mean and standard 
deviation (+), with values underneath the bars for the mean of each groups. MMSE 
score was significantly improved after testosterone treatment in both arms and after 
washout and placebo treatment in treatment AB.  *p< 0.05 in comparison  to baseline 
of each arm of the treatments. No significant differences were observed between non-







BL A WO B 
MMSE non‐APOE e4 (n=14) 27.14 28.00 27.86 28.21 
MMSE APOE e4 (n=8) 27.50 28.38 28.25 28.00 




















BL B WO A 
MMSE non‐APOE e4 (n=18) 27.11 27.41 27.78 27.89 
MMSE APOE e4 (n=4) 27.75 27.08 27.75 27.50 

















Figure 7.1 (b): The MMSE score for treatment AB (A) and treatment BA (B) 
at 4 different time points : BL= Baseline (Week 0), A_= Mean of Testosterone 
treatment,  WO=Wash-out (Week 28), B = Mean of Placebo treatment. Bar 
represent mean and standard deviation (+), with values underneath the bars for the mean 
of each groups. MMSE score was significantly improved following testosterone 
treatment compared to placebo in treatment BA only, regardless of APOE (Graph B).  
#p< 0.05 in comparison between groups. No significant differences were observed 






Baseline (Week 0) 
End of 1st Treatment 
(Week 24) Washout (Week 28) 
End of 2nd Treatment 
(Week 52) 
MMSE Treatment A (Testo) ‐‐> B (Placebo) 27.27 28.27 28.00 28.23 















Figure 7.2: MMSE score comparison between treatment arm AB and treatment 
BA. Bars represent the means +standard deviation, with actual mean values shown 
underneath the bars of each group  No significant differences were observed between 






BL A_2 A_4 A_6 WO B_1 B_2 B_3 
IR non‐APOE ε4 (n=14) 43.21 44.14 43.21 45.21 47.29 51.43 43.71 44.62 
IR APOE ε4 (n=8) 46.25 47.25 46.25 49.88 49.00 50.75 50.13 51.29 


























BL B_2 B_4 B_6 WO A_1 A_2 A_3 
IR non‐APOE ε4 (n=18) 41.22 46.78 42.94 44.06 47.29 50.12 44.22 45.89 
IR APOE ε4 (n=4) 47.50 48.50 43.75 44.25 47.75 49.75 52.50 49.75 
























Figure 7.3 : Immediate Recall (Total Learning from Trial 1 to Trial 5) score for 
treatment AB (A) and treatment BA (B) at 8 different time points. BL= 
Baseline, A_2 to A_6 (Graph A) & B_2 to B_6 (Graph B) = First Treatment period ,  
WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 (Graph B) = Second Treatment or 
Cross-over period. Bars represent mean and standard deviation (+), with values 
underneath the bars for the mean of each group. Immediate recall score (as measured by 
RAVLT) was significantly increased over time at visit 9 (week 36) in both arms, 
regardless of APOE (Graph A and B)  *p< 0.05 in comparison to baseline for each arm 
of the treatments. No significant differences were observed between non-APOE ε4 and 
APOE ε4 groups. However, participants with APOE ε4 tend to recall the words better 







BL A_2 A_4 A_6 WO B_1 B_2 B_3 
SDR non‐APOE ε4 (N=14) 8.57 8.71 8.14 9.00 9.57 9.86 8.71 9.62 

















Short‐term Delayed Recall 
 
(B) 
BL B_2 B_4 B_6 WO A_1 A_2 A_3 
SDR non‐APOE ε4 (n=18) 8.22 9.78 8.29 9.11 9.88 9.47 8.50 10.06 
SDR APOE ε4 (n=4) 8.25 9.00 8.75 8.75 8.75 9.75 10.75 10.00 

















Short‐term Delayed Recall 
* 
 
Figure 7.4 : Short-term delayed recall for treatment AB (A) and treatment BA 
(B) at 8 different time points. BL= Baseline, A_2 to A_6 (Graph A) & B_2 to B_6 
(Graph B) = First Treatment period ,  WO=Wash-out, B_1 to B_3 (graph A) & A_1 to 
A_3 (Graph B) = Second Treatment or Cross-over period. Bars represent mean and 
standard deviation (+), with values underneath the bars for mean of each group. Short-
term delayed recall score  (as measured by Trial 6 RAVLT) was significantly increased 
at the end of testosterone treatment compared to baseline (*p< 0.05) at treatment BA 
only, regardless of APOE (Graph B). No significant differences were observed between 






BL A_2 A_4 A_6 WO B_1 B_2 B_3 
LDR non‐APOE ε4 (n=14) 7.64 8.64 8.00 8.29 9.07 9.57 8.79 9.35 
















Long‐term Delayed Recall 
 
(B) 
BL B_2 B_4 B_6 WO A_1 A_2 A_3 
LDR non‐APOE ε4 (n=18) 8.47 9.00 8.35 7.89 9.88 9.24 8.06 9.61 

















Long‐term Delayed Recall 
 
Figure 7.5: Long-term delayed recall for treatment AB (A) and treatment BA 
(B) at 8 different time points.  BL= Baseline, A_2 to A_6 (Graph A) & B_2 to B_6 
(Graph B) = First Treatment period ,  WO=Wash-out, B_1 to B_3 (graph A) & A_1 to 
A_3 (Graph B) = Second Treatment or Cross-over period. Bars represent mean 
+standard deviation, with values underneath the bars for mean of each group. There 
were no significant differences in long-term delayed recall score (as measured by Trial 
7 RAVLT) between any of the groups of either arm. No significant differences were 






BL A_2 A_4 A_6 WO B_1 B_2 B_3 
LOT non‐APOE ε4 (n=14) 16.43 19.14 17.14 17.36 15.86 17.50 16.93 15.00 























Learning Over Trials (LOT) 
 
(B) 
BL B_2 B_4 B_6 WO A_1 A_2 A_3 
LOT non‐APOE ε4 (n=18) 17.33 17.06 17.65 16.56 15.24 15.12 15.61 14.78 
























Learning Over Trials (LOT) 
 
Figure 7.6: Learning Over Trials (LOT) score for treatments AB (A) and BA 
(B) at 8 different time points. BL= Baseline, A_2 to A_6 (A) & B_2 to B_6 (B) = First 
Treatment period ,  WO=Wash-out, B_1 to B_3 (A) & A_1 to A_3 (B) = Second 
Treatment or Cross-over period. LOT = Total Learning – (5 x Trial 1) (Tierney et al., 
1994). Bars represent mean +standard deviation, with mean values shown below the 
bars. LOT score  (as measured by RAVLT) was significantly increased following 
testosterone treatment compared to the end of placebo treatment in treatment AB (A). 
#p< 0.05 in comparison between groups. No significant differences were observed 
between non-APOE ε4 and APOE ε4 groups. However, APOE ε4 participants tended to 









Figure 7.7 List A Recognition score for treatments AB (A) and BA (B) at 8 
different time points. BL= Baseline, A_2 to A_6 (A) & B_2 to B_6 (B) = First 
Treatment period ,  WO=Wash-out, B_1 to B_3 (A) & A_1 to A_3 (B) = Second 
(Cross-over) Treatment. Bars represent mean +standard deviation, with mean values 
underneath the bars for each group. There were no significant differences observed in 
List A recognition (as measured by RAVLT) between any of the groups of either arm 
(A and B).  No significant differences were observed between non-APOE ε4 and APOE 
ε4 groups. However, APOE ε4 participants tended to recognize words from list A better 










Figure 7.8 : List B Recognition score for treatment AB (A) and treatment BA 
(B) at 8 different time points. BL= Baseline, A_2 to A_6 (Graph A) & B_2 to B_6 
(Graph B) = First Treatment period ,  WO=Wash-out, B_1 to B_3 (graph A) & A_1 to 
A_3 (Graph B) = Second Treatment or Cross-over period. Bars represent mean and  
standard deviation (+), with values underneath the bars for mean of each group. There 
were significant differences of List B recognition (as measured by RAVLT) observed in 
all of the groups of both arms, regardless of APOE (Graph A and B).  No significant 










Figure 7.9 : Distracters Correctly Identified (True negatives) score for treatment 
AB (A) and treatment BA (B) at 8 different time points. BL= Baseline, A_2 to 
A_6 (Graph A) & B_2 to B_6 (Graph B) = First Treatment period ,  WO=Wash-out, 
B_1 to B_3 (graph A) & A_1 to A_3 (Graph B) = Second Treatment or Cross-over 
period. Bars represent mean and standard deviation (+), with values underneath the bars 
for mean of each group. There were significant decrease of true negatives score (as 
measured by RAVLT) observed in all of the groups in treatment AB (Graph A) and 
following testosterone treatment in treatment BA, regardless of APOE (Graph B). 
*p< 0.05 in comparison to baseline. Participants in both arms have better recognition 
memory over time, maybe due to the practice effect. No significant differences were 






BL A_2 A_4 A_6 WO B_1 B_2 B_3 
VL non‐APOE ε4 (n=14) 5.71 6.00 5.93 5.64 5.36 6.29 5.79 5.31 

























BL B_2 B_4 B_6 WO A_1 A_2 A_3 
VL non‐APOE ε4 (n=18) 5.44 5.59 6.18 5.11 5.24 5.00 5.17 5.44 























Figure 7.10: Verbal Learning score for treatments AB (A) and BA (B) at 8 
different time points. BL= Baseline, A_2 to A_6 (A) & B_2 to B_6 (B) = First 
Treatment period ,  WO=Wash-out, B_1 to B_3 (A) & A_1 to A_3 (B) = Second 
(Cross-over) Treatment. Bars represent mean +standard deviation, with mean values 
underneath the bars of each group. There were no significant differences in Verbal 
Learning (as measured by RAVLT) observed between any of the groups of either arm. 
There were significant differences between non-APOE ε4 and APOE ε4 groups, such 
that APOE ε4 participants had higher verbal learning scores. Verbal learning = Trial 5 – 











Figure 7.11: Verbal Forgetting (VF) score for treatments AB (A) and BA (B) 
at 8 different time points. BL= Baseline, A_2 to A_6 (A) & B_2 to B_6 (B) = First 
Treatment period ,  WO=Wash-out, B_1 to B_3 (A) & A_1 to A_3 (B) = Second 
(Cross-over)Treatment. Verbal forgetting (loss of information) = Trial 6 – Trial 5 
score45 (recall after interference). Bars represent mean +standard deviation, with mean 
values underneath the bars of each group. There were no significant differences 
observed between any of the groups of either arm. However, a trend towards a decrease 
in verbal forgetting was observed following testosterone treatment. No significant 






BL A_2  A_4  A_6  WO B_1  B_2  B_3  
GDS non‐APOE ε4 (n=14) 6.71 5.21 3.36 4.36 2.93 2.00 2.57 2.77 
GDS APOE ε4 (n=8) 7.63 6.50 3.50 4.63 4.50 4.50 3.88 4.00 






















BL B_2  B_4 B_6 WO A_1 A_2 A_3 
GDS non‐APOE ε4 (n=18) 4.94 4.44 4.39 4.17 4.56 4.56 5.00 4.28 
GDS APOE ε4 (n=4) 13.25 8.75 8.50 8.25 6.50 7.50 6.25 5.50 
























Figure 7.12 (a) : Depression score for treatment AB (A) and treatment BA (B) 
at 8 different time points. BL= Baseline, A_2 to A_6 (Graph A) & B_2 to B_6 (Graph 
B) = First Treatment period ,  WO=Wash-out, B_1 to B_3 (graph A) & A_1 to A_3 
(Graph B) = Second Treatment or Cross-over period. Bars represent mean mean and 
standard deviation (+), with values underneath the bars for mean of each group. 
Depression score (as measured by GDS) was significantly decreased following 
testosterone treatment, washout, and following placebo treatment in both arms, 
regardless of APOE (Graph A & B).  p< 0.05 in comparison to baseline of each arm of 
the treatments. # p< 0.05 in comparison between groups. Significant difference was 
observed between non-APOE ε4 and APOE ε4 group at baseline in treatment BA 






BL A WO B 
GDS non‐APOE e4 (n=14) 6.71 4.14 2.93 2.43 
GDS APOE e4 (n=8) 7.63 5.17 4.50 3.98 























BL B WO A 
GDS non‐APOE e4 (n=18) 4.94 4.78 4.56 4.52 
GDS APOE e4 (n=4) 13.25 6.50 6.50 6.83 























Figure 7.12 (b) : Depression score for treatment AB (A) and treatment BA (B) 
at 4 different time points. BL= Baseline, B = Mean of Testosterone treatment ,  
WO=Wash-out, B = Mean of Placebo teatment. Bars represent mean and standard 
deviation (+), with values underneath the bars for mean of each group. Depression score 
(as measured by GDS) was improved by testosterone treatment and carry-over effect 
was observed in treatment AB, regardless of APOE (Graph A)*p< 0.05 in 
comparison to baseline of each arm of the treatments. #p< 0.05 in comparison between 
groups. Significant difference was observed between non-APOE ε4 and APOE ε4 group 







Week 0 Week 8 Week 16 Week 24 Week 28 Week 36 Week 44 Week 52 
GDS Treatment A(Testo) ‐‐> B(Placebo) 7.05 5.68 3.41 4.45 3.50 2.91 3.05 3.20 



















Figure 7.13: GDS score comparison between treatment arms AB and BA. Bars 
represent mean +standard deviation, with values underneath bars being the mean of 
each group. No significant differences  were observed between any of the groups of 










          (A) 
Baseline (BL) 
The end of Testo 
(A_6) Washout (WO) 
The end of 
Placebo (B_3) 
PH non‐APOE ε4 (n=14) 75.43 72.64 79.29 78.62 
PH APOE ε4 (n=8) 71.50 75.25 73.75 79.86 





















Physical Health (PH) 
 
(B) 
BL B_6 WO A_3 
PH non‐APOE e4 (n=18) 71.06 73.72 77.22 73.69 
PH APOE e4 (n=4) 61 71.25 77.75 79.25 


























Figure 7.14 : Physical health (PH) score for treatment AB (A) and treatment 
BA (B) at 4 different time points. BL= Baseline (Week 0), A_6 & B_6 = End of 
First Treatment period (Week 24),  WO=Wash-out (Week 28), B_3 & A_3 = End of 
Second Treatment or Cross-over period (Week 52). Bars represent mean and standard 
deviation (+), with values underneath the bars for mean of each group. There were no 
significant differences of PH score (as measured by SF-36) observed in treatment AB 
(Graph A). However, PH score were significantly increased starting after placebo 
treatment, washout, and after testosterone in treatment BA, regardless of APOE 
(Graph B).  *p<0.05 in comparison to baseline of each arm of the treatments. No 








The end of Testo 
(A_6) Washout (WO) 
The end of 
Placebo (B_3) 
MH non‐APOE ε4 (n=14) 76.07 78.14 83.21 85.62 
MH APOE ε4 (n=8) 74.25 79.75 83.25 84.86 
























BL B_6 WO A_1 
MH non‐APOE e4 (n=18) 78.61 78.72 81.44 78.17 
MH APOE e4 (n=4) 55.75 79.00 75.75 72.00 





















Mental Health (MH) 
* * * 
 
Figure 7.15 : Mental health (MH) score for treatment AB (A) and treatment 
BA (B) at 4 different time points. BL= Baseline (Week 0), A_6 & B_6 = End of 
First Treatment period (Week 24),  WO=Wash-out (Week 28), B_3 & A_3 = End of 
Second Treatment or Cross-over period (Week 52). Bars represent mean and standard 
deviation (+), with values underneath the bars for mean of each group. MH score 
significantly increased at washout and after placebo in treatment AB (Graph A). 
Whilst in treatment BA, significant increased of PH score were observed starting 
after placebo treatment, washout, and after testosterone, regardless of APOE.  *p<0.05 
in comparison to baseline of each arm of the treatments. #p<0.05 in comparison 
between groups. No significant difference was observed between non-APOE ε-4 and 















End of 2nd 
Treatment 
(Week 52) 
PH Treatment A(Testo) ‐‐> B(Placebo) 74.00 73.59 77.27 78.63 




































End of 2nd 
Treatment 
(Week 52) 
MH Treatment A(Testo) ‐‐> B(Placebo) 75.41 78.73 83.23 84.89 























Figure 7.16 Physical Health score (A) and Mental Health score (B) comparison 
between treatment arms AB and BA. Values are presented as mean +standard 
deviation. No significant differences were observed between any of the groups of either 







Upon examining the relationship between circulating levels of testosterone and 
cognition in older men, it is important to note that only small amounts of total plasma 
testosterone (+2%) may pass the blood-brain barrier and enter the brain (Sodergard, 
1987). Given that lower levels of testosterone are associated with cognitive impairment, 
testosterone administration might have a beneficial effect. Although studies examining 
the association between testosterone levels and cognition have frequently used measures 
of free testosterone, in this study total testosterone was measured as this has previously 
been shown to be a sensitive and valid measure for hormone treatment studies. Indeed, 
our study has shown significant improvements on MMSE scores after testosterone 
treatment in both arms of the study compared to baseline (Figures 7.1 A and B). 
Interestingly, in treatment AB significant effects were also observed in the washout 
and placebo treatments. These results suggest that carry-over effects from the 
testosterone treatment lasted at least 28 weeks post-testosterone treatment. These 
apparent beneficial effects of testosterone on general cognition are in line with results 
obtained in a previous study by Slabbekoorn et al. (1999) which indicated that changes 
in cognition from hormone manipulation do not return to baseline levels but remain or 
continue to change in the same direction after cessation of hormone treatment. 
Therefore, carry-over effects of testosterone treatment delay further memory 
impairment.  
In addition, another study by Cherrier et al. (2001) found that testosterone 
supplementation in elderly men improved visuospatial abilities as well as verbal 
memory even in the short-term period of 6-weeks. It remains unclear whether the 
improvements in cognition are due to increased testosterone levels, or estradiol levels, 
or both. Beneficial effects of testosterone treatment have also been observed by Muller 
et al. (2005) who demonstrated a positive relationship between overall cognitive 
functioning and free testosterone levels in older men.  
Verbal memory has been measured in a variety of standardized episodic memory 
measures. RAVLT was chosen in this study because of its ease of administration and its 
sensitivity to impairment in different memory components (Dal Forno et al., 2005). 





memory, which allows the evaluation of acquisition and recall of information 
(Mitrushina et al., 2005). Because of possible rapid effects of testosterone, RAVLT 
were administered once every 2 months to monitor changes in verbal memory. As 
mentioned before, global cognitive changes as measured by MMSE were improved 
following testosterone treatment in this study. However, verbal memory and recall was 
not significantly improved following testosterone supplementation as measured by 
RAVLT (Tables 7.1 – 7.4, and Figures 7.3 – 7.7 and 7.11). This is in line with findings 
from the Hogervorst et al. (2004) study which showed that some neuropsychological 
tests could be more sensitive to hormone levels than others. Our RAVLT data (Fig 7.10 
and Learning curve in Appendices) show that the increasing number of words recalled 
were more likely due to the improvement of memory over time because of practice or 
learning effects, rather than testosterone treatment itself. In addition, there may be a 
psychological effect of using the cream which we could not control for. That is, the 
participants strived to do their best in each tests (placebo effects) to receive the 
treatment. Therefore, it is quite difficult to differentiate between testosterone and 
placebo effects in terms of increasing verbal memory and words recall over time in this 
study. These results are in accordance with a study by Emmelet-Vonk et al. (2008), 
which studied men aged 60-80 years old with testosterone levels < 13.7 nmol/L. Their 
cognitive levels were measured by the same word lists of RAVLT in each treatment 
group. Other studies by Wolf and Kirschbaum (2002) and Yonker et al. (2006) further 
indicate non-significant associations between testosterone and episodic memory. 
Most studies of testosterone treatment in testosterone deficient men have found no 
effects on cognition. It has been hypothesized that this could be due to decreased 
sensitivity of androgen receptors after prolonged exposure to low testosterone 
conditions (Hogervorst et al., 2005). Alternatively, Cherrier et al. (2007) observed 
memory performance in 57 healthy elderly men after replacing testosterone with 50, 
100, or 300 mg weekly injections. They found that only men with moderate testosterone 
increases demonstrated verbal and spatial memory improvement whilst men with low or 
high increases did not. The total testosterone levels shown in this study (Chapter 6) have 
shown high increases following testosterone treatment. Therefore, improvements in 
verbal memory following this testosterone treatment were subtle.  This may indicate an 





Another study by Wolf et al. (2002) also suggests that testosterone has no effect on 
verbal memory and is negatively associated with verbal fluency in men. Although this 
study did not explain the negative associations, the results are  in line with those of 
another study which investigated the effects of long-term testosterone replacement on 
several neuropsychological tests (Sih et al., 1997), and also found negative associations 
Initially, this study used four different types of RAVLT at the visits to minimize 
learning effects which could overshadow any treatment effects. However, the use of 
different types of RAVLT in this study may have reduced the sensitivity in detecting 
any subtle testosterone treatment effects on verbal memory.  
Depression affects a large number of elderly individuals and has been associated with 
cognitive decline (Yaffe et al., 1999) and increased risk of mild cognitive impairment 
(MCI) (Geda et al., 2006). Depression is also a common feature of testosterone 
deficiency and it usually responds well to  testosterone treatment (Gooren, 2007). With 
testosterone levels in the hypogonadal range, depression was a common occurrence 
(Zitzmann et al., 2006).  Assessments may have been complicated by this fact as 
performance in cognitive tests can be influenced by depression (Yeap et al., 2008). The 
results of these experiments show that participants with APOE ε4 alleles tend to have 
higher depression scores when compared to non-APOE ε4 carriers (Fig 7.12 A&B). 
Interestingly, the depression score of participants with APOE ε4 (n=4)  in treatment 
BA was significantly different than the non-APOE ε4 at baseline, even they have 
been categorized to be depressed based on GDS cut-off score (Fig 7.12 B). Overall, as it 
was expected, depression was shown to be significantly reduced following testosterone 
treatment in both treatment arms (Fig 7.12 A&B), although in treatment BA the effect 
was only seen in APOE ε4 carriers, and may not have been due to treatment as GDS 
scores dropped initially in the placebo treatment time, which preceded testosterone 
treatment. The results for the APOE ε4 carriers more likely reflects the low number of 
participants (n=4). The baseline already-low GDS scores (mean = 5) in treatment BA 
for the non- APOE ε4 carriers (unlike the higher baseline GDS scores in the AB 
treatment group, means of 7 and 8)  makes it rather difficult to determine a drop in 
depression using this scoring system.   Interestingly, in arm treatment AB, the 
testosterone effect was carried over to the washout and placebo treatment, with further 





with placebo treatment observed for the APOE ε4 carriers in treatment BA (Fig 7.12 
B). may be due to the  baseline condition of most participants.  The APOE ε4 carriers 
had high depression levels at  baseline, giving the treatment greater opportunity to 
improve GDS scores following treatment. As mentioned earlier though, the significant 
reduction of depression followed placebo treatment, which together with the large error 
bars on the graphs, more likely reflects the low number of participants. The results of 
treatment AB however are in agreement with Seidman et al.,2001 who reported that 
total testosterone levels are negatively associated with depression in middle-aged men.  
The association between depression and AD is still unclear. Associations are 
complicated by the possibility that depression may be a prodromal symptom of AD, 
which may appear before the recognition of AD. As a result, there are still insufficient 
data to determine whether depression represents an early symptoms or an independent  
risk factor of AD (Jorm, 2001).  
There are limited data on the effects of testosterone on the quality of life in testosterone 
deficient men. However the information that exists suggests that testosterone can 
improve the quality of life significantly (restoring to the same level as men with normal 
testosterone levels) and the more severe the symptoms before treatment, the greater the 
benefits of testosterone replacement (Moncada, 2006). Although the effect of 
testosterone deficiency on quality of life has not been well established, it is clear that 
testosterone deficiency in the elderly has a negative effect on physical, mental and 
social functioning (Novak et al., 2002). 
In this study, quality of life comprising physical health and mental health were not 
significantly improved by testosterone treatment. Although, in treatment BA, both 
physical and mental health scores were significantly increased after being treated with 
testosterone compared to baseline. However, it is important to note that there were 
“carry-over effect” observed in which physical health (PH) and mental health (MH) at 
washout were still significantly different from baseline (Figure 7.14 B and Figure 7.15 
B). In accordance with our results, Reddy et al., 2000 and Kenny et al., 2002 also failed 
to show testosterone therapy-induced improvements in quality of life  testosterone 
therapy. These two studies used the SF-36 test too. Using a different measure, namely 





significant difference following the assessment of quality of life in healthy elderly men 
treated with testosterone for 24 weeks. 
However, in a study by Snyder et al., 1999 which used the SF-36 test for assessment, 
transdermal testosterone treatment in men over 65 years of age improved the patients’ 
perception of physical functioning (but no other domains of the SF-36) compared with 
placebo. This study observed the effect of testosterone treatment for 36 months, whilst 
the treatment in the current study lasted only 6 months. The testosterone replacement 
therapy by Kenny et al., 2002 for 12 months also did not show improvement of quality 
of life. The effect of testosterone on quality of life in this study was not significant 
enough to be detected – this may be because the quality of life was determined to be 
quite adequate in these participants at baseline.    
It is possible that the SF-36 assessment is too general and not particularly suitable for 
assessing quality of life in a testosterone deficient population (Jorm, 2001). There are 
other more specific scales to measure quality of life in testosterone deficient men, such 
as The Aging Male’s Symptoms (AMS) (Daig et al., 2003) and the Age-Related 
Hormone Deficiency-Dependent Quality of Life questionnaire (A-RHDQoL) (McMilan 
et al., 2003). The questionnaires detailed in these studies may be more specific in 
addressing issues related to hormone deficiencies, and may assess better the effects of 
testosterone replacement therapy in men with low testosterone and show that quality of 
life can improve following testosterone treatment. 
A  study from my supervisor’s laboratory (Sohrabi, et al., 2009) has shown that mental 
health and quality of life in memory complainers were independent of APOE genotype. 
Results in the current study were consistent with these previous findings as they did not 
show significant differences between APOE ε4 and non-APOE ε4 carriers in relation to 
quality of life, in the AB treatment arm, although there appears to be a trend towards 
better physical health in both APOE ε4 and non-APOE ε4 carriers at all stages 
following testosterone treatment (Fig.7.14). A similar trend is visible in the BA 
group, however this is possibly due to the (only 4) APOE ε4 carriers having a low 
baseline score, which is followed by the apparently high physical health scores at 
washout stage, which is obviously not due to the subsequent testosterone treatment in 





size of the whole BA cohort is too small for good statistical analysis, the SF36 test 
from which the physical health scores were obtained is not appropriate for assessment 
of testosterone treatment, or both. From the perspective of mental health scores, in the 
AB  group there appears to be a trend towards better mental health in both APOE ε4 
and non-APOE ε4 carriers over the stages following testosterone treatment. In the BA 
group, no change can be seen in the non-APOE ε4 carriers (Fig. 7.15), however due to 
the low baseline score of the APOE ε4 carriers, it appears that the placebo treatment has 
raised mental health levels, which then stay high for the rest of the trial.  This 
discrepancy, again, may be due to the very small sample sizes for APOE ε4 carriers 
compared to non-APOE ε4 rather than any effect of possession of APOE ε4 alleles. 
Controlled clinical trials of testosterone supplementation in healthy elderly men with 
partial androgen deficiency have yielded inconsistent results in relation to quality of 
life. Some studies have found an increased sense of well-being (Tenover, 1992 ; Park et 
al., 2003) while others have observed no significant  effects (Reddy et al., 2000). 
Assessment of quality of life offers a window of opportunity into the effects of 
testosterone intervention on the patients and caregivers' perceived well-being and may 
assist clinicians in determining the potential functional benefits and risks of therapy. 
This study had some limitations. This study was underpowered, with relatively small 
sample sizes (n=44) to find associations between testosterone treatment and cognition, 
despite its cross-over design. There may be age dependent optimal testosterone levels 
which vary for different brain functions which we did not investigate in this study. 
Furthermore, the chosen instrument of RAVLT may lack sensitivity to detect small or 
subtle changes in cognitively intact participants within 6 months of testosterone 
treatment. Therefore, longer duration of studies may have yielded greater effects of 
testosterone on cognition and verbal memory (Yonker et al., 2006 ; Gordon et al., 
1986).  It is also important to note that comparisons with other studies are difficult since 
there were large variations in testosterone levels across studies despite having similar 
age ranges. Furthermore, many studies have used different cognitive tests to assess 
similar brain functions, and sometimes have used insensitive tests. Another potential 
explanation for differences in results is that many studies have measured total 
testosterone (Hassler et al., 1992 ; Gordon, 1986 ; Tan, 2005) rather than free 





However, this study has attempted to measure general cognition (with verbal memory, 
in particular), depression level, and quality of life at various time points of treatment 
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Effects of testosterone treatment 
on brain metabolite levels 






Alzheimer’s Disease (AD) cognitive symptoms arise only after extensive synaptic loss 
and neuronal death has already occurred. As a result, diagnosis is usually made many 
years after the start of the disease process. A screening process that could provide early, 
accurate diagnosis of AD would enable earlier intervention, and thus allow current and 
future treatments to be more effective. Potential biomarkers for AD screening are being 
sought from many fields including genetic analysis, blood proteomics, cerebrospinal 
fluid proteomics and brain imaging. With respect to imaging techniques, both structural 
and functional neuroimaging methods are being tested.   
AD is characterized by early loss of memory, with the hippocampus and entorhinal 
cortex being the first sites of pathological changes. Brain structural changes include 
generalized cerebral atrophy, ventricular enlargement and mild to moderate white 
matter changes or leukoaraiosis. Focal temporal atrophy can be detected using 
computerised tomography, and a suggested diagnostic marker for AD involves the use 
of angled temporal lobe views to detect medial temporal lobe atrophy associated with 
the disease (O’Brien, 2007). Unfortunately this has been found to have limited utility 
both in early disease and in the differentiation of AD from other causes of dementia. 
Magnetic resonance imaging (MRI) has been widely investigated in AD and consistent 
with the temporal development of plaque and NFT pathology, very early structural 
changes have been demonstrated in the hippocampus and entorhinal cortex. However, 
the particular structure that would be most useful for early diagnosis remains unclear 
(Scheltens et al., 2002, Du et al., 2001). Atrophy of the hippocampus and entorhinal 
cortex can be assessed using simple validated scales, and such atrophy occurs in 80-
90% of AD cases and in around 5-10% of control subjects (Du et al., 2001). Other early 
changes in AD include atrophy of the posterior cingulate (Scahill et al., 2002), not a 
prominent site of pathology but changes may be related to loss of afferent input from 
associated fibres. 
Serial MRI has been useful in increasing our understanding of disease progression in 
AD and other dementias. Atrophy rates of around 2% per year occur in AD compared to 
0.25-0.5% in control subjects (O’Brien, 2007), and using serial MRI, it has been 





be detected by cross-sectional volumetric measurement (Ridha et al., 2006). Serial MRI 
has sometimes been used as an outcome measure in clinical trials, being a robust 
biological measure that shows little variability. Power calculations have shown that 
clinical studies of disease progression can be undertaken with significantly fewer 
subjects when using serial MRI as opposed to a clinical outcome measure (Fox et al., 
2000). Using this method, it has been possible to measure a decreased rate of 
hippocampal atrophy in those receiving cholinesterase inhibitors (Hashimoto et al., 
2005), Serial MRI in another study measured increased brain atrophy in a group of 
patients given the active amyloid vaccine. This was suggested to be due to  increased 
clearance of amyloid plaques from the brain (Fox et al., 2005). 
Atrophy of the medial temporal lobe (MTA), including the hippocampus and entorhinal 
cortex, is a sensitive marker for AD, and studies have shown that decreased volume of 
the medial temporal lobe is also marker for dementia in patients with mild cognitive 
impairment (MCI) (Esther et al., 2004). However, MTA is present in other dementias as 
well, for example in frontotemporal lobe degeneration (FTLD), vascular dementia 
(VaD) and dementia with Lewy bodies (DLB). It may also be seen in normal aging. 
Volumetric assessment of MTA is difficult because of the time-consuming analysis 
required, and because automated hippocampal volume measurement techniques are not 
widely available. In contrast, the assessment of MTA using a standardized visual rating 
scale is a quick and easy measurement, with comparable predictive accuracy. Such 
visual assessment of MTA from brain MRI using a standardized rating scale is powerful 
and can function as an independent predictor of conversion to dementia in relatively 
young MCI patients (Scher et al., 2007). In fact, the MTA scale has been shown to be a 
better predictor of memory impairment when compared to neuropsychological tests 
(Scheltens et al., 2002). AD hippocampal volumes have been measured to be 11.5% 
smaller than in control cases, with similar size differences for the median left (12%) and 
median right (11.6%). Hippocampal shape analysis has shown that differences are more 
evident in the hippocampal body than in the head, and more consistent differences have 
been found in the left hippocampus than the right (Scher et al., 2007, Kantarci et al., 
2004).  
Functional MRI is another form of scanning that can measure brain activity indirectly, 





signal, thus a vascular response leads to a signal increase that is related to neural 
activity. It has several potential advantages, particularly for clinical trials, as it is a non-
invasive technique that does not require the injection of contrast agent or radiation 
exposure and thus can be repeated many times during a longitudinal study. fMRI has 
relatively high spatial and reasonable temporal resolution, and can be acquired in the 
same session as structural MRI (Sperling, 2011).  
In an AD brain, volume loss has been intrepreted to reflect neuron loss, possibly 
together with non-neural changes, such as loss of glial components. Such changes are 
now thought to be detectable using yet another relatively new technology - proton 
magnetic resonance spectroscopy (1H MRS), which has the potential to provide non-
invasive assessments of metabolic and functional correlates of dementia in research and 
clinical settings (Lin et al., 2005). An MRS spectrum shows frequency or chemical shift 
(compared to a reference chemical) on the horizontal axis, which allows the 
identification of the metabolites being investigated, and the vertical axis shows the 
signal strength in arbitrary units. MRS allows for non-invasive and repeated 
quantitation of several different brain metabolites, most commonly N-acetyl aspartate 
(NAA), choline (Cho), myo-Inositol (mI), and creatinine (Cr) containing compounds.  
Each of these metabolites is thought to be sensitive to a different aspect of in vivo 
pathologic processes at the molecular or cellular level (Kantarci et al., 2007). Increases 
in choline and myo-Inositol (markers of membrane turnover) have been demonstrated in 
several studies of AD brains, implying significant cellular membrane (and glial) 
pathology. Large decreases in brain NAA (a marker of neuro-axonal integrity) are 
commonly seen in grey and white matter in AD (as well as in other forms of dementia), 
indicating the presence of significant axonal damage. Levels of NAA also appear to 
correlate with disease severity. Recent studies suggest MRS has the potential to 
distinguish AD patients from healthy control at pre-clinical stages of the disease in 
which AD-modifying therapies are likely to be most beneficial (Fallini et al., 2005). For 
example, in a study of cognitively normal older adults, higher ratios of mI/Cr and 
Cho/Cr were associated with higher Aβ loads, as measured by PiB retention. Higher 
Cho/Cr was found to be associated with worse performance on domain-specific 
cognitive tests independent of Aβ load, suggesting that Cho/Cr elevation may also be 





elevation such as Lewy body or ischemic vascular disease in addition to Aβ load 
(Kantarci et al., 2011).  
Another recent study carried out MRS on MCI patients to see if it was possible to 
predict conversion to dementia within the 2-year period after baseline assessment. The 
brain regions examined were the posteromedial bilateral parietal lobe and left medial 
occipital lobe. After the 2 year follow-up, 27 (38%) patients converted to AD. The mean 
NAA/Cr ratio in the poster medial bilateral parietal cortex was 1.38 in converters versus 
1.49 in non-converters (p<0.0001). In this study, neither the APOE ε4 genotype nor 
leucoaraiosis was predictive of conversion to dementia (Modrego et al., 2011). Several 
other studies have looked at various concentrations or ratios of the 4 metabolites 
(NAA/Cr, Cho/Cr, mI/Cr and NAA/mI ratios), such as one study which found that the 
NAA/Cr ratio in the posterior cingulate gyri showed considerable potential for 
distinguishing amnestic MCI from normal elderly controls (Wang et al., 2012), and 
another study which compared AD and subcortical ischemic vascular dementia (SIVD), 
which are known to have overlapping pathologies and risk factors, and found that the 
pattern of mI concentration changes differed between the two disorders; mI was 
increased in AD but not increased in SIVD (Shiino et al., 2012). All these results 
suggest MRS may provide a valuable biomarker for predicting the development of AD 
as well as to differentiate between AD, vascular dementia and MCI.  
Another recent study showed that the discrimination between early AD and elderly 
healthy control subjects can be improved by adding MRS measures to MRI measures: it 
was found that combining MRI and MRS measures resulted in a sensitivity of 97% and 
a specificity of 94% compared to using MRI or MRS measures alone (sensitivity: 87%, 
76%, specificity: 86%, 83% respectively) (Westman et al., 2011).  In AD patients, 1H 
MRS measurements of NAA/Cr and mI/Cr ratios correlated with the 
neuropsychological measures of cognitive function. This correlation was found to be 
region-specific, depending on the cognitive domain being studied. For example, 1H 
MRS metabolite changes in patients with AD correlate with verbal memory loss in the 
left medial temporal lobe, and correlate with language impairment and visuo-





Since a variety of metabolite differences have been recorded, possibly due to the region-
specific nature of these differences, more studies need to be conducted to characterise 
these MRS differences further, and to discover which metabolite differences and which 
brain regions are the most appropriate for differentiating people with early stages of AD 
from healthy elderly controls. 
With regard to the monitoring of treatment effects, there are very few studies that have 
directly examined testosterone’s effects on brain activity (Moffat et al., 2004). Applying 
this new MRS technology to measure brain metabolite changes in a testosterone 
treatment trial may indicate how testosterone is affecting brain function, thus providing 
valuable information. Overall, this chapter will investigate the effects of testosterone on 
brain metabolite changes and atrophy rates, as well as the association between MTA 
scale measurements and neuropsychological performance. 
 
8.2 Aims 
The aims of my study were: 
 To determine whether testosterone treatment can influence brain 
metabolite levels in testosterone deficient men; 
 To determine whether testosterone treatment alters rates of medial 
temporal lobe atrophy; 
 To determine whether testosterone treatment in men influences 
hippocampal atrophy, as assessed by the MTA scale; 
 To determine whether there is any correlation between MTA scale 
measurements and neuropsychological performance following 











All participants were randomized in both arms of the treatment, the details of which 
have previously been described in section 6.3. Testosterone deficient men were seen at 
baseline and underwent structural brain MRI and MRS, following completion of the 
neuropsychological assessment. Participants attended follow-up MRI and proton MRS 
imaging at the following intervals from baseline: at 24 weeks which was the endpoint of 
the first treatment (either treatment A or B), and at 52 weeks which was the end of the 
second treatment (either treatment B or A) respectively. 
 
 1H MR Spectroscopy- Chemical Shift Imaging (CSI) 
1H  MR Spectroscopy (MRS) spectra were acquired on a 1.5 T Philips Gyroscan ACS-
NT system using a quadrature Head coil. MRI of the brain was done before the 
commencement of MRS for assessment of brain condition at that time. The first step of 
the MRI was a SCOUT / SURVEY. Twenty axial or transversal scout images were 
obtained by T2/FLAIR ( Fluid Attenuated Inverse Recovery) using a thickness of 5 mm 
and 0.5 mm gaps. From these sequences, evaluation of the whole brain for lacunar 
infarcts or lesions was possible. Twenty sagittal scout images were then acquired by 
T1/FFE (Fast Field Echo) using a 5 mm thickness and 0.5 mm gap. This sequence 
represents the long axis of the hippocampus for coronal slice determination by MRS. 
The next acquisitions were 20 coronal scout images with T2/TSE ( Turbo Spin Echo ) at 
a thickness of 5 mm and gaps of 0.5 mm. Slices were made perpendicular to the long 
axis of the hippocampus body. For serial acquisition, the same voxel size was used for 
each patient in coronal slides and repositioned as accurately as possible by the same 
study radiographer who was blinded to clinical / cognitive information. 
2D Spectroscopic Imaging (SI) methods (TR = 1500 ms, TE = 272, matrix = 512 x 512) 
were used for spectra generation. An Echo Time (TE) of 272 ms and water suppression 





plane of the 2D SI grid can be angulated with the echo defined volume, the direction 
can be freely chosen to be transverse, sagital or coronal so 2D SI could be use to capture 
an irregular shape structure in whole voxel.  Five spectroscopic points were generated 
on the right and left hippocampi, right and left medial temporal lobe, and one in the 
white matter of the thalamus, this last one providing a “normal” spectrum which served 
as a control (no pathologies observed). Acquired spectra were reviewed visually by an 
experienced neuro-radiologist for quality as well as artifacts that would interfere with 
metabolite quantization. The metabolite ratios NAA/Cr and Cho/Cr were generated 
from the software of the Gyroscan ACS-NT system, using the physiologically stable 
metabolite Creatine (Cr) as the internal reference metabolite. Due to the selection of 
long echo time in this study, myo-Inositol was not available. A total of 1980 spectra 
were acquired. Total scan time for MRI and MRS acquisition was 50-60 minutes for 
each patient. 
 
Medial Temporal Atrophy (MTA) rating 
A standardized Scheltens scale was used to assess atrophy of the right and left medial 
temporal lobes including the hippocampus from hard film copies of coronal slice T1-
weighted images, with slice thicknesses being 8 mm. Atrophy is graded on a 5-point 
scale (0=absent, 1=minimal, 2=mild, 3=moderate and 4=severe) based on the height of 
the hippocampus, the width of the choroid fissure, and the width of the horn. (Figure 
8.1). These MTA ratings were performed at three time points, which were at baseline 







Figure 8.1: Medial Temporal Atrophy (MTA) visual assessment scale. MTA scaling 
performed on T1-MR coronal slices. The right and left sides are rated separately and 
also combined. Score range of atrophy: 0=absent, 1=minimal, 2=mild, 3=moderate and 
4=severe. 
For the purpose of statistical analysis, two experienced radiologists (blinded to 
treatments and age) were employed to provide two sets of results to assess atrophy in 
the right and left medial temporal lobes. In addition, the right and left MTA scales were 









The Statistical Package of Social Sciences (SPSS version 19, SPSS Inc, Chicago, USA) 
was used for data analysis. The Shapiro-Wilk test was used to examine normality of 
distribution of continuous variables for each group. All of the data were found to be not 
normally distributed (non-parametric data), therefore Friedman’s Test and/or Wilcoxon 
signed-rank test was used to look at differences between groups. The inter-class 
correlation coefficient was used to assess the inter-rater reliability of the qualitative 
MTA scale using Kappa Measure Agreement. Regression analysis was done in order to 
determine whether the efficacy of testosterone treatment in men can be determined by 
the rate of hippocampal atrophy. Partial correlations between MTA scores and measures 
of neuropsychological assessment (Mini Mental State Examination, Geriatric 
Depression Scale,, and Rey Auditory Verbal Learning Test) were examined using 
Spearman Rho correlation, controlling for the effect of age and education.   
 
Measures 
The details about the neuropsychological, and clinical measures used in this study can 
be found in Chapter 7, page 267. Briefly, to measure the general cognitive functions and 
the potential cognitive decline severity Mini Mental State Examination (MMSE) and 
Geriatric Depression Scale (GDS) were used. The verbal memory was assessed using 












8.4.1 Effects of testosterone on brain metabolites as measured by 1H MR 
Spectroscopy 
To determine the effects of testosterone on brain metabolite levels, the N-Acetyl-
Aspartate, Choline (Cho) and Creatinine (Cr) levels were assessed using 1H MRS and 
the  NAA/Cr and Cho/Cr ratios were calculated. For an individual metabolite, the parts 
per million (ppm) refer to the unit of measure used to identify a metabolite’s peak 
location or resonance on the x-axis. The ppm is calculated by dividing the difference in 
frequency (in Hertz) of two peaks (with one peak being the reference) by the operating 
frequency of the MR scanner (in Hertz). The signal intensity (amplitude on the y-axis) 
and line width provide the "area" which can be used to quantify the amount of the 
observed metabolites (Figure 8.2). Every metabolite has a normal concentration that 
generates a pattern of peaks which is uniform from person to person unless there is an 
underlying pathology. Therefore, diagnosis with MRS can be made by comparing 
between normal and abnormal peak patterns. According to numerical peak-height ratios 
with the assumption that Cr=1, a ratio of NAA/Cr of 1.25 + 0.07 would suggest a 
dementia diagnosis. A value of NAA/Cr >1.11 may be classified as probable AD 







Figure 8.2: Example of a 1H MRS-2DCSI set of scans with 5 different 
spectroscopic points obtained using a Gyroscan Intera 1.5T (Philips). 1: right 
hippocampus. 2: left hippocampus. 3: right medial temporal (MT) lobe 4: left MT 
lobe 5: thalamus (normal) area 
The mean and standard deviation for longitudinal metabolite changes between 
testosterone and placebo treatment as revealed by NAA/Cr and Cho/Cr ratios are shown 
in Figures 8.3 and 8.4. There were no significant changes in the two ratios in either the 
left or right hippocampi, or the medial temporal lobes over the three time points 
(between baseline, treatment A, and treatment B) based on Friedman’s test and 























































































Figure 8.3 : NAA/Cr ratios measured at four different spectroscopic points in 
treatment AB (A), and treatment BA (B). There were no significant changes 


















































































Figure 8.4 : NAA/Cr ratios measured at four different spectroscopic points in 
treatment AB (A) and treatment BA (B). There were no significant changes over 





8.4.2 Effects of testosterone on medial temporal atrophy (MTA) 
The variability between the ratings put forward by the three different raters were 
investigated. There was little agreement with Kappa Measure of Agreement between 
raters 1 and 2 (0.01, 0.02), versus rater 3 (0.015). Therefore, the MTA scores were 
generated from two out of three radiologists whose scores were in close agreement. 
MTA scale results were generated for the right and left temporal lobes separately, as 
well as combined, to generate one score which ranged from  0-4, with a greater score 
indicating more atrophy (as demonstrated in Fig. 8.1). The MTA scaling was done at 
three time points (as used in section above) in both arms of the experiment, with 



















Figure 8.5: Boxplots of right MTA and left MTA scaling results (n=22) of subject 
brains from both arms of the study: treatment AB (1st row) and treatment BA 
(2nd row).  
Significant reductions in atrophy were observed on the left MTA scale of treatment 
BA, compared to baseline. There were no other significant differences observed. Data 











Figure 8.6 : Boxplots of combined right and left MTA scaling results (n=22) of 
subjects from both arms of the study: treatment AB (left ) and treatment BA 
(right).  Significant reductions in atrophy following testosterone and placebo treatments 
were observed only in arm treatment BA compared to baseline; *p<0.05, in 
comparison to baseline. 
 
Due to the small number of participants in the two arms of the study, the added 
statistical power that might be obtained following pooling of the MTA results of all 















Figure 8.7: Boxplot of the combined MTA measurements (n=44) of both arms of 
the study: right MTA and left MTA (both on top row), and combined right and left 
MTA (2nd row). Data are presented using the scale range of 0-4 (as described in Fig. 
8.1), showing the medians + quartiles. Significant differences were observed in the left 
MTA measurements, as well as the combined right and left MTA results following both 
treatments (testosterone and placebo) compared to baseline. In the right MTA scaling 
results, a significant reduction in MTA scaling was observed following testosterone 
treatment only. However, pooling the results from the two treatment arms no longer 
takes into account the order of the testosterone and placebo treatments; *p<0.05 in 






Figure 8.8: Boxplot of Right and Left Medial Temporal Atrophy (MTA) results for 
treatment AB (1st row) and treatment BA (2nd row), as assessed by rater 1. 
Data are presented in the scale range from 0-3 showing the median + quartiles.  
 
The results of the Friedman Test for treatment AB as well as treatment BA  
indicated that there were no significant differences across the three time points 
(baseline, testosterone treatment, and placebo treatment) for the right MTA results: Х2 
(2, n=22) = 1.5, p>0.005,  left MTA results : Х2 (2, n=22) = 4, p>0.867005, and 
combined MTA results : Х2 (2, n=22) = 3.44, p>0.005. However, there is a general trend 
suggesting that decreases in MTA scale results (i.e. reductions in MTA) could be 
achieved through testosterone treatment. This trend can be found in both arms of the 








8.4.3 Baseline Medial Temporal Atrophy (MTA) scale as a predictor of 
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Figure 8.9: Scatter plots of linear regression analyses showing the levels of 
correlation between baseline MTA scale and testosterone treated-MTA scale 
results. The results have been grouped according to APOE ε4 status for both 
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Figure 8.10 : Scatter plots of linear regression analyses showing the levels of 
correlation between baseline MTA scale and testosterone treated-MTA scale 
results, after pooling treatment AB (A) and treatment BA results. Participants 
are still grouped according to  APOE ε4 status.   
From Figure 8.9 and Figure 8.10 above, it appears that the non-APOE ε4 participants 







8.4.4 Correlation between medial temporal atrophy and neuropsychological 
changes. 
The cognitive function assessments of the subjects in this clinical trial were carried out 
at the same three stages as the MRI/MRS assessments. Thus cognitive function was 
assessed before any treatment had begun (baseline), then 24 weeks later after the first 
treatment of either testosterone (AB group) or placebo (BA group), then 52 weeks 
later after the second placebo (AB group) or testosterone (BA group) treatment.  
The neuropsychological tests carried out were the Mini Mental State exam (MMSE), 
Geriatric Depression Scale (GDS), and the Rey Auditory Verbal Learning Test 

















Spearman's rho MMSE_BL_AB Correlation Coefficient -.053 .006 -.032
Sig. (2-tailed) .816 .978 .888
MMSE_6_AB Correlation Coefficient -.301 -.293 -.320
Sig. (2-tailed) .173 .186 .147
MMSE_9_AB Correlation Coefficient -.196 -.102 -.211
Sig. (2-tailed) .382 .653 .345
GDS_BL_AB Correlation Coefficient -.166 -.148 -.168
Sig. (2-tailed) .461 .510 .454
GDS_6_AB Correlation Coefficient -.139 -.160 -.117
Sig. (2-tailed) .538 .477 .603
GDS_13_AB Correlation Coefficient .293 .250 .294
Sig. (2-tailed) .185 .262 .185
N (for all of above) 22 22 22
**. Correlation is significant at the 0.01 level (2-tailed). 























Spearman's rho MMSE_BL_AB Correlation Coefficient -.072 -.084 .052
Sig. (2-tailed) .749 .711 .817
MMSE_6_AB Correlation Coefficient -.392 -.385 -.265
Sig. (2-tailed) .071 .077 .234
MMSE_9_AB Correlation Coefficient -.150 -.089 .008
Sig. (2-tailed) .504 .694 .973
GDS_BL_AB Correlation Coefficient -.267 -.341 -.199
Sig. (2-tailed) .230 .121 .374
GDS_6_AB Correlation Coefficient -.264 -.386 -.286
Sig. (2-tailed) .235 .076 .198
GDS_13_AB Correlation Coefficient .280 .129 .288
Sig. (2-tailed) .207 .568 .193
N (for all of above) 22 22 22
**. Correlation is significant at the 0.01 level (2-tailed). 













MTA End of 
Testo AB 
RIGHT&LEFT 
MTA End of 
Placebo AB
Spearman's rho MMSE_BL_AB     Correlation Coefficient -.076 -.044 .051
 Sig. (2-tailed) .737 .844 .821
MMSE_6_AB  Correlation Coefficient -.359 -.329 -.243
 Sig. (2-tailed) .101 .135 .276
MMSE_9_AB Correlation Coefficient -.198 -.134 -.100
Sig. (2-tailed) .376 .552 .657
GDS_BL_AB Correlation Coefficient -.267 -.214 -.122
Sig. (2-tailed) .230 .339 .589
GDS_6_AB Correlation Coefficient -.234 -.226 -.142
Sig. (2-tailed) .295 .313 .530
GDS_13_AB Correlation Coefficient .282 .192 .373
Sig. (2-tailed) .204 .392 .087
N (for all of above) 22 22 22
**. Correlation is significant at the 0.01 level (2-tailed). 





















End of Testo 
BA 
Spearman's rho MMSE_BL_BA Correlation Coefficient .065 .098 .016
Sig. (2-tailed) .773 .665 .945
MMSE_6_BA Correlation Coefficient .054 .055 .048
Sig. (2-tailed) .810 .810 .833
MMSE_13_BA Correlation Coefficient -.157 -.043 -.048
Sig. (2-tailed) .486 .850 .831




Sig. (2-tailed) .148 .029 .016
GDS_6_BA Correlation Coefficient .155 .-348 .328
Sig. (2-tailed) .491 .112 .136










N (for all of above) 22 22 22
**. Correlation is significant at the 0.01 level (2-tailed). 






















End of Testo 
BA 
Spearman's rho MMSE_BL_BA Correlation Coefficient -.015 .004 -.070
Sig. (2-tailed) .949 .985 .756
MMSE_6_BA Correlation Coefficient .192 .112 -.016
Sig. (2-tailed) .391 .621 .943
MMSE_13_BA Correlation Coefficient -.048 .037 .049
Sig. (2-tailed) .830 .870 .830
GDS_BL_BA Correlation Coefficient .-294 .303 .305
Sig. (2-tailed) .184 .170 .167
GDS_6_BA Correlation Coefficient .212 .078 .037
Sig. (2-tailed) .344 .731 .869















**. Correlation is significant at the 0.01 level (2-tailed). 











MTA End of 
Placebo BA 
RIGHT&LEFT 
MTA End of 
Testo BA 
Spearman's rho MMSE_BL_BA Correlation Coefficient .026 -.198 .075
Sig. (2-tailed) .907 .378 .740
MMSE_6_BA Correlation Coefficient .201 -.392 .120
Sig. (2-tailed) .369 .072 .595
MMSE_13_BA Correlation Coefficient -.166 -.204 -.058
Sig. (2-tailed) .459 .364 .797
GDS_BL_BA Correlation Coefficient .334 .346 .293
Sig. (2-tailed) .129 .115 .185
GDS_6_BA Correlation Coefficient .253 .224 .122
Sig. (2-tailed) .255 .316 .590














**. Correlation is significant at the 0.01 level (2-tailed). 




















Spearman's rho MMSE_BL Correlation Coefficient -.020 -.010 .015
Sig. (2-tailed) .896 .948 .923
MMSE_Testo Correlation Coefficient -.226 -.171 -.172
Sig. (2-tailed) .140 .267 .265
MMSE_Placebo Correlation Coefficient -.146 -.075 -.126
Sig. (2-tailed) .345 .627 .416
GDS_BL Correlation Coefficient .056 .161 .-147
Sig. (2-tailed) .717 .296 .342
GDS_Testo Correlation Coefficient .145 .356
*
.164
Sig. (2-tailed) .349 .018 .288
GDS_Placebo Correlation Coefficient .260 .311
*
.178
Sig. (2-tailed) .089 .040 .249
N (for all of above) 44 44 44
**. Correlation is significant at the 0.01 level (2-tailed). 


















Spearman's rho MMSE_BL Correlation Coefficient -.060 -.085 .016
Sig. (2-tailed) .699 .584 .919
MMSE_Testo Correlation Coefficient -.215 -.147 -.096
Sig. (2-tailed) .161 .342 .534
MMSE_Placebo Correlation Coefficient -.035 -.072 .009
Sig. (2-tailed) .824 .644 .952
GDS_BL Correlation Coefficient .011 .004 .073
Sig. (2-tailed) .943 .979 .640
GDS_Testo Correlation Coefficient .134 .073 .115
Sig. (2-tailed) .385 .638 .456
GDS_Placebo Correlation Coefficient .303
*
.069 .206
Sig. (2-tailed) .045 .658 .179
N (for all of above) 44 44 44
**. Correlation is significant at the 0.01 level (2-tailed). 













Spearman's rho MMSE_BL Correlation Coefficient -.037 .004 -.019
Sig. (2-tailed) .811 .977 .901
MMSE_Testo Correlation Coefficient -.258 -.184 -.191
Sig. (2-tailed) .091 .232 .214
MMSE_Placebo Correlation Coefficient -.038 -.028 -.162
Sig. (2-tailed) .808 .856 .293
GDS_BL Correlation Coefficient .035 .053 .083
Sig. (2-tailed) .824 .731 .592
GDS_Testo Correlation Coefficient .130 .113 .136
Sig. (2-tailed) .401 .464 .378
GDS_Placebo Correlation Coefficient .292 .141 .214
Sig. (2-tailed) .054 .361 .164
N (for all of above) 44 44 44
**. Correlation is significant at the 0.01 level (2-tailed). 






From all the results above, it can be seen that in the treatment group BA,  there were 
positive correlations between subject’s GDS and right and left MTA scale results, 
following testosterone treatment (Tables 8.4 and 8.5). In the treatment group AB, this 
association was not seen. If the results from the patients in both arms are pooled 
according to treatment type (i.e., either testosterone treatment, or placebo treatment, 
regardless of treatment order), we found positive correlations between GDS results and 
right MTA scale results (but not left MTA scale results) following testosterone 
treatment. The number of subjects in this trial is small, but the positive correlations 
suggest that serial measurements of atrophy in the medial temporal lobe/hippocampus 
region will help to indicate whether testosterone reduces the rate of brain atrophy. 
Changes in brain atrophy appear to be reflected by changes in depression levels, as 
determined by the GDS. However, there were no significant correlations found between 
the MTA scale and either the MMSE or the RAVLT. While the finding reported in this 
chapter hold promise for the role of testosterone in protecting against atrophy of brain 
regions most susceptible to AD related neurodegeneration a larger study with a more 
robust neuropsychological battery will need to be undertaken for the clinical 
















In this chapter, we have summarised results of a serial MRI study and a multiple voxel 
serial MRS study that were carried out on the low-testosterone subjects in this clinical 
study, in order to evaluate the effect of testosterone treatment on brain region atrophy 
and brain metabolite levels, compared to the original baseline levels. To our knowledge, 
this longitudinal study is the first that has involved the systematic acquisition of 
multiple serial spectra from patients in a testosterone clinical study. Brain metabolite 
levels (N-acetyl aspartate (NAA), choline (Cho) and creatinine (Cr)) were measured and 
the NAA/Cr and Cho/Cr ratios were calculated, to assess whether testosterone treatment 
could influence these  parameters.  
At baseline, lower NAA/Cr ratios in the left and right hippocampi and medial temporal 
lobe were observed, when compared with the thalamus white matter which provided 
“normal” spectra (control spectra - no pathologies observed). However, no significant 
alterations in Cho/Cr ratios were observed. These findings are consistent with a 
previous longitudinal study undertaken over a 13 month period14 which showed a 
greater decline in the NAA/Cr ratio in AD patients compared to controls (-1.8%/year in 
AD, 0.5%/year in controls) though non-significant rates of change were observed for 
Cho/Cr ratios in these same cases (1.2% in AD, 2.6% in controls). The reduction in 
NAA levels likely reflects neuronal loss or dysfunction. The 44 low-testosterone 
participants in this study did not have AD, but it needs to be remembered that they were 
subjective memory complainers, with MMSE scores ranging from 24-30, and a group 
average of 2. The 14 participants with MMSE scores  <26 could probably be rated as 
approaching mild cognitive impairment.  Decreased NAA levels have also previously 
been associated with increasing age in healthy participants.  
Serially-acquired MRS, used as an outcome measure in this testosterone clinical trial, is 
dependent on a number of factors, including the variability and reproducibility of the 
technique. An ideal biomarker of neuroimaging should make it possible to, (1) detect 
early neurodegenerative pathology, (2) reflect pathological stage across the entire 
severity spectrum, (3) predict when an individual with early pathology may become 





relevant to an AD biomarker is to be able to differentiate between AD and other forms 
of dementia.  
Studies of different common dementias have shown that NAA/Cr ratios are decreased in 
dementias that are characterized by neuron loss such as AD, frontotemporal lobe 
dementia (FTLD), and vascular dementia. It also seems that MI/Cr ratios are elevated in 
dementias that are pathologically characterized by gliosis such as AD and FTLD, 
whereas Cho/Cr ratios are elevated in dementias characterized by significant cholinergic 
deficit such as AD and dementia with Lewy bodies (Kantarci et al., 2004).  
Positron emission tomography imaging using PiB to bind to amyloid is currently more 
sensitive and recent studies suggest this is an excellent method to detect pre-clinical 
neurodegeneration. AD brain atrophy as detected by MRI both precedes and parallels 
cognitive decline. Significant plaque deposition also occurs prior to clinical decline. 
However cognitive decline is not directly due to amyloid deposition, rather the 
neurodegeneration that also occurs as part of the pathology of AD. Thus, PiB PET 
imaging and MRI could have complimentary roles in the pre-clinical diagnosis of AD 
(Jack et al., 2009).  
To date the potential 1H MRS biomarkers have provided little or no advantages over 
other neuroimaging biomarkers. Thus, MRS biomarkers appear to be sensitive, however 
complimentary diagnostic tools are needed to help with diagnosis, as well as differential 
dementia diagnosis. Instead, recent studies in AD suggest that NAA may be more useful 
as a prognostic marker for monitoring neurodegeneration, stabilization, or 
improvement, and for evaluating therapeutic responses to novel drugs (Chen et al., 
2000).  
Few longitudinal studies have used brain magnetic resonance spectroscopy as a 
predictor of conversion to dementia. One recent longitudinal study gave encouraging 
evidence that MRS (looking at the posteromedial bilateral parietal lobe and left medial 
occipital lobe) in MCI may identify patients at risk of early conversion to dementia 
(Modrego et al., 2011) . This study used MRS data at baseline and then followed-up 2 
years later to examine rates of conversion from MCI to AD. Their results showed that 
the mean NAA/Cr ratio in the posteromedial bilateral parietal cortex was 1.38 in 





the effects of successful testosterone treatment on brain metabolite levels are not yet 
clear. If, however, future studies demonstrate that NAA depletion or Cho elevation are 
reversed to a significant extent as a result of testosterone treatment,  the measurement of 
these AD “biomarkers” using current MRS methodology may prove extremely useful in  
assessing treatment efficacy.  
Unfortunately, MRS results of NAA/Cr ratio as well as Cho/Cr ratio did not show any 
significant changes following treatments in these current experiments. This may be due 
to the technical limitation of the low gradient 1.5 T MRI which was inadequate to 
exhibit the spectrum changes of brain metabolites. In order to acquire and detect brain 
metabolite changes accurately in future experiments, an MRI 1.5 T with a high gradient, 
or more preferably an MRI 3T may be necessary.       
A study by DeCarli et al. (2007) has shown that qualitative ratings of MTA may have 
added impact in a clinical trial in a prospective and blinded manner for subjects with 
memory complaints, who may or may not be included in the MCI category. The MTA 
scale used in this study was simple, had good reliability, and could be easily 
implemented into standard clinical practice, albeit there were no alterations of MTA 
scale over time. Moreover, Schelten’s MTA scale has been compared to a computerized 
hippocampal volume measurement method and gave similar prediction accuracy 
(Westman et al., 2011).   
Animal studies have shown that testosterone treatment is indeed neuroprotective 
following motor neuron loss, and testosterone has been shown to attenuate somal and 
dendritic atrophy (Little et al., 2009; Fargo et al., 2007). However, there is still a lack of 
clinical studies which have investigated the effect of testosterone treatment on rates of 
brain atrophy. Based on published literature, this is the first study which has utilised the 
MTA scale to assess the effects of testosterone treatment on preserving brain structure. 
The MTA scale measurement showed no significant changes for either the right MTA, 
left MTA, or combined MTA of treatment AB (Figs 8.5 and 8.6). With follow-up 
measurements at 6 month intervals or less as in this study, it is unlikely that small 
changes in brain anatomy would be detectable, even in the early stage of AD (Mizuno et 
al., 2000). However, significant reductions in atrophy were observed in the left MTA 





the participants of both arms (Figure 8.7). These results are unlikely to be due to the 
effect of testosterone treatment since the initial reduction in MTA was observed 
following placebo treatment (which in the BA arm of the study was prior to 
testosterone treatment). The MTA changes that were observed over 6 months in this 
experiment are in accordance with results of a study by Murphy et al. 2010, who 
showed that increased MTA after six months was associated with subsequent memory 
decline in healthy elderly people. However, it is still unclear which region of the medial 
temporal lobe degenerates first in the earliest stage of AD. 
The effect of APOE genotype was also investigated in this study since studies by Raz et 
al. 2005 and Du et al. 2005 have shown that both APOE genotype and age alter 
hippocampal atrophy and its rate of volume loss. Moreover, possession of APOE ε4 
alleles has been shown to be associated with less frontal and more medial temporal lobe 
atrophy in AD (Geroldi et al., 1999). In another study, Lehtovirta et al., 1995 
demonstrated that compared to healthy participants, ε4 homozygous people had more 
pronounced right hippocampal atrophy than ε4 heterozygous and non-APOE ε4 carriers. 
Such a gene dose effect of APOE ε4 has not been firmly established in non-demented 
elderly people. In this study, there were no differences observed in MTA scale results 
between APOE ε4 and non-APOE ε4 carriers. However, this is most likely due to the 
small number of participants in this study, resulting in a lack of statistical power to 
demonstrate significant differences between the APOE ε4 and non-APOE ε4 carriers. 
Nevertheless, these results were in agreement with a study by Lemaitre et al., 2005 
which found no effect of APOE ε4 on hippocampal atrophy in healthy elderly 
individuals. However, to date, associations between APOE genotype and medial 
temporal lobe atrophy rates (including the hippocampus) remain inconclusive. 
The baseline MTA scale results were essential in determining the efficacy of 
testosterone treatment. The baseline MTA results could be interpreted as the sum of all 
structural changes occurring prior to the six months testosterone treatment. As shown in 
Fig 8.9 A&B, participants who started with high atrophy levels at their baseline 
measurement (MTA scale >2) showed a reduction in MTA scale following 6 months 
testosterone treatment in both arms, even after pooling all of the participants (Fig 8.10). 
This effect was observed in non-APOE ε4 carriers only but not in APOE ε4 carriers. 





to testosterone treatment in terms of modifying medial temporal atrophy. In addition, 
longitudinal data by Cohen et al., 2001 have shown that APOE ε4 heterozygotes have 
greater annual rate of hippocampal volume loss compared to non-APOE ε4 carriers. 
Therefore, another possible explanation for the results in this study in relation to APOE 
genotype is that testosterone may reduce the atrophy rate in APOE ε4 carriers, but to a 
lesser extent than that observed in non-APOE ε4 carriers.  
For participants younger than 75 years, an MTA score of > 2 is considered to be 
abnormal, whilst for participants greater than 75 years, a score of > 3 is abnormal 
(Shonk et al., 1995). The data distribution in this chapter showed that the cohort 
included men with normal as well as abnormal classifications in the age category of less 
than 75 years.  
A psychological assessment of memory function and evaluations of structural changes 
in the medial temporal lobe are important for early diagnosis of AD. Therefore, the 
relationship between MTA and cognitive performance has been widely studied. In this 
experiment, no correlation between MTA and cognitive performance was found, as 
assessed by MMSE and RAVLT (see Tables 8.1-8). Concordantly, Crivello et al. 2010 
did not find any interactions between APOE genotype or age and cognitive decline in 
the healthy elderly. A study by Mizuno et al. 2000 found no correlation between 
hippocampal volume and verbal memory. However, a recent study by Duchesne et al. 
2009 did demonstrate a relationship between baseline MRI and MMSE after a 1 year 
follow-up using voxel-based morphometry (VBM).  
In relation to depression, structural brain changes have been correlated with level of 
depression and cognitive performances. Lower depression scores (ie less depression) 
have been found to correlate with greater levels of medial temporal atrophy amongst 
those with cognitive impairment, suggesting that decreasing insight into cognitive status 
may lead to lower depression scores (Greig et al., 2008). The results in the experiments 
here have shown a strong negative correlation (p< 0.05) between right and left MTA 
levels and depression levels as measured by the Geriatric Depression Scale (GDS); 
(although in treatment BA only, Tables 8.4 & 8.5). The results indicate that the lower 
the depression level, the lower the medial temporal atrophy was found to be following 





is possible this could be due to the fact that the BA group only had 4 APOE ε4 
carriers (who as mentioned above have a greater likelihood of not responding as much 
to testosterone treatment), whereas the AB group had 8 out of the 22 participants 
being APOE ε4 carriers. 
The pattern of medial temporal atrophy observed in this study was shown to be 
improved to some extent by testosterone treatment. Future studies carried out on a 
larger cohort, possibly using longer treatment times and different doses, will determine 
the significance of the current results, and evaluate the full potential of testosterone 
treatment in the prevention or reduction of cognitive decline.   
The results presented in this chapter have highlighted the importance of MRI as a 
powerful biomarker and MRS as a potentially useful biomarker for evaluating 
testosterone treatment. Both imaging biomarkers (MRI and MRS) would be more robust 
if combined with additional biomarkers (such as blood biomarkers or PiB-PET 
imaging). However, with MRS techniques being researched in earnest in recent years, 
longitudinal studies may soon provide earlier and more accurate MRS-based diagnostic 
tools. Future applications in the clinical setting may add such in vivo direct imaging 
techniques to allow more accurate assessment of hippocampus volume as well as brain 
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Extensive research has been undertaken, particularly in the last 20 years, to improve our 
knowledge of androgen replacement therapy in the aging male, although conclusions 
from this research, on many aspects, remain controversial.  A marked reduction in 
testosterone levels has a number of physiological and psychological effects. Recenly, 
reduced testosterone has been linked to an increased risk of developing AD. This 
testosterone effect on AD risk is thought to arise from testosterone’s numerous 
influences on the brain and on A metabolism. Firstly, testosterone is produced in the 
testis, and a small amount reaches the brain and binds to the androgen receptor (AR) in 
target cells, and this has been shown to provide some neuroprotection (in some studies 
but not all) (Pike et al., 2006). Testosterone may also be aromatized into estradiol 
(shown in many cell culture studies) (Haren et al., 2002) and estradiol has been shown 
to influence Aβ levels (Gandy et al., 2001). Importantly,  testosterone levels are 
inversely correlated with plasma Aβ levels (Gillet et al., 2003). Thus, many clinical 
trials and animal studies are currently being undertaken to assess the potential of 
testosterone as a neuroprotective agent.  
In addition to testosterone, other hormones of the hypothalamic-pituitary-gonadal 
(HPG) axis such as luteinizing hormone (LH) have also gained attention as evidence has 
shown they may also influence the pathogenesis of AD. A marked reduction in 
testosterone levels causes disruption to the HPG axis. The subsequent loss of negative 
feedback by these hormones on the hypothalamus and pituitary leads to increased 
release of LH levels.  Compared to age-matched controls, serum levels of LH have been 
shown to be higher in subjects with AD (Bowen et al., 2000; Short et al., 2001). 
Furthermore, increased serum LH levels have been associated with poorer cognitive 
performance in post-menopausal women (Rodrigues et al., 2008) and serum LH levels 
have been found to correlate with plasma Aβ40 levels in cognitively normal elderly men 
(Verdile et al., 2008). Coupled with findings that gonadotropin releasing hormone 
(GnRH) agonists decrease Aβ levels in mouse brain (Bowen et al., 2004; Casadesus et 
al., 2006), these findings indicate that increased gonadotropin levels, particularly LH 
may be physiologically relevant in AD as they potentially modulate neurodegeneration 
in the aging brain.  It is unlikely that any one of the hormones from the HPG axis plays 







While any specific underlying causes of AD are still yet to be determined, many risk 
factors have been identified. Three such risk factors, which are most likely inter-
dependent, were investigated in this thesis: lack of testosterone, elevated LH levels due 
to the loss of negative feedback on the HPG axis, and increased Aβ levels. Many studies 
have examined the relationship between these three risk factors and the development of 
AD biomarkers. However, good randomized, double blind, placebo-controlled clinical 
studies in aging men are still lacking. The research presented in this thesis examined the 
cellular, structural and neuropsychological changes in response to exogenous 
testosterone supplementation using two models of testosterone depletion. The first 
involved in vivo validation of testosterone, LH and LH lowering agents in an animal 
model (castrated Guinea Pig). The second involved a trial of testosterone in testosterone 
deficient  men  with subjective memory complaints. 
 
9.1 Effects of peripheral testosterone supplementation in castrated guinea pigs, 
which were used as an animal model for low testosterone levels and impaired HPG 
axis 
A lack of the sex hormone testosterone results in increased pathology characteristics of 
AD, including decreased expression of APP in the brain (particularly the hippocampus),  
increased production of APP-CTF fragments and increased cerebral Aβ levels 
(Drummond et al., 2009). The results presented in Chapter 3 show the effect of 
exogenous testosterone administration on testosterone levels, Aβ, and APP and its 
metabolites in castrated guinea pigs. As expected, castration of the guinea pigs (GDX) 
caused a significant reduction in plasma testosterone levels, and the administration of 
high levels of testosterone increased the plasma testosterone levels which progressively 
returned to the non-GDX level. CSF Aβ40 levels in the guinea pigs increased after 
castration and levels correlated with low testosterone levels. The administration of 
testosterone, at either a low dose or high dose significantly reduced the CSF Aβ40 
levels to non-GDX levels after 36 days. Nevertheless, the Aβ40 levels in plasma 





high dose testosterone supplementation. Thus, the testosterone appears to decrease 
Aβ40 levels in the CNS, yet increase Aβ40 levels in the plasma. This phenomenon is 
considered to be the result of rapid clearance from the brain, nevertheless further, more 
extensive studies are needed to confirm this observation. The results suggest strongly 
that the measurement of blood plasma Aβ levels only is not necessarily appropriate or 
sufficient for the monitoring of testosterone therapy for AD prevention. 
Interestingly, Aβ levels were found to be high in GDX hippocampi after 18 days of low-
level testosterone supplementation, yet Aβ levels did normalize after 36 days. In 
contrast, high-level testosterone supplementation resulted in a decrease in Aβ levels 
after 18 days, with the same lower levels measured again at 36 days of supplementation, 
suggesting Aβ levels had stabilised earlier on the higher dose. These findings suggest 
that high testosterone levels can regulate Aβ levels in the blood and brain, especially in 
the hippocampus, and that the testosterone levels can influence the time taken for 
normal Aβ levels to be reached.  Testosterone supplementation in the GDX was also 
found to increase levels of α-APPs in the frontal cortex. This result suggests that 
testosterone supplementation can influence the metabolism of α-APPs, an APP cleavage 
product known to have a neuroprotective role, Increasing production of α-APPs has also 
been associated with a decrease in production of Aβ. The results from Chapter 3 provide 
further evidence of a role for reduced testosterone levels in AD pathogenesis. 
 
9.2 Effects of CNS as well as peripheral administration of LH in castrated guinea 
pigs  
There is growing evidence that increases in gonadotropin levels associated with aging 
may also contribute to AD pathogenesis. The results in Chapter 4 support this notion, as 
results demonstrated that direct exposure of the brain to LH can cause a significant 
increase in Aβ production, as measured in the frontal cortex and in the hippocampus, 
resulting in an increase in CSF and cerebral Aβ levels. Furthermore, APP metabolites 
were found to be altered in the hippocampus 28 days after LH administration. Hence, 
the hippocampus appears to be a major target for LH. Unfortunately,  LH levels 
couldn’t be directly measured in the guinea pigs. This study has revealed that LH 





increases in Aβ levels in the blood. Studies of LHR (-/-) APPsw mice have shown that 
removing the LH receptor results in  lower Aβ plaque deposition, less astrogliosis and 
less tau phosphorylation (Lin et al., 2010).    
It is not clear how LHR ablation reduces A levels. The mRNA levels of enzymes 
involved in the amyloidogenic and non-amyloidogenic APP cleavage pathways were 
measured in the LHR (-/-) mice, as well as mRNA levels of A degrading enzymes 
such as insulin degrading enzyme and neutral endopeptidase, These mRNA levels were 
found to be unchanged, suggesting post-translational mechanisms are involved in the 
changes in A levels.  LH works not only through the LHR, but also through other 
pathways that may influence the amyloidogenic process, thus the LH signalling 
pathways in neurons are still not well understood. Other possibilities that need further 
investigation include the role of astrocytes and microglia in removing A from the 
brain. Astrogliosis is believed by many to be a reaction to Aβ deposition, yet 
astrogliosis is also known to inhibit microglial phagocytosis, an effect also likely to 
reduce Aβ removal. Therefore, the mechanisms by which LH modulates Aβ metabolism 
remain to be determined. 
 
9.3 Effects of a peripheral LH lowering agent in castrated guinea pigs 
Chapter 4 provided further evidence that LH levels can influence AD pathogenesis, as 
direct application of human LH to the guinea pig CNS resulted in an accumulation of 
Aβ in a similar manner to that reported for neuronal cells in culture and in vivo. In 
Chapter 5 we did further investigations of LH, using LH implanted in the periphery. In 
contrast with results in Chapter 4, the application of human LH to the guinea pig 
periphery resulted in reduced cerebral Aβ levels. Although not consistent with findings 
obtained in mouse models, it provides an interesting line of research that can be further 
explored in the guinea pig. 
Leuprolide, a potent GnRH agonist, was also used in this study to investigate further the 
role of LH in guinea pigs. In vivo studies of leuprolide, as a suppressor of LH (to lower 
endogenous LH (Ravivarapu, 2000), found that administration to  female mice causes a 





of the experiments showed that leuprolide treatment can reduce Aβ40 levels in the 
brains of guinea pigs, however the effect appears to be limited to the frontal cortex. The 
concomitant trend toward increased α-APPs levels indicates that leuprolide may be 
promoting the non-amyloidogenic pathway. 
Testosterone reduces cerebral Aβ levels (Chapter 3) and LH increases CSF and cerebral 
Aβ (Chapter 4). To explore these findings further, we tried to determine whether there 
are additional benefits when these two treatments are combined, in other words, we 
wished to determine if the effects are additive.  Additional results from Chapter 5 
suggest that there are no additional benefits with respect to Aβ levels when testosterone 
treatment is combined with leuprolide treatment. However, the combined treatment may 
be promoting the non-amyloidogenic pathway further, as indicated by a greater increase 
in α-APPs levels. Taken together, this animal study has added further evidence of the 
role of testosterone and LH on regulating Aβ. It has also shown a promising result for 
future clinical study by modulating the testosterone as well as LH levels. 
 
9.4 Effects of testosterone supplementation on blood biomarkers in testosterone 
deficient men 
 
There are lessons to be learned not only from the animal studies but also from clinical 
studies which have investigated the effects of testosterone replacement therapy in men. 
It is well known from the animal studies that the effects of testosterone mediated 
through androgen receptors (AR) are widespread and complex, and influence certain 
aspects of cognition and behaviour. Studies of exogenous testosterone administration in 
men have provided mixed results. However, from studies of people with Subjective 
Memory Complaints (SMC), Mild Cognitive Impairment (MCI) or AD, there does 
appear to be an association between low testosterone levels and (increased) risk of AD. 
A more comprehensive investigation of hormones, lipid profiles and related proteins, 
such as total testosterone, dihydrotestosterone (DHT), estradiol, LH, cholesterol, LDL, 





to obtain a more complete picture of the interactions between the components of the 
HPG axis, and to characterise better the effects of these interactions on Aβ metabolism.  
From our clinical trial on elderly testosterone deficient men (Chapter 6), testosterone 
treatment for 6 months caused a significant increase in plasma total testosterone levels, 
which returned to baseline levels when the treatment was terminated. Similar results 
were observed with DHT, an active testosterone metabolite, also a potent androgen that 
cannot be aromatized to estrogen (Cunningham, 1989). However, a significant rise in 
estradiol levels was not seen,  which suggests there must have been greater conversion 
of testosterone into DHT. These results are not unexpected, as the route of testosterone 
administration favours this outcome: transdermal testosterone administration (as 
opposed to intramuscular or by pellet) normally only raises estradiol levels slightly, 
while quadrupling DHT levels, due to 5α-reductase enzymes in the skin (Swerdloff et 
al., 2000). Consequently, testosterone treatment also resulted in a significant decrease in 
LH levels, through the feedback mechanism on the HPG axis.  
Testosterone and DHT treatment has been shown  to influence lipoprotein levels, early 
studies showed that both HDL and LDL levels could be lowered by transdermal DHT 
treatment for 3 months (Vermuelen et al., 1985). Later studies then showed that the 
effect of testosterone on lipoprotein metabolism was highly dependent on whether the 
administration of testosterone resulted in physiological or supraphysiological 
concentrations (Alexandersen et al., 2004). In accordance, the testosterone therapy 
carried out in this study showed significant effects on HDL, such that a significant 
decrease in levels was observed following testosterone treatment. However, out of the 
lipoprotein components measured in these experiments, only HDL was found to change 
significantly – there were no significant differences observed in cholesterol, 
triglyceride, or LDL levels. In addition, testosterone treatment did not alter the 
Chol/HDL or LDL/HDL ratios, recognized as major risk factors for cardiovascular 
disease. The effects of testosterone treatment were not limited to lipoprotein 
metabolism, insulin pathways were also affected. In accordance with previous studies 
which showed that testosterone therapy can improve insulin sensitivity (Shabsigh, 2005; 
Pasquali et al., 1991; Simon et al.,1992) the results from this study revealed a trend 
towards  increased insulin sensitivity following testosterone treatment. However, it is 





replacement therapy and cholesterol, LDL, HDL, and insulin, the more complex and 
variable the effects seem to be. The effects can vary due to the methods of testosterone 
preparation and administration, the testosterone doses used, the duration of testosterone 
treatments, and the ethnicity and age of the participants (Robert et al., 2000; Minneman 
et al., 2008; Makinen et al., 2007).  
In the elderly male, prostate cancer is common and its incidence increases with 
increasing age (Bowen et al., 2000). Therefore a potential problem in terms of 
testosterone treatment in elderly men is whether testosterone treatment increases the risk 
of developing prostate cancer. The effects of testosterone treatment on the prostate are 
very important when considering its safety, and for this purpose PSA (prostate specific 
antigen) levels should be carefully monitored. The results in this study suggest that PSA 
levels do not increase as a result of testosterone treatment, when carried out as done in 
this study. Therefore, these results together with the almost unchanged lipid profile 
suggest that the application of 100mg testosterone cream each day for 6 months is safe 
and does not have any adverse effects. 
Testosterone treatment was not found to influence plasma Aβ levels significantly. Both 
Aβ40 and Aβ42 levels were measured and not found to be significantly different, 
although there seemed to be a trend towards decreasing levels following testosterone 
treatment.  
This study hoped to estimate effects of testosterone treatment on CSF markers of AD. 
The CSF biomarkers or analytes to be tested included Aβ42, total tau, phospho-tau, 
tau/Aβ42, and phospho-tau/Aβ42. Unfortunately CSF collection is not a comfortable 
procedure, and too few subjects were keen to have their CSF tested. The data that was 
obtained  includes CSF data from three healthy (subjective memory complainer) 
participants from the main clinical study and two participants who have been diagnosed 
with AD from a side study (results not shown). As expected, AD participants had 
significantly lower baseline CSF Aβ42 levels when compared to the healthy 
participants. These low CSF Aβ42 levels reflect deposition of Aβ in plaques (Strozyk et 
al., 2003; Tapiola et al., 2009). Overall, the testosterone treatment showed a trend 
towards lowering CSF Aβ42 levels (although there was variation between individuals), 





number of participants clearly lowers the significance of these observations, yet the 
observations are nevertheless encouraging. High CSF total tau and phospho-tau levels 
would normally be expected in AD patients as a reflection of active axonal and neuronal 
damage (Blennow et al., 1995). However, in this study, total tau and phospho-tau levels 
in the AD participants were almost the same as those of the healthy (subjective memory 
complainer) participants. In terms of testosterone effect on tau levels, this study 
demonstrated that testosterone lowers tau (but not phospho-tau levels) in the healthy 
participants, yet had no effect in the 2 AD participants (results not shown).  Meanwhile, 
changes in tau/Aβ42, and phospho-tau/Aβ42 were not observed. 
ApoE plays an important role in the periphery as a mediator of lipoprotein metabolism 
and lipid clearance. In the central nervous system, apoE plays a role in the redistribution 
of lipids and cholesterol during membrane repair and it is believed to be important for 
maintaining synaptic plasticity especially after neuronal injury. ApoE’s importance in 
the central nervous system is underscored by the low abundance of other 
apolipoproteins. ApoE has been linked to AD in many ways.  One of the first 
indications that apoE might be involved in AD came from the immunochemical 
localization of apoE in extracellular amyloid plaques and in neurons containing 
neurofibrillary tangles (Wisniewski, 1992). It was then discovered that possession of 
APOE4 alleles meant a higher risk of AD, and it was soon described as the main  risk 
factor for late onset AD. Many studies then found that, compared to the more common 
apoE3 isoform, apoE4 enhances Aβ aggregation, increases Aβ deposition, and reduces 
Aβ clearance (Schemechel, 1993; Berr et al., 1994) , whereas ApoE2 has a protective 
effect (Corder et al., 1993). ApoE4 is also associated with poor neuronal repair. The 
mechanism whereby apoE4 promotes AD is not yet established, it may involve more 
than one of the above factors. Considerable evidence supports all of the above 
mechanisms. For example, in vitro studies have also shown that all apoE isoforms 
inhibit Aβ aggregation with apoE4 being less effective than apoE3 (Ma et al., 1994; 







APOE allele status was also taken into account in this study. There were no significant 
differences observed between APOE ε4 carriers and non-APOE ε4 carriers for all of the 
blood measurements as well as BMI and body fat percentage. Participants with APOE 
ε4 had a slightly higher BMI and body fat percentage when compared to participants not 
carrying APOE ε4. Interestingly, there was no significant increase of total testosterone 
levels in the APOE ε4 participants when compared with those who were non-APOE ε4. 
The results suggest that APOE ε4 status might not be a determinant of testosterone 
therapy response in this study. However, this result may have occurred due to the small 
as well as unequal number of participants in regards to APOE ε4 allele status. 
Furthermore, conflicting conclusions concerning the potential effects of APOE ε4 allele 
status may also have arisen from differences in clinical study design. 
 
9.5 Effects of testosterone supplementation on cognitive performances and quality 
of life in testosterone deficient men 
 
It has been known since the 1970s that circulating testosterone levels decline gradually 
with age. More recently, the relationship between low levels of testosterone and 
cognitive decline has been the subject of intense research since a number of studies 
showed that hormone replacement therapy could reduce the risk of developing AD (in 
men as well as in women). The results from Chapter 7 have added to the evidence 
indicating that testosterone can improve cognition and quality of life in the elderly. 
Cognitive function of the study participants (in general) improved with testosterone 
therapy. Testosterone deficient men given testosterone treatment (in both arms of the 
study) showed a significant increase in their MMSE scores. Neither age nor education 
was a statistically significant factor when added as a covariate. Previous studies have 
produced similar results, as high testosterone has been found to be associated with 
improved performance in several cognitive tests (Barret-Connor et al., 1999), when 
compared to men with lower plasma testosterone levels (Yaffe et al., 2002). For 
example, testosterone supplementation in elderly men has been shown to improve 
performance in working memory tasks (Janowski et al., 2000) and to improve spatial 





had no effect on verbal memory and was negatively associated with verbal fluency in 
men (Wolf et al., 2000). In line with Wolf et al., 2002, testosterone treatment in this 
study have not shown an improvement in verbal memory. 
In terms of quality of life, testosterone treatment was found to reduce depression 
significantly in both arms of the study, as measured by Geriatric Depression Scale 
(GDS). These results are in accordance with another study in which androgen depletion 
by chemical castration resulted in an increase in depression (Almeida et al., 2003). 
However, although testosterone treatment has been shown to improve muscle strength, 
bone mineral density and some other symptoms of hypogonadism, improvements in 
depression are not consistently found (Seidman, 2007) . In terms of physical health and 
mental health, testosterone does not seem to have a significant effect in this study.   
Overall, general cognitive screening instruments, which include the MMSE, RAVLT, 
GDS, and SF36 have proven to be beneficial for monitoring effects of testosterone 
treatment on cognitive function when used in a patient population with low testosterone 
levels, who are at risk of cognitive impairment due to either age or the presence of 
memory dysfunction.  
 
9.6 Effects of testosterone supplementation on AD-related brain metabolites and 
medial temporal structure in testosterone deficient men 
 
Some of the more prominent early features of AD include mild memory impairment,  
structural atrophy of the medial temporal lobe and changes in the levels of certain brain 
metabolites such as myo-inositol (mI, thought to be a glial marker, increases in AD) and 
N-acetyl aspartate (NAA, decreases in AD, interpreted as a marker of neuronal loss) 
(Mizuno et al., 2000). Magnetic resonance spectroscopy (MRS) is used to detect 
changes in NAA/creatine or mI/creatine, yet in our measurements summarised in 
Chapter 8, it can be seen that no significant changes were detected in brain metabolite 
levels following testosterone treatment. On the other hand, medial temporal atrophy 
(MTA) was assessed using a standardised visual rating scale, and it was found that 





by 1, regardless of sequence effect of the treatment (Chapter 8). Medial temporal lobe 
atrophy seen in MRI is indeed macroscopic result of neuronal loss and synapses 
(Bobinski et al., 2000) 
The presence of APOE ε4 allele participants was investigated for the response to 
testosterone treatment. Participants who started with high atrophy rates at their baseline 
(MTA scale >2) have shown reduction of MTA scale following 6 months testosterone 
treatment in both arms, even after pooling all of the participants. This effect was 
observed in non-APOE ε4 carriers only but not in APOE ε4 carriers. These results may 
indicate that the carriers of the APOE ε4 allele may not be responsive to testosterone 
treatment in terms of modifying medial temporal atrophy. Another hypothesis is 
testosterone effect on APOE ε4 participants (which have greater rates of atrophy 
compared to non-APOE ε4) (Cohen et al., 2001) may only maintain the integrity of 
medial temporal lobe structure, thereby preventing its atrophy rates.  
In Chapter 6, a significant increase in the number of red blood cells was found to occur 
following testosterone treatment. This increase in red blood cells is believed to help 
regenerate stem cells proposed to stimulate hippocampal neurogenesis, which one might 
assume would be reflected in an improvement in the MTA scale. However, given the 
smaller potential of neurogenesis (DeCarolis, 2010), one can probably assume that the 
effect of testosterone treatment as measured here is due to a reduction in brain atrophy.  
In relation to cognitive performance and quality of life, testosterone treatment was 
found to decrease depression to some extent, and in fact a positive correlation was 
found between the reduction in medial temporal atrophy and the decrease in depression. 
This supports previous studies which showed that stress or depression can damage the 
hippocampus, leading to its atrophy (McEwen, 1999).  
This study has demonstrated that medial temporal structure changes can be detected 
even after a short time period. Such changes may allow assessment of a drug’s effect in 
the prodromal phase of AD, such that any positive effects on atrophy may be 
measurable prior to the appearance of detectable cognitive changes. Taken together, this 
study has found that MRI, but not MRS may provide a potentially powerful biomarker 








Our understanding of testosterone replacement therapy in the aging male has greatly 
improved over the last 20 years. However, good randomized, double-blind, placebo-
controlled clinical studies are still lacking. In Indonesia in particular, no such 
testosterone clinical study as a potential approach for the prevention and treatment of 
AD has been carried out till now.  There is a need for longitudinal clinical studies to 
help us to understand better whether testosterone replacement therapy is of value in the 
prevention, delay and/or treatment of AD. This thesis has added to the growing 
evidence that  testosterone replacement in testosterone deficient patients (as well as in 
animal models) has potential benefits with respect to brain health and cognition, and has 
increased our understanding of likely side-effects. A combination of biomarkers : blood 
measurements, neuropsychological assessment, CSF Aβ42 and tau measurements 
(although in very limited samples), and neuroimaging tools (MRI and MRS) 
investigated in this double-blind randomized placebo-controlled crossover study has 
shown these markers to be most powerful tools in the early diagnosis of AD, in the 
understanding of the pathophysiology of AD, and in the monitoring of AD treatment.  
This study has also provided further evaluation of the safety of testosterone replacement 
therapy, with results suggesting the therapy utilised here causes no increased risk of 
prostate cancer or increased cardiovascular risk. Hence, if this study is initiated in the 
right “critical time” following testosterone deficient men with future suggestions 
applied, it will be a significant future implications for prevention as well as early 
detection of AD. Taken together, the animal studies and human studies in this thesis 
have demonstrated and explored further the links between testosterone, LH, and Aβ, 
three main players in the pathogenesis of AD. Furthermore, this study suggests that, 
with the aid of AD biomarkers mentioned above, there may be a window of opportunity 
for the pre-symptomatic detection of AD, and the prevention, and/or delay of AD 





Other potential treatments that can enhance androgen status include non-steroidal, small 
molecule compounds (selective androgen receptor agonists (SARMS).These have high 
affinity for the androgen receptors in the brain.There is the potential to signal through 
the androgen receptor and only activate essential pathways (e.g. anabolic pathways in 
the brain). SARMs are not commercially available yet, although investigations are 
under way into the therapeutic implications for androgen deficient males, including 
those with memory complaints. SARMS may also be safer for patients, since there is no 
potential prostate stimulation. 7α-methyl-19-nor-testosterone (MENT), which is less 
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Table 1 Individual Testosterone levels Treatment AB 
Patient APOE T Baseline AB Mean T Testo AB Mean T Placebo AB Treatment effect AB*
1 E4 ‐ 9.53 24.48 8.10 16.38
2 E4 ‐ 14.21 32.12 18.69 13.43
3 E4 ‐ 25.97 37.67 23.09 14.58
4 E4 ‐ 19.87 18.38 15.61 2.76
5 E4 ‐ 17.23 16.95 14.32 2.63
6 E4 ‐ 23.09 26.29 17.88 8.41
7 E4 ‐ 17.44 23.02 19.91 3.11
8 E4 ‐ 20.04 25.67 15.81 9.86
9 E4 ‐ 17.72 30.31 18.34 11.97
10 E4 ‐ 11.68 9.01 10.37 ‐1.35
11 E4 ‐ 14.42 20.31 12.78 7.53
12 E4 ‐ 16.33 28.83 14.89 13.94
13 E4 ‐ 13.24 20.03 19.23 0.80
14 E4 ‐ 9.85 21.56 9.78 11.78
15 E4 + 16.75 27.58 15.36 12.22
16 E4 + 22.09 38.73 21.54 17.18
17 E4 + 18.34 42.33 16.64 25.69
18 E4 + 21.67 31.76 20.19 11.57
19 E4 + 13.83 37.56 13.12 24.44
20 E4 + 16.09 39.05 15.56 23.50
21 E4 + 10.82 20.05 10.27 9.77
22 E4 + 12.07 30.43 10.09 20.34
 
*Treatment effect = mean Testosterone treatment – mean Placebo treatment 











Table 2. Individual Testosterone levels Treatment BA 
Patient APOE T Baseline BA Mean T Placebo BA Mean T Testo BA Treatment effect BA*
1 E4 ‐ 17.13 17.70 67.84 50.14
2 E4 ‐ 24.03 19.27 30.78 11.51
3 E4 ‐ 11.55 11.27 30.26 18.98
4 E4 ‐ 14.98 13.02 18.09 5.07
5 E4 ‐ 24.89 21.21 31.90 10.69
6 E4 ‐ 10.30 13.33 16.25 2.92
7 E4 ‐ 14.73 15.36 15.64 0.27
8 E4 ‐ 21.81 28.20 27.97 ‐0.23
9 E4 ‐ 19.10 17.66 22.47 4.80
10 E4 ‐ 22.78 24.55 47.95 23.40
11 E4 ‐ 14.46 13.46 26.06 12.60
12 E4 ‐ 20.94 18.10 33.82 15.72
13 E4 ‐ 19.31 19.00 23.28 4.28
14 E4 ‐ 27.77 28.52 22.70 ‐5.82
15 E4 ‐ 23.85 20.22 48.47 28.24
16 E4 ‐ 10.40 12.67 16.58 3.92
17 E4 ‐ 17.96 17.55 33.30 15.74
18 E4 ‐ 11.06 14.32 17.95 3.62
19 E4 + 25.34 21.98 29.48 7.51
20 E4 + 9.08 15.53 23.11 7.59
21 E4 + 14.60 15.08 9.60 ‐5.47
22 E4 + 21.29 16.07 8.78 ‐7.29
 
*Treatment effect = mean Testosterone treatment – mean Placebo treatment 














Table 3. Individual DHT levels Treatment AB 
Patient APOE DHT Baseline AB Mean DHT Testo AB Mean DHT Placebo AB Treatment effect AB*
1 E4 ‐ 0.90 7.06 1.17 5.89
2 E4 ‐ 2.53 11.75 2.59 9.16
3 E4 ‐ 3.57 11.93 2.38 9.55
4 E4 ‐ 2.43 6.58 2.02 4.55
5 E4 ‐ 2.36 4.30 1.35 2.95
6 E4 ‐ 1.04 9.03 1.29 7.74
7 E4 ‐ 1.59 8.71 2.87 5.84
8 E4 ‐ 2.57 8.96 1.40 7.56
9 E4 ‐ 3.05 8.77 1.81 6.96
10 E4 ‐ 1.42 2.40 1.76 0.64
11 E4 ‐ 1.59 10.01 1.62 8.39
12 E4 ‐ 1.59 7.87 2.07 5.80
13 E4 ‐ 0.60 5.27 1.71 3.56
14 E4 ‐ 0.62 5.48 1.55 3.92
15 E4 + 3.22 16.77 2.32 14.45
16 E4 + 2.08 16.81 1.58 15.23
17 E4 + 3.16 15.19 2.92 12.26
18 E4 + 1.77 10.86 1.51 9.34
19 E4 + 1.53 11.82 0.26 11.56
20 E4 + 1.18 6.78 1.14 5.63
21 E4 + 0.67 5.15 1.05 4.10
22 E4 + 1.03 8.40 1.02 7.37
 
*Treatment effect = mean Testosterone treatment – mean Placebo treatment 



















Mean DHT Placebo 
BA 




1 E4 - 3.50 3.43 18.8 15.4
2 E4 - 4.19 3.16 12.4 9.28
3 E4 - 1.76 1.31 7.83 6.52
4 E4 - 1.20 1.26 4.71 3.45
5 E4 - 2.04 1.42 3.31 1.88
6 E4 - 1.07 1.82 7.06 5.23
7 E4 - 3.27 1.38 7.39 6.01
8 E4 - 2.95 3.13 4.90 1.76
9 E4 - 1.66 1.87 6.47 4.59
10 E4 - 2.79 2.57 13.1 10.5
11 E4 - 1.57 1.61 8.55 6.93
12 E4 - 1.96 1.52 13.1 11.6
13 E4 - 1.80 1.11 5.61 4.50
14 E4 - 2.17 2.01 10.1 8.10
15 E4 - 1.52 1.65 13.5 11.8
16 E4 - 1.64 1.16 5.92 4.76
17 E4 - 1.21 1.12 8.51 7.38
18 E4 - 2.32 0.98 10.6 9.65
19 E4 + 2.57 2.17 14.1 11.9
20 E4 + 0.51 3.35 6.95 3.60
21 E4 + 1.92 1.92 3.16 1.23
22 E4 + 2.04 1.79 4.94 3.15
 
*Treatment effect = mean Testosterone treatment – mean Placebo treatment 






















1 E4 - 60 101.7 70 31.7 
2 E4 - 60 103.3 86. 7 16.7 
3 E4 - 80 93.3 80 13.3 
4 E4 - 80 56.7 73.3 -16. 7 
5 E4 - 50 43.3 46. 7 -3.33 
6 E4 - 60 53.3 70 -16.7 
7 E4 - 100 86.7 96. 7 -10 
8 E4 - 100 75 83.3 -8.33 
9 E4 - 80 66.7 96. 7 -30 
10 E4 - 90 93.3 86. 7 6.67 
11 E4 - 80 93.3 56.7 36.7 
12 E4 - 140 145 133.3 11.7 
13 E4 - 90 91. 7 130 -38.3 
14 E4 - 50 45 60 -15 
15 E4 + 90 90 73.3 16.7 
16 E4 + 60 50 70 -20 
17 E4 + 50 120 86. 7 33.3 
18 E4 + 120 118.3 93.3 25 
19 E4 + 90 83.3 110 -26.7 
20 E4 + 90 76.7 56. 7 20 
21 E4 + 80 80 90 -10 
22 E4 + 80 121.7 83.3 38.3 
 
*Treatment effect = mean Testosterone treatment – mean Placebo treatment 
11 participants had lower estradiol levels compared to placebo (yellow boxes), 2 
participants started with high estradiol levels at  baseline. 















Mean E Placebo 
BA Mean E Testo BA 
Treatment 
effect BA* 
1 E4 - 70 80 210 130
2 E4 - 130 88.3 106.7 18.3
3 E4 - 100 88.3 106.7 18.3
4 E4 - 40 41.6 40 -1.67
5 E4 - 50 46.7 53.3 6.67
6 E4 - 40 45 46.7 1.67
7 E4 - 50 53.3 46.7 -6.67
8 E4 - 80 80 60 -20
9 E4 - 100 83.3 83.3 0
10 E4 - 50 60 100 40
11 E4 - 100 105 96.7 -8.33
12 E4 - 70 66.7 130 63.3
13 E4 - 90 66.7 70 3.33
14 E4 - 90 51.6 63.3 11.7
15 E4 - 90 68.3 143.3 75
16 E4 - 60 65 66.7 1.67
17 E4 - 130 173 210 36.6
18 E4 - 40 43.3 60 16.6
19 E4 + 80 80 83.33 3.33
20 E4 + 70 58.3 83.3 25
21 E4 + 110 91.6 73.3 -18.3
22 E4 + 120 93.3 93.3 0
 
*Treatment effect = mean Testosterone treatment – mean Placebo treatment 
5 participants had lower estradiol levels compared to placebo (yellow boxes), 3 
participants started with high estradiol levels at baseline. 

















BMI The End 
of Testo AB 
BMI The End 
of Placebo AB 
Treatment effect 
AB 
1 E4 - 27 23.1 25.2 -2.1
2 E4 - 21.2 21 20.9 0.1
3 E4 - 23.9 24.9 24.9 0
4 E4 - 23.1 23.3 23.3 0
5 E4 - 29.8 29.1 28.4 0.7
6 E4 - 30 28.5 29.7 -1.2
7 E4 - 25.6 25.4 25.2 0.2
8 E4 - 25.7 27 27.4 -0.4
9 E4 - 23.7 24.1 23.8 0.3
10 E4 - 28.2 29.5 29.4 0.1
11 E4 - 27.1 27.2 27.5 -0.3
12 E4 - 23 24.2 23.7 0.5
13 E4 - 25.8 25.1 25.6 -0.5
14 E4 - 24.6 24.4 24 0.4
15 E4 + 21.8 23.9 24.2 -0.3
16 E4 + 24.4 24.1 23.8 0.3
17 E4 + 28.7 27.1 27.2 -0.1
18 E4 + 26.6 26.2 25.7 0.5
19 E4 + 21.8 21.9 21.7 0.2
20 E4 + 32.4 32.5 32.3 0.2
21 E4 + 33.9 34.1 33.2 0.9
22 E4 + 32.6 32.4 32.5 -0.1
*Treatment effect = mean Testosterone treatment – mean Placebo treatment 
8 participants had lower BMI compared to placebo (yellow boxes), 8 participants were 
obese, 11 participants were overweight and 3 participants were underweight at baseline. 
Normal reference range = 16-19 kg/m2, cut off score of 22 kg/m2 considered to be 














BMI The End of 
Placebo BA 




1 E4 - 25.3 26 26.4 0.4 
2 E4 - 22.4 21.5 20.9 -0.6 
3 E4 - 28.2 28.7 27.7 -1 
4 E4 - 24.5 24.8 23.8 -1 
5 E4 - 22.4 22.6 23.6 1 
6 E4 - 27.8 28.5 26.5 -2 
7 E4 - 21.1 20.1 20 -0.1 
8 E4 - 22.4 22.3 21.8 -0.5 
9 E4 - 25.5 25.2 25.7 0.5 
10 E4 - 13.6 14.8 14 -0.8 
11 E4 - 26.9 27.4 26.7 -0.7 
12 E4 - 26.4 26.1 26 -0.1 
13 E4 - 21.6 20.3 19.6 -0.7 
14 E4 - 24.2 25.6 24.6 -1 
15 E4 - 19.3 18.8 19.4 0.6 
16 E4 - 26.6 25.9 25.2 -0.7 
17 E4 - 31 31 31.4 0.4 
18 E4 - 26.1 26.4 26.2 -0.2 
19 
E4 
+ 23.7 23.9 24.2 0.3 
20 
E4 
+ 30.1 30.3 29.4 -0.9 
21 
E4 
+ 20.9 23.3 24 0.7 
22 
E4 
+ 23.5 24.2 24.6 0.4 
 
*Treatment effect = mean Testosterone treatment – mean Placebo treatment 
14 participants had lower BMI compared to placebo (yellow boxes), 4 participants were 
obese, 13 participants were overweight, and 5 participants were underweight at baseline. 
Normal reference range = 16-19 kg/m2, cut off score of 22 kg/m2 considered to be 


















BF The End of 
Testo AB 




1 E4 - 25.4 24.7 25.4 -0.7
2 E4 - 17 15.8 17 -1.2
3 E4 - 19.3 20.7 21.5 -0.8
4 E4 - 18.1 18.5 20 -1.5
5 E4 - 33.1 32.5 31.7 0.8
6 E4 - 27.3 28.1 27.9 0.2
7 E4 - 21.5 20.6 21.8 -1.2
8 E4 - 20.2 23.6 22.1 1.5
9 E4 - 22.4 21.3 21.8 -0.5
10 E4 - 27 28.2 27.4 0.8
11 E4 - 26.2 26.8 29.1 -2.3
12 E4 - 19.9 21.2 20.1 1.1
13 E4 - 22.3 19.7 19.8 -0.1
14 E4 - 22.3 23.2 23.1 0.1
15 
E4 
+ 14.5 18.7 19.4 -0.7
16 
E4 
+ 24.6 23.9 23 0.9
17 
E4 
+ 19.8 20.2 17.3 2.9
18 
E4 
+ 23.1 23.5 24.3 -0.8
19 
E4 
+ 22.2 21.5 21.1 0.4
20 
E4 
+ 32.5 32 34.2 -2.2
21 
E4 
+ 35.4 32.8 30.4 2.4
22 
E4 
+ 32.5 29.5 28 1.5
*Treatment effect = mean Testosterone treatment – mean Placebo treatment 
11 participants had a lower body fat percentage compared to placebo (yellow boxes), 5 
participants were obese at baseline. 















BF The End of 
Placebo BA 




1 E4 - 20.7 21.5 22.7 1.2 
2 E4 - 19.5 19.1 17.5 -1.6 
3 E4 - 27.3 27.9 27.8 -0.1 
4 E4 - 22.3 23 21.7 -1.3 
5 E4 - 15.9 16.6 19.2 2.6 
6 E4 - 29.1 31.3 25.1 -6.2 
7 E4 - 17.6 15.6 14.3 -1.3 
8 E4 - 15.7 15.9 14.8 -1.1 
9 E4 - 26.2 24.9 28.8 3.9 
10 E4 - 2.5 5.7 3.6 -2.1 
11 E4 - 25.4 28.8 26.6 -2.2 
12 E4 - 20.5 22.2 19.8 -2.4 
13 E4 - 15.8 15.4 13.5 -1.9 
14 E4 - 21.9 23.2 23.4 0.2 
15 E4 - 13.8 13 14.4 1.4 
16 E4 - 28.8 27 27.5 0.5 
17 E4 - 27.9 28.9 27.2 -1.7 
18 E4 - 25.3 25.5 26.4 0.9 
19 
E4 
+ 22.9 22.9 25.6 2.7 
20 
E4 
+ 28.6 29.2 28.9 -0.3 
21 
E4 
+ 19.1 19.6 17.8 -1.8 
22 
E4 
+ 22.2 23.7 24.1 0.4 
*Treatment effect = mean Testosterone treatment – mean Placebo treatment 
13 participants had a lower body fat percentage compared to placebo (yellow boxes), 5 
participants were obese at baseline. 






































































Total Cholesterol Treshold levels (at Baseline) : 
< 4.6 mmol/L = low 
4.6 – 5.2 mmol/L = desirable 
5.3 – 6.2 mmol/L = moderate 
> 6.2 mmol/L = high  
 
 
All of the participants in the two arms of the study started with  low, desirable, or 
moderate levels of total cholesterol levels at baseline. 
From the graphs above, in treatment arm AB,  we can see that those who started off 
with higher than normal (desirable) levels of total cholesterol showed significant 
decreases in total cholesterol, LDL, and HDL following testosterone treatment. For 
those who started off with low and desirable total cholesterol levels at baseline, it may 
be that the treatment was not able to reduce levels further, because the body’s 
metabolism compensated and produced cholesterol to maintain cholesterol levels above 
a certain minimum level. Therefore, these people were not likely to show any change. 
Thus, the results from the participants who started off with low and normal levels of 
total cholesterol may have masked any significant changes in partipants who started off 
with moderate total cholesterol. Meanwhile, in treatment arm BA, no significant 
changes were observed in those participants who started off with moderate total 
cholesterol levels. This may be due to the small number of participants, which was only 
4. No significant changes were observed in those participants with low or moderate 
starting total cholesterol levels (as observed in the previous arm). 
 
